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ABSTRACT

Group A Streptococcus (GAS, Streptococcus pyogenes) is a Gram-positive bacterial
pathogen responsible for life-threatening, invasive human diseases, including
necrotising fasciitis and streptococcal toxic shock syndrome. In the last 30 years, a
global increase in the rates of severe and fatal forms of GAS infection has been noted.
Coinciding with this epidemiological trend has been a pandemic spread of particularly
hypervirulent GAS, notably a clone of the M1T1 serotype. Studies investigating this
serotype highlight the unique genetic makeup of M1T1 GAS and its interactions with
the host innate immune response as key elements coordinating the virulence of this
serotype. Phage-mediated horizontal gene transfer and selective pressure exerted by
polymorphonuclear leukocytes (PMNs) for mutations in the control of virulence
regulator operon (covRS) bestow M1T1 GAS with enhanced pathogenic capacity.
However, isolates of virulent GAS also occur in genetic backgrounds lacking phageencoded factors, such as sda1, and other M1T1-specific core genomic elements
necessary for covRS mutation. In this study, high-throughput next-generation
sequencing was utilised to generate a draft genome sequence of NS88.2, an emm98.1
GAS isolate exhibiting a hypervirulent and PMN resistant phenotype. The multi-locus
sequence type (MLST) was determined from the NS88.2 draft genome sequence,
which was compared to fully sequenced GAS strains by whole genome BLAST
alignment. NS88.2 was found to have a MLST sequence type of 205, and regions of
nucleotide sequence divergence between NS88.2 and other GAS included the multiple
gene regulator (MGA) and fibronectin, collagen and T-antigen (FCT) loci. The NS88.2
MGA locus showed low sequence similarity to GAS of other emm-types, and the FCT
locus corresponded to an FCT type 3. A ~30 kb region containing putative prophagelike elements constituted the majority of NS88.2 novel sequence data, however
v

interrogation of these elements did not reveal novel genes with obvious roles in
modulating PMN responses. Bioinformatic prediction of genes encoding cell surface
and secreted proteins was conducted, and identified 10 putative cell surface proteins
and 190 putative proteins with secretion signal peptides. The addition of this genome
draft to public databases will facilitate other studies of GAS genome biology, and
further in-depth analyses of the NS88.2 isolate described here.
The phage-encoded extracellular DNase streptodornase 1 (Sda1) has previously been
shown as essential for M1T1 GAS acquisition of covRS mutations. Mutations of covRS
in M1T1 GAS bestow hypervirulent and PMN resistant qualities. These phenotypes are
also observed in the NS88.2 isolate, which encodes a truncated, non-functional covS
gene, but not the sda1 gene. In this study, NS88.2 and derivative strains with intact
covS (NS88.2rep) or reverse complemented inactive covS (NS88.2covS) were
examined to determine potential novel mechanisms by which these strains interact with
the innate immune response. Phenotypic comparison of NS88.2, NS88.2rep and
NS88.2covS to M1T1 GAS demonstrated that similar to M1T1 GAS, mutation of covS
impairs the ability of NS88.2 and NS88.2covS to adhere to HEp-2 cells in vitro, murine
skin in vivo, and to biofilm production relative to NS88.2rep. The ability of NS88.2
strains to degrade neutrophil extracellular traps (NETs) was determined, and in
congruence with previously described genome data describing the absence of sda1,
these strains showed significantly reduced ability to degrade NETs over virulent M1T1
GAS. In extension to the NS88.2 genomic sequence draft, proteomic and
transcriptomic approaches utilising 2D-PAGE and transcriptional microarray analyses
were undertaken. Proteomics revealed that covS-mutation lead to increased amounts
of streptococcal collagen-like protein A (SclA), general stress protein 24 (Gls24) and
other known or potential virulence factors in culture supernatants. Analysis of the
NS88.2 transcriptome demonstrated that sclA was upregulated by covS mutation, and
vi

that gls24 was highly upregulated in response to incubation in whole blood. NS88.2
isogenic deletion mutants of sclA and gls24 exhibited significantly reduced ability to
proliferate in whole blood, and reduced ability to resist killing by purified PMNs. This
study describes genomic, transcriptomic and proteomic characterisation of a non-M1T1
GAS isolate, and identification of a novel role for two GAS virulence determinants in
modulating interactions with PMNs.
Infection of PMNs with M1T1 GAS rapidly triggers an apoptotic cell death program,
however the impact of differentially PMN-resistant GAS strains on PMN cell death
responses is unclear. In this study, the interactions of PMNs with PMN-resistant
(NS88.2) and PMN-sensitive (NS88.2rep) GAS were characterised to determine the
effect on PMN cell death modality. In vitro infection of purified PMNs demonstrated that
PMNs phagocytosed significantly less virulent NS88.2 than avirulent NS88.2rep and
subsequently generated less reactive oxygen species. PMNs that had phagocytosed
NS88.2rep also underwent a higher degree of mitochondrial membrane depolarisation
than NS88.2. Scanning electron microscopy of NS88.2rep infected PMNs indicated
morphological signs of apoptotic cell death, which was supported by biochemical
evidence of nuclear DNA fragmentation and caspase-3 activation. Conversely,
apoptotic markers were absent in NS88.2 infected PMNs, which displayed ultrastructural markers of oncotic cell death and loss of plasma membrane integrity.
Intradermal infection of C57BL/6 mice determined that phagocytosis of NS88.2 was
impaired in vivo, which contributed to the survival and virulence of this strain.
Immunohistological analysis of murine dermal tissue showed that infection by
NS88.2rep lead to migration of murine PMNs, and cells associated with infection
stained strongly for apoptotic markers associated with a pro-resolution of inflammation
phenotype. Murine dermal tissue infected with NS88.2 also exhibited murine PMN
influx,

however

was

absent

for

apoptotic

markers

and

exhibited

adverse
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histopathologies. This study indicates that the manner of PMN cell death program
induced by GAS infection may enhance GAS virulence and affect disease pathologies.
The work described here illustrates interactions between the human innate immune
response and GAS in a non-M1T1 genetic background. These findings emphasise
heterologous mechanisms by which GAS of different serotypes resist killing by PMNs,
and how PMN cell death responses are shaped by virulent and avirulent GAS. A
deepened understanding of both host and GAS cellular and molecular interactions
during infection holds high potential to identify novel targets that can be exploited for
the development of improved diagnostics and therapeutics for GAS diseases.
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CHAPTER 1: REVIEW OF THE LITERATURE
1.1

Overview

Streptococcus pyogenes (Group A Streptococcus, GAS) is the etiological agent of mild
skin and mucosal conditions such as impetigo and pharyngitis (Bisno and Stevens,
1996), in addition to life-threatening invasive diseases such as the “flesh eating
disease” necrotising fasciitis (Donaldson et al., 1993) and streptococcal toxic shock
syndrome (McCormick et al., 2001). Invasive GAS infections frequently lead to
mortality, with over 500,000 deaths annually resulting from GAS infections and their
sequelae (Carapetis et al., 2005). In recent decades, higher rates of GAS diseases
have been reported despite the efficacy of antimicrobial agents (Efstratiou, 2000).
Paralleling this resurgence, the globally disseminated M1T1 GAS serotype is frequently
isolated from severe invasive infections (Aziz and Kotb, 2008). Virulence of the M1
serotype and other serotypes is promoted by multiple virulence factors contributing to
innate

immune

avoidance

and

systemic

dissemination

throughout

the

host

(Cunningham, 2000; Walker et al., 2014). Evasion of the innate immune response is an
essential precursor to invasive disease, and while the pathogenic mechanisms
underlying M1T1 virulence continue to be studied intensively, non-M1T1 GAS immune
interactions are less understood. A mounting body of evidence suggests critical roles
for host immune mediators in determining the severity of infection (Norrby-Teglund and
Johansson, 2013). Cellular agents of the innate immune response mediate the initial
host interactions with GAS, and are responsible for orchestrating subsequent
antimicrobial responses (Goldmann et al., 2004; Loof et al., 2007). Numerous genetic
elements coordinate both the susceptibility of the host to infection, and the virulence of
GAS isolates (Abdeltawab et al., 2008; Walker et al., 2007). This duality of pathogen
and host derived genetic factors suggest that in-depth analyses encompassing both
sides of infection are requisite to understanding the complete disease process.
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Presented here is a review of the literature regarding GAS epidemiology and disease
pathologies, host responses to GAS infection and GAS virulence factors which mitigate
innate immune responses during infection.
1.2

Classification of streptococci

Streptococcus is a genus of Gram-positive, chain forming, non-motile coccal bacteria,
phylogenetically divided into more than 50 species and subspecies. Many
streptococcal species are pathogenic agents of humans and domesticated animals
(Facklam, 2002). Historically, classification of streptococcal species was based upon
their haemolytic potential, and was later expanded to differentiate between the
carbohydrate “group” antigens of the bacteria (Lancefield, 1928; Schottmüller, 1903).
1.2.1

Lancefield classification

The Lancefield system of classification groups streptococci into categories based on
the presence of specific cell wall polysaccharides (groups A, B, C, F and G) or
lipoteichoic acids (group D) (Cunningham, 2000). The streptococcal group A
carbohydrate is composed of N-acetyl-β-D-glucosamine linked to a polymeric
rhamnose backbone. Group A of the Lancefield classification system consists
predominantly of Streptococcus pyogenes (Lancefield, 1962), however other
streptococcal species, Streptococcus dysgalactiae subsp. equisimilis and the
Streptococcus anginosus group may also contain the group A carbohydrate (Facklam,
2002).
1.2.2

M-typing

The GAS M protein (encoded by the emm gene) is a major surface protein which
extends from the streptococcal cell wall (carboxy terminal) as an α-helical, coiled-coil
dimer with conserved, variable and hypervariable regions (Fig. 1.1) (Fischetti, 1989).
Immune selection of the variable and hypervariable regions is hypothesised to have
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resulted in broad diversification of the M protein (Bessen et al., 2008). This variation
forms the basis of GAS serological M-typing, and uses standardised typing sera
(Cunningham, 2000; Fischetti, 1989). However, many difficulties with M serotyping
have arisen, including achieving full coverage of >100 M serospecificities of GAS
(Cunningham, 2000), difficulty in the preparation of M protein antisera (Vitali et al.,
2002) and notably, the lack of reactivity of some GAS isolates to reference M-antisera
(Relf et al., 1992). Simultaneous serotyping of the surface T-antigen, encoded by the
tee gene, is occasionally performed in conjunction with M typing to differentiate
between M-nontypeable strains (Jones et al., 1991). Assignment of a T-serotype can
distinguish between M-nontypeable GAS strains, however issues in interpreting Tserotyping results can arise through cross-reactivity of many GAS strains to reference
T antisera (Johnson et al., 2006).
1.2.3

emm-typing

Due to the difficulties in serologically typing streptococcal M protein, molecular typing
methods based upon analysis of the 5’ sequence of the emm gene, encoding the
hypervariable amino terminus of M protein, are now routinely used (Beall et al., 1996;
Vitali et al., 2002). The heterogeneous 5’ end of emm genes encoding the
hypervariable region, determines the serotype specificity of the M protein. Sequencing
this region provides more discriminatory data over serological methods for
distinguishing between GAS isolates. Emm-typing is conducted by sequencing ~150
bases from the 5’ end of the emm PCR product and grouping together sequences
showing >95% homology as emm types, whilst separating emm-types showing a
maximum of 80% homology (Efstratiou, 2000). Currently, >250 emm types and
subtypes have been collected, emphasising the hypervariability of the emm gene
(Smeesters et al., 2010). Other emm based typing methods rely on PCR using emm
type specific oligonucleotides (Vitali et al., 2002).
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Fig. 1.1 General structure of the group A streptococcal M protein. The α-helical, coiledcoil region extends approximately 50 nm away from the bacterial cell wall. Indicated are the
amino-terminal hypervariable and variable (containing A and B repeats) regions which
dictate the M serotype specificity and the conserved (containing C and D repeats) region
which also contains the LPxTG Gram-positive cell wall anchor and positively charged tail.
The number and sequence of the A and B repeats is dependent on the M type. Adapted
from Fischetti (1989).

1.2.4

emm-patterning

Many GAS strains encode multiple emm or emm-family genes, forming the basis for
grouping of emm chromosomal patterns or subfamilies (Hollingshead et al., 1993). The
five major pattern groupings (A - E) are defined by the number of emm genes encoded,
the subfamily content of each gene and their relative order (Fig. 1.2) (Hollingshead et
al., 1993). Designation of an emm pattern is determined by PCR amplification patterns
using emm subfamily specific primer sets (Hollingshead et al., 1993). Strains of the
4

same M serotype may encode different emm patterns, and vice versa as a single M
pattern encompasses many M serotypes (Bessen et al., 1996).

Fig. 1.2 Chromosomal arrangement of the five major emm pattern groups A - E. emm
pattern groups are designated according to amplification using emm and emm-family (mrp and
enn) gene subfamily (SF) specific primers. Bordering the emm and emm-family genes are the
mga regulator and C5a peptidase (scpA) genes. Intergenic distances between emm genes in
emm patterns A and B may vary due to large DNA insertions. The tissue tropism classically
associated with each emm pattern is also indicated. Figure is adapted from Hollingshead et al.
(1993) and Cunningham (2000).

1.2.5

Vir-typing

An alternative molecular method utilising long PCR and restriction fragment length
polymorphisms (RFLPs) to differentiate between GAS strains has also been proposed
(Gardiner et al., 1995). This approach is applied to the multiple gene regulator (MGA)
region of GAS, the same region dictating GAS M patterns, which comprises of the Mprotein family genes mrp (M-protein related protein, also known as fcrA), emm and
enn, which are flanked by C5a peptidase (scpA) and a regulatory gene mga (also
known as virR or mry) (Gardiner et al., 1995). A strong correlation between RFLPs of
many GAS isolates and emm sequence types was found using this technique, and
provides advantages over routine emm sequencing as a more rapid method of typing in
response to outbreaks (Gardiner et al., 1998).
5

1.3

Pathologies and epidemiology of GAS disease

1.3.1

Non-invasive GAS disease

Group A streptococci are responsible for a diverse range of mild, superficial diseases
including streptococcal pharyngitis (“strep throat”), scarlet fever and impetigo. While
GAS may asymptomatically colonise host epithelia, acute symptomatic streptococcal
infection is the most common bacterial cause of pharyngitis, causing approximately 15
- 30% of cases in children and 5 - 10% of cases in adults (Bisno, 2001). Streptococcal
pharyngitis results from symptomatic bacterial colonisation of the oropharyngeal
epithelium, typically manifesting as a sudden onset of throat pain, fever, headache and
nausea or vomiting (Bisno, 2001). Scarlet fever is often linked with pharyngitis and is
exhibited symptomatically as large red rashes and bright red tongue discolouration.
Investigations utilising molecular typing have found that streptococcal superantigens,
SSA, SpeC and SpeA may mediate the virulence of scarlet fever and contribute to
scarlet fever outbreaks (Perea-Mejia et al., 2002; Tse et al., 2012). Group A
streptococci frequently colonise the skin to cause impetigo. Impetigo, also known as
pyoderma, is caused by symptomatic infection of the epidermis by GAS, commonly
occurring at exposed surfaces such as the face or extremities. Impetigo is
characterised by suppurative lesions which rupture to form yellow crusts (Bisno and
Stevens, 1996). Deeper invasion through local trauma, abrasions, severe acne or
eczema, may cause conditions such as erysipelas or cellulitis, depending on the
degree of penetration of the superficial and subcutaneous layers (Bisno and Stevens,
1996).
1.3.2

Invasive GAS disease

The entry of GAS into deeper, sterile tissue from superficial infection sites or direct
inoculation from penetrating injuries, burns, trauma or surgery, may lead to the
development of severe, invasive GAS diseases such as necrotising fasciitis (NF),
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sepsis and streptococcal toxic shock syndrome (STSS) (Bisno and Stevens, 1996;
Stevens et al., 2005). NF, otherwise known as the “flesh eating disease”, results from
GAS infection and subsequent necrosis of subcutaneous fat, superficial fascia and
superficial-deep fascia. Initial symptoms often present the skin as intact, however
secondary gangrene commonly follows late in the course of infection (Donaldson et al.,
1993). NF and other soft tissue infections are routinely treated by surgical debridement
of necrotic tissues, with amputation as an emergency measure (Stevens et al., 2005).
Soft tissue infections such as NF and cellulitis may develop concurrent STSS
(McCormick et al., 2001). STSS is mediated by secretion of streptococcal
superantigens or pyrogenic toxins that initiate massive, non-specific stimulation of Tcell populations, leading to overwhelming cytokine release (McCormick et al., 2001;
Lappin and Ferguson, 2009). STSS is exhibited clinically as hypotension, renal
dysfunction, erythematous macular rash, coagulopathy, soft tissue necrosis or
respiratory stress (Lappin and Ferguson, 2009). Despite the sensitivity of GAS to
penicillin, large quantities of the pathogen are able to reach stationary growth phase in
invasive infections such as STSS, reducing the antimicrobial efficacy of this antibiotic
(Baxter and McChesney, 2000). Currently, paired penicillin and clindamycin treatment
is recommended for soft-tissue and systemic GAS infections, due to suppression of
GAS toxins and modulation of cytokine production (Stevens et al., 2005).
1.3.3

Immunologically-mediated sequelae

Recurring GAS infections may give rise to immunologically-mediated complications
such as acute rheumatic fever (ARF) and acute post-streptococcal glomerulonephritis
(APSGN). ARF stems from the production of auto-reactive antibodies and T cells
following GAS infection, leading to inflammation of heart muscle (carditis), joints
(arthritis), central nervous system (chorea) and skin (erythema marginatum)
(Cunningham, 2008). Molecular mimicry between streptococcal M-protein epitopes and
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host tissue, particularly heart muscle myosin, is believed to be a major underlying
cause of ARF. This hypothesis is supported by evidence that T-cell clones from
rheumatic heart disease patients possess cross-reactivity between myosin, mitral valve
associated proteins and streptococcal M peptides (Fae et al., 2006). Other potential
mechanisms underlying ARF include immune cross-reactivity of other GAS molecules
including the group A carbohydrate, and the accumulation of type IV collagen on ARFassociated GAS, triggering the production of collagen-specific autoantibodies (Dinkla et
al., 2003; Dinkla et al., 2009). Development of ARF is triggered 1 - 5 weeks after
primary infection by GAS, commonly in the form of streptococcal pharyngitis (Walker et
al., 2014). APSGN describes post-infection, immune-mediated sequelae which may
also arise following either cutaneous or pharyngeal infection. Outbreaks of APSGN
have declined over the last decade however higher incidences are still reported in
Africa, South America, New Zealand and Kuwait (Cunningham, 2008).

APSGN is

characterised by oedema, hypertension, haematuria and proteinacious sediment in
urine, all of which are linked to renal impairment due to inflammation of renal glomeruli
(Cunningham, 2008). Several mechanisms by which APSGN is triggered have been
proposed, including immune reactions within glomeruli resulting from cross-reactive
renal antigens or from the deposition of circulating streptococcal antigen-antibody
immune complexes (Cunningham, 2000; Walker et al., 2014). Early treatment of
pharyngitis with penicillin has been shown to inhibit the development of APSGN (Holm,
1988).
1.3.4

GAS disease epidemiology

It has been noted that particular GAS strains and serotypes appear to preferentially
infect different tissue sites, either the epidermis of the skin, or the epithelial layer of the
oropharynx (Bessen et al., 1996). Tissue tropism of GAS has historically been viewed
as dependent upon the specific emm pattern of each isolate. GAS ‘specialist’ strains
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which preferentially infect the throat and cause pharyngitis are associated with emm
patterns A - C, whilst strains which preferentially infect the skin and cause impetigo are
typically emm pattern D (Fig. 1.2) (Bessen et al., 1996). Strains which belong to emm
pattern E may infect either tissue site with no recorded specificity (Bessen et al., 1996).
In a laboratory-based study of three regions in the U.S.A, the risk factors of invasive
GAS infection for adults were: exposure to one more children with sore throats, HIV
infection and a history of injecting drug use (Factor et al., 2003). A larger, populationbased surveillance study across Europe found environmental factors such as advanced
age and overcrowding, increased the severity and likelihood of infection respectively
(Lamagni et al., 2008). Infection by GAS is also subject to seasonal variation, with
colder or more temperate climates and seasons favouring pharyngeal infection and
warmer climates and seasons favouring impetigous infection (Lamagni et al., 2008).
Both mild and severe GAS infections occur in developing and developed countries
worldwide. The frequency of severe GAS diseases has been increasing since the mid1980s, with 1.78 million cases reported annually worldwide (Carapetis et al., 2005).
Multiple pathogenic factors are believed to have played roles in the recent resurgence
of severe GAS infections, including the phage-mediated acquisition of additional
virulence factors (Aziz and Kotb, 2008) and emergence of particularly virulent
subclones of certain M serotypes (Musser et al., 1995). A hypervirulent GAS subclone
of the M1T1 serotype has spread on a global scale, which has paralleled the rise of
invasive GAS infections (Aziz and Kotb, 2008). Contrasting the spread of the M1T1
serotype, the indigenous Aboriginal population of Australia’s Northern Territory suffer
from endemic skin and pharyngeal diseases caused by diverse serotypes and strains
of GAS (Gardiner and Sriprakash, 1996). As a consequence of this endemic GAS
disease, Aboriginal communities display one of the highest rates in the world of
autoimmune sequelae, such as acute rheumatic fever and rheumatic heart disease,
following primary GAS infection (Carapetis et al., 1996). Intriguingly, GAS isolates from
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Aboriginal communities do not conform to the classic emm pattern tissue tropism
profile, as up to 70% of emm pattern A - C GAS isolates from these communities were
taken from impetigous sores (Bessen et al., 2000). However, in the same region emm
pattern D GAS are nonetheless the most prevalent emm pattern isolated (Bessen et
al., 2000). Necrotising fasciitis isolates from rural indigenous communities also show
emm diversification not observed in urban populations (Hassell et al., 2004).
1.4

Establishment of GAS infection

1.4.1

Adhesion to the host

The initiation of superficial GAS infection requires adherence of bacteria to host
epithelial cells. Humans are widely accepted to be the exclusive reservoir of GAS, with
nasopharyngeal mucosa and impetigous sores serving as the primary sites of infection
and routes of GAS transmission between hosts (Fiorentino et al., 1997). The
establishment of oropharyngeal infection is dependent on the ability of GAS to
overcome mechanical obstacles, such as clearance by salivary flow and cell shedding,
in order to adhere to the epithelium. To achieve this, GAS hijack host extracellular
matrix (ECM) molecules such as fibronectin, fibrinogen, and laminin. GAS exhibits a
bewildering array of putative adhesins which bind host ECM molecules (Table 1.1).
However, not all GAS adhesins are expressed simultaneously by all strains, and some
may have differing affinities for different host cell types (Courtney et al., 2002). One
proposed model for the adhesion of GAS to host receptors is a two-step mechanism
involving a low-affinity binding mediated by GAS lipoteichoic acid (LTA) through its lipid
moiety, followed by a higher-affinity binding through an adhesin such as PrtF1/SfbI or
M protein, to a specific host cell membrane receptor (Hasty et al., 1992) (Fig. 1.3). The
second step of this adhesion model determines the tissue specificity of the interaction
and would partly explain the variable propensities of GAS strains to preferentially infect
different host tissue sites.
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Fig. 1.3 Two-step mechanism for the attachment of group A Streptococci to host
receptors. The first step of this mechanism involves the non-specific, low-affinity interaction of
GAS lipoteichoic acid (LTA) with hydrophobic regions of host cell receptors. This low-affinity
binding facilitates the second higher-affinity binding, bringing a specific GAS adhesin in
contact with host receptors which affect a stronger irreversible adhesion of pathogen to host.
Reproduced from Hasty et al., 1992.

1.4.2

Adaptive response to the colonisation state

During colonisation, GAS must be able to scavenge sufficient nutrients in order to
survive. Cynomologous macaques have been utilised as a non-human primate model
of streptococcal pharyngitis, and during 86-day infection with M1T1 GAS the initial
colonisation phase was dominated by the up-regulation of carbohydrate metabolism
genes (Virtaneva et al., 2005). Regulation of salivary persistence mechanisms is
controlled by a two-component regulator sptRS, which can significantly remodel the
GAS transcriptome to promote complex carbohydrate utilisation via increased starch
degradation and maltose uptake (Shelburne et al., 2005). GAS can utilise α-glucans
degraded by human α-amylase via the maltose transporters MalE and MalT, both of
which contribute to salivary nutrient uptake and enhance the ability of GAS to colonise
the murine oropharynx (Shelburne et al., 2008).
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Fibronectin, macrophage scavenger
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Fibronectin, fibrinogen, laminin, CD46,
galactose, fucose/fucosylated glycoprotein,
collagen
Fibronectin

Lipoteichoic
acid

M protein

Host receptor(s)

GAS Adhesin

Table 1.1 Putative adhesins of group A streptococcus (GAS)A

1.5

Interaction of GAS with the innate immune system

1.5.1

Innate immunity

Immunity can be defined as resistance to infection by external agents that would
otherwise lead to a disease state. The human immune system is composed of two
networks, the innate and the adaptive immune systems, that recognise and respond to
infections resulting in the destruction of foreign antigens (Pommerville, 2010). The
innate immune system is characterised by its rapid response time, limited antigenic
specificity and lack of immunological memory (Pommerville, 2010). This system
includes physical barriers against infection, constitutive chemical barriers that inhibit
microbial colonisation, receptors which detect the entry of foreign microbes and
specialised immune cells responsible for promoting subsequent antimicrobial
responses (Gallo and Nizet, 2008). Epithelial cells cover the interface between the
body and external environment, and release antimicrobial peptides (AMPs) that prevent
colonisation of epithelial surfaces. Humans produce a diverse range of AMPs, such as
cathelicidin (LL-37), which show broad spectrum antimicrobial activity against Grampositive and Gram-negative bacteria, fungi and some viruses (Radek and Gallo, 2007).
Commonly, AMPs possess a net cationic charge, >50% hydrophobic residues and an
amphipathic nature (Diamond et al., 2009). These characteristics allow AMPs to
interact with bacterial outer membranes, as AMPs frequently exhibit antimicrobial
activity via membrane permeation (Diamond et al., 2009).
The complement system is composed of intrinsic immune molecules which
‘complement’ immune responses by detecting the presence of foreign antigens and
promoting subsequent phagocytosis and killing of invaders. Activation of the
complement system may be triggered via three separate pathways, known as the
classical, mannose-binding lectin and alternative pathways (Pommerville, 2010). The
alternative and the lectin pathways can be activated in the absence of antibodies, via
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binding of C3b or mannose-binding lectin to the microbial cell surface (Abbas and
Lichtman, 2009). The downstream effects of all three complement pathways result in
generation of C5a and C5b peptides, and coating of the microbial cell surface in C3b
(Abbas and Lichtman, 2009). Circulating C5a is a potent phagocyte chemo-attractant
whilst bound C5b initiates formation of the membrane attack complex (MAC), a
transmembrane pore effecting microbial lysis via water and ion influx. Opsonisation of
the microbial cell surface by C3b is recognised by complement receptors of
phagocytes, resulting in engulfment and intracellular killing.
1.5.2

Cellular innate immune mediators

Specialised immune cells known as phagocytes mediate direct killing of microbes via
phagocytosis. Two major classes of professional phagocytes include mononuclear
phagocytes, consisting of monocytes, macrophages and dendritic cells (DCs); and
polymorphonuclear leukocytes (PMNs); consisting of neutrophil, eosinophil and
basophil granulocytes (Pommerville, 2010). DCs and macrophages are derived from
monocyte precursors during infectious and inflammatory episodes, and form a bridge
linking innate and adaptive immunity by presenting antigenic material to T lymphocytes.
Other cells, including natural killer cells (NKs), are also classified as innate immune
leukocyte. NKs have numerous roles in innate immunity, primarily involving targeting of
infected or ‘stressed’ cells for elimination.
PMNs are the first innate immune cells to be recruited in response to infection, and the
most abundant class of PMN are neutrophil granulocytes (Athens et al., 1961).
Neutrophils are also the most abundant cell type circulating in the blood, after red blood
cells, but have a short half-life as they are rapidly and spontaneously apoptotic
(Kobayashi et al., 2005). As such, the majority of haematopoiesis occurring in adult
humans is devoted to maintenance of neutrophil populations (Athens et al., 1961).
Macrophages mature from circulating blood monocytes cells, which arise from bone
marrow precursor cells. Macrophages can further differentiate into specialised resident
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macrophages such as microglial cells in the central nervous system or alveolar
macrophages in the lungs (Adams and Hamilton, 1984). Unlike neutrophils,
macrophages are less abundant in the blood however resident macrophages persist in
extravascular tissue sites for long periods of time, and so may mediate the first
interactions between pathogens and the immune system prior to neutrophil recruitment
(Goldmann et al., 2004). Neutrophils migrate to sites of infection due to pathogen and
host-derived chemo-attractant signals, such as bacterial lipopolysaccharides and
complement component C5a via chemotaxis (Witko-Sarsat et al., 2000). Tissue
resident macrophages and dendritic cells also release cytokines in response to
detecting pathogenic invasion, attracting neutrophil migration and stimulating
surrounding vascular endothelial cells to produce adhesion molecules. Neutrophils and
monocytes circulating in the blood weakly bind these adhesins, and via a multi-step
‘rolling’ process, are exposed to greater concentrations of chemokines causing them to
migrate between the cells of the endothelium to the site of infection (Pommerville,
2010).
Recognition of pathogens activates phagocytes to begin phagocytosis, whereby the
plasma membrane of the phagocyte is extended around the microbe forming an
intracellular vesicle, referred to as a phagosome. Phagosomes are subsequently fused
with lysosomes, forming phagolysosomes, which deliver a combination of AMPs
produced intracellularly by the phagocyte (Witko-Sarsat et al., 2000). Other enzymes
are also released into phagolysosomes which synthesise reactive oxygen species
(ROS) with which to counter infection (Fig. 1.4). The interaction of the chemo-attractant
signals with neutrophils ‘primes’ the phagocyte for microbicidal activities including the
production of ROS, phagocytosis and degranulation (Kobayashi et al., 2005).
Neutrophils also release extracellular traps (NETs) composed of DNA with associated
histone and granular antimicrobial peptides which serve to ensnare bacteria, exposing
them to higher local concentrations of bactericidal peptides (Brinkmann et al., 2004).
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Fig. 1.4 Neutrophil synthesis and secretion of multiple anti-microbial peptides and
reactive oxygen species (ROS) from varied cellular compartments. Azurophillic granules
produce a potent antibacterial agent of Gram-negative bacteria, bactericidal permeability
increasing protein (BPI); four broad spectrum antibacterial agents, elastase, cathepsin G,
protease 3, azurocidin; and also myeloperoxidase. Specific and tertiary granules release
lactoferrin and lipocalin which scavenge iron from bacterial pathogens; a peptidoglycan
hydrolase lysozyme, antimicrobial peptide LL-37 and three matrix metalloproteinases (MMP) 8,
MMP9 and MMP25. Myeloperoxidase and phagocyte oxidase (Phox) are responsible for the
down-stream production of oxygen radicals and ROS. Figure reproduced from (Nathan, 2006).

1.5.3

Toll-like receptor recognition of GAS

Cellular surveillance and recognition of foreign agents by the innate immune system is
an essential prerequisite to effector recruitment and induction of appropriate
responses. One class of cell receptors involved in recognition of highly conserved
microbial components are the Toll-like receptors (TLRs). There are currently more than
10 known TLRs, which recognise multiple pathogen-associated molecular patterns
(PAMPs) including; LTA and peptidoglycan (recognised by TLR2), lipopolysaccharide
(recognised by TLR4), and unmethylated bacterial CpG DNA (recognised by TLR9)
(Takeda et al., 2003). Studies investigating the receptors involved in recognition of
GAS infection have shown that TLR signalling, particularly through the MyD88 adapter
molecule, plays a vital role in induction of host defences and inflammation (Fig. 1.5)
(Loof et al., 2010; Loof et al., 2008). Given that TLR2 recognises multiple Grampositive bacterial ligands, it is likely this TLR plays a major role in GAS recognition and
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responses.

Indeed,

induction

of

streptococcal

cell-wall

extract-induced

joint

inflammation is dependent on TLR2/MyD88 signalling (Joosten et al., 2003).
Macrophages and DCs are commonly viewed as central coordinators of immune
responses, a view that has been supported by studies showing that macrophages and
DCs are both essential for control of GAS infection (Goldmann et al., 2004; Loof et al.,
2007), likely through their secretion of multiple cytokines such as IL-1ß, IL-6, TNFα and
IL-12 (Goldmann et al., 2005b; Loof et al., 2008).
1.5.4

Leukocyte signalling events

Macrophage and DC recognition of GAS is partially mediated by TLRs, and interactions
with multiple bacterial factors by different TLRs appears to provide immune redundancy
in inducing cytokine responses. This is exemplified by the activation of macrophages
via TLR4 signalling from non-structural elements such as GAS cytolysin streptolysin O
(SLO), and the inability of singular TLR1, TLR2, TLR4 and TLR9 deficiencies to
prevent stimulation of DC cytokine responses (Loof et al., 2008; Park et al., 2004).
However, downstream signalling via MyD88 is critical for coordinated immune
responses, an aspect prominent in clinical studies of patients lacking MyD88, whom
are highly predisposed to pyogenic infections (von Bernuth et al., 2008). MyD88
participates in macrophage and DC TLR-stimulated TNFα production (Gratz et al.,
2008; Loof et al., 2010). MyD88 is absolutely required for DC type-1 interferon
responses, which are triggered via Interferon Regulatory Factor (IRF) 5 (Gratz et al.,
2011). In contrast, MyD88 is partially dispensable for type 1 interferon production by
macrophages, which requires IRF3, TANK-binding kinase 1 (TBK1) and the STING
adaptor (Gratz et al., 2011). Although GAS is typically considered an extracellular
pathogen, recent studies indicate intracellular receptors such as TLR9, are important
for cytokine responses via hypoxia-inducible factor 1-alpha (HIF-1α) signalling, and
also contributes to macrophage GAS killing and ROS production (Zinkernagel et al.,
2012).
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Fig. 1.5 Cellular receptors and signalling pathways involved in GAS recognition and
inflammatory mediator release. Inflammatory mediators are released from multiple
leukocyte types during GAS infection; including PMNs, monocytes, macrophages and
dendritic cells. GAS and GAS-derived LTA; SLO, and soluble M1 protein (sM1), activate
cellular responses to infection. Receptors involved in recognition of GAS include TLRs,
TREM-1, complement receptors (CR), immunoglobulin receptors (FcR), Mac-1, and NLRP3.
Ligand binding to these receptors leads to downstream signalling via MyD88, HIF-1α, STING,
IFR3, IRF5, and TBK1. Recognition of GAS triggers release of interleukins, TNF-α, IFN-β,
HBP, resistin and LL-37.

1.5.5

Non-TLR recognition of GAS

Other non-TLR receptors on macrophages have been shown to respond to GAS
infection. Secretion of SLO mediates activation of the intracellular inflammasome
component NLRP3 and promotes caspase-1 mediated IL-1ß secretion independently
of both TLR and MyD88 signalling (Harder et al., 2009). A recent report describes
secondary modulation of macrophage cytokine responses by the TREM-1 receptor,
which when inhibited has a therapeutic effect in murine models of GAS sepsis (Horst et
al., 2013). The recent work of Baruch et al. demonstrates SLO-mediated host signalling
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via induction of endoplasmic reticulum stress (Baruch et al., 2014). Adherence of silexpressing GAS to epithelial cells and macrophages increases host asparagine
synthetase expression and asparagine production, driving GAS proliferation and
virulence (Baruch et al., 2014).
1.5.6

Excessive host responses contributing to GAS disease pathology

Sufficient excitation of immune mediators is necessary to mount an adequate response
to combat GAS infection. A large body of evidence suggests however, that excessive
and misdirected host responses underlie damaging pathologies during severe GAS
infection (Lappin and Ferguson, 2009). This effect has been historically attributed to the
effects of GAS superantigenic stimulation of T-cell responses during STSS (Kotb,
1995; Norrby-Teglund et al., 2000). However, the interactions of PMNs and the classic
GAS virulence factor M protein have also been recently implicated in mediating this
process (Norrby-Teglund and Johansson, 2013). Serotype M1 protein released from
the GAS cell surface forms complexes with fibrinogen that bind to the PMN Mac-1
receptor, both activating PMNs and triggering the release of heparin binding protein
(HBP) (Fig. 1.5) (Herwald et al., 2004). HBP is a potent inducer of vascular
permeability, and release of this protein elicits pulmonary lesion formation and vascular
leakage (Gautam et al., 2001; Herwald et al., 2004). PMN-mediated HBP release
synergistically enhances inflammatory cytokine responses from M protein-stimulated
peripheral blood monocytes during necrotising infections (Pahlman et al., 2006).
Individuals with IgG antibodies directed towards the central region of the M protein elicit
higher HBP release, and subsequently, are more at risk of suffering a pathologically
excessive inflammatory response to M1 protein-fibrinogen-IgG complexes (Kahn et al.,
2008). Direct injection of purified M1 protein is sufficient to trigger PMN granulemediated severe lung damage, which is markedly reduced in neutropenic mice
(Soehnlein et al., 2008). The M1 protein structure plays an important role in triggering
HBP-mediated lung injury, as mutated, non-fibrinogen binding M1 protein exhibits
19

diminished capacity to cause pulmonary haemorrhage (McNamara et al., 2008). The
precise organisation of fibrinogen molecules into a supra-molecular, cross-like network
by M1 protein is essential for PMN activation, and is conformationally distinct from
normal fibrin clots (Macheboeuf et al., 2011). A novel marker of septic shock severity,
resistin, has also been found to predominately originate from M protein-activated PMNs
during both systemic and localised severe GAS infection, and contributes to local
tissue damage (Johansson et al., 2009). Of particular note, resistin release is triggered
by streptococcal cell wall extracts and M protein, but not by GAS superantigens
(Johansson et al., 2009).
Other GAS virulence factors, particularly SLO, have been found to modulate PMN
responses and contribute to tissue inflammation and destruction. Expression of SLO
during cutaneous infection induces toxic PMN/platelet aggregates that mediate the
progression of microvascular thrombosis and ischemic tissue necrosis (Bryant et al.,
2005). SLO binding by PMNs has also been shown to mediate HBP, LL-37, alphadefensin and elastase release (Nilsson et al., 2006). Interestingly, host NKs have been
found to increase the severity of GAS septic shock, as depletion of this cell type
induces a protective reduction in systemic pro-inflammatory cytokine levels (Goldmann
et al., 2005a). The role of host genetic factors contributing to severe sepsis has also
been investigated. Goldmann et al. utilised differential susceptibilities of distinct mouse
strains to severe GAS infection to demonstrate that failure to control infection and
evocation of excessive inflammatory responses by susceptible mice result in extensive
tissue destruction (Goldmann et al., 2003). This finding has been refined in studies
ascribing differences in severity of STSS to host polymorphism in the human leukocyte
antigen complex (Goldmann et al., 2005b; Kotb et al., 2002). Human MHC class II
haplotype DRB*1501/DQB1*0602 is less commonly associated with STSS in the
presence of NF, while DRB1*07/DQB1*0201 predisposes towards such disease
manifestations. A complementary systems genetics approach was recently utilised to
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identify a panel of host genes bestowing predisposition towards severe GAS sepsis
(Abdeltawab et al., 2008). Pathological levels of the product of one these genes,
Prostaglandin E, directly influences the severity of GAS infection (Goldmann et al.,
2010).
1.5.7

Host leukocyte cell-death responses during GAS infection

Programmed cell death plays a decisive role in determining the outcome of microbial
infections and inflammation. A variety of cell death mechanisms have been described
in response to infection by different pathogens (Kennedy and DeLeo, 2009). Apoptosis
limits the potential of damaged PMNs to ignite inflammatory responses. Coordinated
PMN apoptotic shutdown initiates a state of cellular torpor, and administration of
apoptotic PMNs actively promotes anti-inflammatory responses (Ren et al., 2008).
Conversely, alternative cell death mechanisms such as regulated necrosis or oncosis
have been described, and are exhibited morphologically via cell and organelle swelling,
cytoplasmic vacuolisation, eventual loss of plasma membrane integrity and escape of
cytoplasmic content, leading to enhanced immune responses (Galluzzi et al., 2012).
Oncosis triggers a proinflammatory cell phenotype resulting in release of damageassociated molecular patterns (DAMPs), and prompts rapid immune responses (Kono
and Rock, 2008). In a landmark study by Kobayashi et al., phagocytosis-induced PMN
transcriptional responses were analysed for a variety of bacterial pathogens, including
GAS (Kobayashi et al., 2003a). This study provided strong evidence of a common
apoptotic program following bacterial uptake and ROS production. This apoptotic
program is accelerated in GAS, and leads to rapid DNA fragmentation. Although GASinduced PMN apoptosis was associated with enhanced virulence potential, the
virulence determinant(s) responsible for this activity were not established (Kobayashi et
al., 2003a). Later work by the same group also indicated PMN phagocytosis-induced
apoptosis is associated with nullified inflammatory capacity and expedites resolution of
inflammation (Kobayashi et al., 2003b; Kobayashi et al., 2003c).
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Several reports emphasise the dominant role of GAS cytolysins, and to a lesser extent
hyaluronic acid capsule, in shaping PMN and other leukocyte cell-death responses.
Early studies of SLO and streptolysin S (SLS) function indicate both are capable of
inducing PMN lysis and skin lesion formation (Betschel et al., 1998; Fontaine et al.,
2003; Limbago et al., 2000; Sierig et al., 2003). GAS strains expressing low and high
amounts of SLO and SLS were used to demonstrate that cytolysins are capable of
triggering caspase-dependent apoptosis of thioglycolate-induced murine PMNs
(Miyoshi-Akiyama et al., 2005), giving credence to the notion that the effect of GAS
cytolysins is strongly concentration dependent, and that differential cytolysin
expression influences strain virulence. This concept may explain, in part, conflicting
reports of macrophage cell-death responses to GAS infection. A phagocytosisindependent, pro-inflammatory macrophage phenotype consistent with oncosis was
reported by Goldmann et al., driven by cytolysin mediated loss of mitochondrial
membrane potential (ψm), ROS production and calpain activation (Goldmann et al.,
2009). Conversely, the work of Timmer et al. found that cytolysin expression by
phagocytosed GAS also depolarises macrophage ψm, however leads to downstream
caspase activation and initiation of the apoptotic cascade (Timmer et al., 2009).
Macrophages are principally responsible for the clearance of apoptotic PMNs, and
either apoptotic or oncotic depletion may exacerbate damage resulting from GASinduced cell death (Silva, 2011). Apoptotic PMNs not cleared by macrophages
eventually lose cell membrane integrity, proceeding to secondary necrosis and
elicitation of inflammatory responses. (Silva, 2010). These data support an emerging
theme in bacterial pathogenesis, whereby direct manipulation of phagocyte cell-death
responses contributes to the level of inflammation during disease (Fig. 1.6) (Kennedy
and DeLeo, 2009). Programmed cell-death of other leukocyte populations in addition to
PMNs has also been described, as GAS infection of DCs induces dendritic maturation,
however the expression of SLO by intracellular bacteria, diverts DCs towards apoptosis
(Cortes and Wessels, 2009).
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Fig. 1.6 Proposed model of PMN cell-death responses to GAS infection. Upon migration
to sites of GAS infection, PMNs degranulate and generate intracellular ROS to kill
phagocytosed bacteria. Under non-pathophysiological conditions, this leads to phagocytosis
induced cell death (PICD) and a state of apoptotic torpor of the PMN (1). Apoptotic PMNs have
diminished inflammatory capacity and expose specific receptors, triggering secondaryphagocytosis of the apoptotic PMNs by mononuclear phagocytes (termed efferocytosis) (2).
Efferocytosis by macrophages promotes anti-inflammatory mediator release and a proresolution phenotype, restoring tissue homeostasis. This system is perverted by GAS at
multiple levels. GAS cytolysins directly induce PMN necrosis, presumably preceded by an
oncotic intermediate step (3). GAS cytolysins can also induce macrophage oncosis or
apoptosis (4). Multiple reports also indicate GAS triggers a rapid, pathophysiological PMN
apoptotic mechanism, which may lead to secondary necrosis exacerbated by apoptotic/oncotic
macrophage depletion, however this remains to be conclusively tested (5). PMN and
macrophage necrosis triggers uncontrolled intracellular damage associated molecular patterns
(DAMPs) and granule component release, and subsequent induction of hyper-inflammatory
responses.

1.5.8

Epithelial cell apoptotic responses

Epithelial cells mediate the first interactions between host and bacteria. Adherence of
GAS to epithelial receptors frequently precedes intracellular invasion of this bacterium
(Nitsche-Schmitz et al., 2007), and multiple pathways of epithelial cell death have been
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reported following GAS infection (Fig. 1.7A). GAS infection of A549 and HEp-2 cells
was found to elicit morphological changes consistent with apoptosis, attributable to the
activity of GAS cysteine protease SpeB (Tsai et al., 1999). The apoptotic Fas receptor
(FasR) and αvβ3 integrins are able to bind SpeB, leading to downstream caspase-8
activation and translocation of truncated-Bid (tBid) and Bax to mitochondria (Tsai et al.,
2004; Tsai et al., 2008). Binding of SpeB to host receptors also upregulates caspase-8
and Bax via JAK-STAT, p38 and p53 signalling (Chang et al., 2009; Lee and Chang,
2010). Internalisation dependent epithelial cell apoptosis in response to GAS infection
has also been reported, whereby fibronectin-mediated binding of GAS to host integrins
triggers actin rearrangement and Rac1 activation (Aikawa et al., 2010; Nakagawa et
al., 2001). Rac1 activation is hypothesised to mediate epithelial cell ROS production,
leading to downstream apoptotic responses (Aikawa et al., 2010; Nakagawa et al.,
2001). A third pathway trigged by extracellular GAS also elicits epithelial apoptosis via
an SLO-dependent mechanism (Cywes Bentley et al., 2005). Secretion of SLO by
encapsulated GAS triggers calcium flux into the cytosol of infected cells, leading to
vacuolisation of the endoplasmic reticulum and cell apoptosis (Cywes Bentley et al.,
2005). Central to these pathways is the role of the mitochondria, as cytochrome c
release and ψm depolarisation are described as key events, and that overexpression of
the anti-apoptotic factor Bcl-2 can inhibit mitochondrial dysfunction. In many studies,
both capase-9 and caspase-3 are reported to mediate the final apoptotic cascade.
Transcriptional analyses of epithelial cells also indicate overall apoptotic responses to
GAS infection, and that GAS elicits upregulation of caspases and calcium regulators
(Klenk et al., 2005; Nakagawa et al., 2004b). It is important to note that different GAS
serotypes do not elicit uniform epithelial responses, and comparison of apoptotic
induction by disparate GAS strains demonstrates multiple caspases are utilised (Klenk
et al., 2007).
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Fig. 1.7 Epithelial cellular responses to GAS infection. A GAS-induced apoptosis of
epithelial cells is triggered via intrinsic and extrinsic pathways. SpeB binding to epithelial αvβ3
integrins or the Fas receptor (FasR) triggers upregulation of caspase-8 (casp-8) via JAK2,
p38, p53 and STAT1 signalling. Procaspase-8 (pro-casp-8) is also activated directly due to
FasR signalling, leading to truncation of cytosolic Bid (tBid) and translocation of tBid to the
mitochondria. Extracellular GAS binding to host integrins is enabled via bridging molecules
such as fibronectin (Fn), and enables Rac1-mediated internalisation of GAS into host
epithelial cells. GAS internalisation and Rac1 activation facilitate production of ROS, leading
to increased p38 phosphorylation. Encapsulated extracellular GAS are not internalised by
epithelial cells and secrete the pore-forming toxin SLO. Integration of SLO into host cell
membranes triggers net calcium (Ca++) flux into the cytosol and endoplasmic reticulum (ER)
stress. All three pathways elicit loss of ψm and release of cytochrome C from the
mitochondria, which precedes activation of caspase-9 (casp-9) and caspase-3 (casp-3) and
apoptosis. Overexpression of the anti-apoptotic factor Bcl-2 by the host can inhibit epithelial
cell apoptosis. B GAS evades xenophagic killing by epithelial cells. GAS binding to the CD46
receptor is an early signal to activate autophagic responses, and GAS are uptaken into early
endosomes in a Rab5-dependent manner, however SLO expression allows GAS to escape
from endosomes into the cytosol. GAS exposure to the cytosol is recognised via ubiquitin
(Ub) adapter proteins that, in conjunction with Rab7 and Rab23, facilitate shuttling of GAS
into GcAVs bearing the classic autophagy LC3 marker. In the absence of SLO, streptolysin S
is sufficient to damage endosomal vacuoles for targeting to GcAVs by Ub-independent,
galectin-8-mediated autophagy. Lysosomal fusion with GcAVs, via Rab7 and Rab9a, effects
xenophagic destruction of intracellular GAS. Expression of SpeB by cytosolic GAS degrades
Ub adapter proteins and prevents targeting of bacteria to GcAVs, enhancing intracellular GAS
survival. Secretion of GAS NADase also protects GAS from xenophagic killing by inhibiting
fusion of GcAVs with lysosomes.

1.5.9

GAS-induced autophagy

Epithelial cell apoptosis has been suggested to protect host cells from infection,
however data validating this hypothesis is lacking, and contention exists regarding
whether epithelial apoptotic cell death is indeed a protective host response, or a
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pathogenic mechanism utilised by GAS (Aikawa et al., 2010; Cywes Bentley et al.,
2005). An alternative epithelial cell defence mechanism against GAS infection has
been recently described. Autophagy, a stress response wherein damaged cellular
components are targeted to degradative endosomal vacuoles, can protect cells from
intracellular GAS (Fig. 1.7B). HeLa cells containing intracellular M6 serotype GAS
recognise cytosol-exposed bacteria and target them for autophagic degradation via
ubiquitinylation, LC3 labelling and the formation of GAS-containing autophagosomelike vacuoles (GcAVs) (Nakagawa et al., 2004a). Expression of SLO by intracellular
GAS is crucial for GAS escape from endosomes into the cytosol and subsequent
targeting to GcAVs (Nakagawa et al., 2004a). Binding of the cell surface CD46 receptor
is an early trigger of GAS-mediated autophagy (Joubert et al., 2009). The Rab-family of
G-proteins is responsible for multiple aspects of GcAV formation. Rab7 protein
performs numerous roles, including targeting of GAS to GcAVs and initial GcAV
formation; and autophagosomal maturation (Yamaguchi et al., 2009). Other Rabenzymes; Rab5, Rab23, and Rab9a; also play distinct roles which include facilitating
GAS uptake into endosomes, targeting of GAS to GcAVs, homotypic fusion of nascent
GcAVs, and autophagosomal maturation (Nozawa et al., 2012; Sakurai et al., 2010).
Recent studies report that GAS is able to subvert autophagy-mediated bacterial
destruction

(also

called

xenophagy)

for

intracellular

survival.

SLO-mediated

translocation of GAS NAD-glycohydrolase (NADase) prevents efficient killing of
serotype M6 GAS via inhibition of autophagosomal fusion with lysosomes (O'Seaghdha
and Wessels, 2013). A novel, ubiquitin-independent pathway of GcAV formation was
also described for primary human keratinocytes in this study. Ubiquitin-independent
GcAV formation was mediated through SLS damage to endosomal vacuoles, leading to
endosomal labelling with galectin-8, and acquisition of the autophagy specific LC3
marker (O'Seaghdha and Wessels, 2013). Infection of HEp-2 cells with M1T1 serotype
GAS reveals significantly greater intracellular survival than by M6 GAS, with M1T1
GAS displaying exposure to the cell cytosol but lack of the LC3 autophagy marker
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(Barnett et al., 2013). Enhanced M1T1 GAS survival was found to be directly linked to
SpeB activity, which degrades cytosolic ubiquitin and the adapter proteins NDP52, p62
and NBR1, to effect highly efficient evasion of cellular xenophagy (Barnett et al., 2013).
1.6

GAS virulence factors bestowing innate immune resistance

GAS expresses multiple virulence factors capable of countering innate immune
responses by diverse mechanisms (Fig. 1.8). Strategies of innate immune resistance
and neutrophil evasion utilised by GAS include suppression of immune surveillance,
interference with complement function, inhibition of antibody-mediated opsonisation,
induction of phagolysis and degradation of NETs (Kwinn and Nizet, 2007).

Fig. 1.8 Diverse mechanisms by which GAS circumvents elements of the innate immune
response. Chemokine recruitment of polymorphonuclear leukocytes (PMNs) by C5a and
interleukin-8 (IL-8) is inhibited by streptococcal C5a (ScpA) and streptococcal cell envelope
(SpyCEP/ScpC) peptidases. Deposition of opsonising complement fragment C3b, C4-binding
protein (C4BP) and complement factor H is blocked by M protein binding. Interaction of
opsonins with host phagocyte complement receptors is cloaked by hyaluronic acid capsule and
M protein bound fibrinogen, fibronectin and plasminogen. Immunoglobulins (Igs) are
nonopsonically bound by Protein H and M protein, with cysteine protease SpeB, endopeptidase
S and Mac-1/2 proteolytically cleaving Igs. streptococcal inhibitor of complement (SIC) inhibits
phagocytosis by preventing formation of the membrane-attack complex (MAC) and inactivates
cathelicidin LL-37 and neutrophil α-defensins. PMNs are lysed by the cytotoxins Streptolysin O
and S (SLO and SLS). Neutrophil extracellular traps (NETs) are degraded by phage-encoded
streptodornase 1 (Sda1). Reproduced from (Nizet, 2007).
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1.6.1

M proteins and M-like proteins

The antiphagocytic activity of group A streptococal M protein has been known for some
decades (Lancefield, 1962). However more recently, the mechanisms underlying this
activity have been ascribed to M proteins from GAS of certain serotypes that are able
to bind different host factors, some of which can interfere with immune function
(Smeesters et al., 2010). It has been shown that GAS M protein binds alternative
complement pathway factor H, which regulates alternative pathway complement
activity by binding fluid-phase and cell surface C3b (Horstmann et al., 1988). M protein
also modulates the classic complement pathway immune responses via binding to
C4b-binding protein (C4BP) (Johnsson et al., 1996). M protein contributes to the
intracellular survival of GAS within phagocytes by inhibiting neutrophil azurophilic
granule-phagosome fusion (Staali et al., 2006; Staali et al., 2003). M1 protein also
promotes resistance to LL-37 when ensnared in PMN NETs, via binding of LL-37 to the
M1 hypervariable region (Lauth et al., 2009). M protein-family proteins such as Mrp and
Enn are structurally similar to M protein as α-helical, coiled coil dimeric fibrils and also
exhibit diverse binding ligands, including fibrinogen. Both M1 protein and Mrp can bind
fibrinogen to the GAS cell surface, which interferes with complement deposition, and
many Enn proteins can also bind IgA (Courtney et al., 2006; Podbielski et al., 1994).
Approximately 15% of GAS express PAM (plasminogen-binding group A streptococcal
M protein) proteins through which GAS are able to affect high-affinity plasminogen
binding through specific M protein domains (Berge and Sjobring, 1993; Svensson et al.,
1999). Recent work has described a new role for GAS plasminogen binding in relation
to GAS innate immune evasion, as bound plasminogen reduces C3b binding to the
bacterial cell surface and protects GAS from neutrophil killing (Ly et al., 2013).
1.6.2

Hyaluronic acid capsule

GAS expresses a capsule composed of hyaluronic acid, a high molecular weight
polymer of alternating residues of N-acetylglucosamine and glucouronic acid (Wessels
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et al., 1991). The genes encoding for capsule production are contained within the
hasABC gene cluster, though hasAB alone is sufficient for capsule synthesis
(Ashbaugh et al., 1998). The hyaluronic acid capsule aids GAS evasion of innate
immune responses via resistance to phagocytosis. It is hypothesised that the capsule
serves as a physical barrier to phagocytosis, as complement deposited on the GAS cell
surface is unable to interact with phagocytic receptors (Dale et al., 1996). Acapsular
GAS mutants show decreased virulence compared to encapsulated strains in murine
infection models (Wessels and Bronze, 1994). Highly upregulated expression of the
has operon has been noted in response to animal passage through mice (Sumby et al.,
2006). The capsule has also been shown to inhibit internalisation of GAS by epithelial
keratinocytes (Schrager et al., 1996).
1.6.3

Streptococcal inhibitor of complement

Deposition of complement on bacterial cell surfaces promotes opsonisation and
phagocytosis by innate immune cells. Streptococcal inhibitor of complement-mediated
lysis protein (SIC) contributes to antiphagocytic activity by interfering with both the
classical and alternative complement pathways in the formation of the MAC (Akesson
et al., 1996). SIC protein binds to the C5b67 and C5b678 complexes, preventing
uptake onto cell membranes and subsequent lysis (Fernie-King et al., 2001).
Inactivation of the sic gene results in a significant reduction of mucosal surface
colonisation by GAS, demonstrating that SIC enhances the colonising ability of
infecting GAS strains (Lukomski et al., 2000a). This hypothesis is supported by
evidence that SIC is able to inhibit secretory leukocyte proteinase inhibitor, lysozyme,
α-defensin and LL-37 (Fernie-King et al., 2002; Frick et al., 2003).
1.6.4

Modification of teichoic acid on the GAS cell surface

Most Gram-positive bacteria incorporate LTA into the cell-wall in order to maintain cellwall shape and regulate autolytic enzyme activity. In GAS, LTA can be modified via D29

alanylation, increasing the net positive charge of the bacterial cell-surface via a Dalanine-D-alanyl carrier protein ligase (DltA) (Kristian et al., 2005). Manipulation of the
net charge of the bacterial cell surface by GAS allows this pathogen to resist
polycationic AMPs such as murine cathlicidin CRAMP and polymyxin B via electrostatic repulsion and thus increase antiphagocytic activity (Kristian et al., 2005). Dalanylation of GAS LTA also affects the transcription and expression of other virulence
factors such as M protein and SIC via unknown mechanisms, resulting in decreased
complement deposition and higher growth rates in human blood (Cox et al., 2009).
1.6.5

S. pyogenes cell envelope proteinase

Impairment of phagocyte recruitment by GAS indirectly hampers the innate immune
response by crippling immune surveillance mechanisms. Previous work by HidalgoGrass et al. isolated GAS from necrotic tissue that expressed an unidentified protease
capable of inhibiting neutrophil recruitment to the site of infection (Hidalgo-Grass et al.,
2004). This activity was later linked to S. pyogenes cell envelope proteinase (SpyCEP,
also known as ScpC). SpyCEP promotes specific cleavage of the potent neutrophil
chemokine IL-8, and strains lacking SpyCEP exhibit attenuated virulence in murine
infection models (Edwards et al., 2005; Hidalgo-Grass et al., 2006). SpyCEP has also
been shown to degrade other chemokines, including granulocyte chemotactic protein 2
and growth-related oncogene alpha, both of which are produced abundantly by human
tonsillar epithelial cells (Sumby et al., 2008).
1.6.6

Streptococcal C5a peptidase

The surface bound GAS virulence factor, Streptococcal C5a peptidase (ScpA) is a
highly specific endopeptidase that inactivates C5a via the cleavage of six amino acids
from the C terminus (Cleary et al., 1992; Fernandez and Hugli, 1978; O'Connor and
Cleary, 1986). ScpA inhibits the phagocytic clearance of GAS, as ScpA-deficient GAS
mutants elicit significantly increased PMN recruitment during infection (Ji et al., 1996).
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Immunisation of mice with an enzymatically inactive peptide of serotype M49 ScpA
reduced the potential of multiple serotypes to colonise the nasopharynx, presenting a
possible candidate for vaccine development (Ji et al., 1997).
1.6.7

Streptococcal Mac-1-like protein

Screening of the GAS secreted proteome by Lei et al. identified a GAS protein bearing
23% amino acid identity between amino acids E319 and V391 to the α-subunit of
human leukocyte adhesion receptor Mac-1, a leukocyte β2 integrin involved in innate
immunity (Lei et al., 2000). Expression of the Mac-1-like protein is regulated via the
control of virulence regulatory sensor kinase (covRS) system (Sumby et al., 2006). This
protein

binds

CD16

(FcγRIIIB)

receptor

on

human

PMNs,

inhibiting

opsonophagocytosis by blocking association of C3bi and antibodies with CD16 (Lei et
al., 2001). The antiphagocytic activity of Mac-1-like protein (also known as
immunoglobulin G-degrading enzyme of S. pyogenes, IdeS) is also attributed to
cysteine proteolytic, IgG-specific degradation (von Pawel-Rammingen et al., 2002). A
variant of the Mac-1-like protein, designated Mac-2, has also been identified. Mac-2
contains ~50% sequence divergence in the central third of the molecule, and inhibits
the host immune response through strong binding to both FcγRII and FcγRIII receptors
(Agniswamy et al., 2004; Lei et al., 2002).
1.6.8

Streptolysins

Induction of neutrophil lysis is an important mechanism of GAS innate immune evasion,
accomplished by the expression of cytolytic toxins. SLO secreted by GAS interacts with
cholesterol in eukaryotic cell membranes, producing multi-subunit, transmembrane
pores, which lead to cell death (Limbago et al., 2000). A non-homologous, but
functionally related haemolysin, SLS is also responsible for the cytolytic killing of
mammalian cells by opening transmembrane pores that result in subsequent osmotic
cell lysis, and is responsible for the typical β-haemolysis of GAS colonies on blood agar
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(Betschel et al., 1998; Datta et al., 2005). Isogenic single and double SLS and SLO
mutants have been used to show that each streptolysin may complement the role of
the other with some degree of functional redundancy (Fontaine et al., 2003).
Expression of either streptolysin was also found to enhance the virulence of acapsular
GAS, protecting more susceptible bacteria from phagocytic clearance (Sierig et al.,
2003).
1.6.9

Streptococcal collagen-like proteins

The Streptococcal collagen-like protein A (SclA) protein contains a collagen-like
domain composed of Gly-X-X triplet amino acid motifs (Lukomski et al., 2000b;
Rasmussen et al., 2000). Immune selection is suggested to have contributed to the
evolution of the collagen-like domain of SclA, as it exhibits hypervariability analogous to
M-protein, and phylogenetic analyses suggest that horizontal gene transfer of the sclA
allele has occurred between multiple M serotypes (Lukomski et al., 2000b; Rasmussen
et al., 2000). The putative collagen-like triple-helix structure of SclA has been
confirmed experimentally, and a plethora of functions have been assigned (Xu et al.,
2002). SclA interacts with mammalian collagen-binding integrin α2β1 specifically
through the collagen-like region, which also enables GAS intracellular invasion, survival
and re-emergence from human pharyngeal epithelial cells (Caswell et al., 2007;
Humtsoe et al., 2005). SclA binds low-density lipoproteins through the variable noncollagenous V region (Han et al., 2006) and thrombin-activatable fibrinolysis inhibitor,
which is capable of inactivating complement C3a and C5a and neutrophil chemoattractant fibrinopeptide B (Pahlman et al., 2007). Recently, it has been indicated that
SclA

may

play

a

role

in

mediating

alternative

complement-mediated

opsonophagocytosis through binding regulatory glycoprotein factor H and factor Hrelated protein 1 (Caswell et al., 2008). Initial characterisation of sclA showed that it is
distally controlled by the Mga regulon (Almengor and McIver, 2004), however mutation
of M1T1 covRS also results in up-regulated sclA expression (Sumby et al., 2006).
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1.6.10 Cysteine protease SpeB
Group A streptococci express a cysteine protease, SpeB (also known as SCP or
streptopain), which has been shown to play a dynamic role in the GAS pathogenesis
cycle. SpeB is an extracellular protein, secreted through the ExPortal microdomain as a
40 kDa zymogen (Rosch and Caparon, 2004), which auto-catalytically truncates to a
mature 28 kDa peptide. SpeB has also been characterised as cell surface associated
(Hytonen et al., 2001). SpeB has a range of effects on host factors, including the
activation of human IL-1β (Kapur et al., 1993); the release of kinins via cleavage of
kininogens (Herwald et al., 1996); activation of cell matrix metalloproteases (Burns et
al., 1996); degradation of LL-37 and IgA, IgM, IgD and IgE (Collin and Olsen, 2003;
Schmidtchen et al., 2002) and specific cleavage of the IgG hinge region (Collin and
Olsen, 2001). Many surface bound and extracellular GAS virulence factors are also
processed by SpeB, including M protein and protein H, fragments which were detected
following SpeB treatment of live GAS cells (Berge and Bjorck, 1995), in addition to
proteolysing streptococcal superantigens, streptodornase and streptokinase (Aziz et
al., 2004b; Rezcallah et al., 2004). Biologically active fragments of C5a peptidase are
liberated from the GAS cell surface by SpeB, which may contribute to virulence via
inhibition of phagocyte recruitment (Berge and Bjorck, 1995). However, conflicting
evidence of the role of SpeB in virulence has been observed. Multiple studies implicate
SpeB as critical for severe infection and dissemination (Berge and Bjorck, 1995;
Lukomski et al., 1998), in contrast to epidemiological evidence that SpeB expression is
inversely proportional to the severity of GAS diseases (Kansal et al., 2000), or that
SpeB in fact, has no effect on invasive streptococcal infection (Ashbaugh and Wessels,
2001). Recent studies utilising more physiologically relevant mouse models suggest
that expression of SpeB promotes bacterial colonisation, whilst the loss of SpeB
expression triggers a ‘switch’ in pathogenesis to favour bacterial dissemination and
invasive infection (Cole et al., 2006; Walker et al., 2007).
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1.6.11 Streptodornases
GAS expresses four classes (subgroups A-D) of streptococcal extracellular nucleases
known as streptodornases (Sda). Streptodornases are predominantly phage-acquired,
and are characterised by their optimal pH and nature of substrate (DNA, RNA or both)
(Wannamaker and Yasmineh, 1967; Winter and Bernheimer, 1964). Aziz et al.
identified a streptodornase D homologue in M1T1 serotype GAS, designated Sda1
(Aziz et al., 2004a). Sda1 shares two conserved domains with other extracellular
nucleases and ~90% amino acid identity to SdaD but with a unique C-terminus. Sda1
is presumed to have been acquired by GAS via phage-mediated lateral gene transfer,
as the sda1 gene is located near a putative prophage attachment point, and is absent
in closely related GAS strains (Aziz et al., 2004a). The importance of Sda1 in virulence
was established by the work of Buchanan et al. in which Sda1 was implicated in
neutrophil resistance through degradation of NETs (Buchanan et al., 2006). Increased
virulence was noted in strains expressing Sda1 compared to Sda1-deficient isogenic
mutants in murine infection models (Buchanan et al., 2006).
1.7

Molecular basis for invasive GAS disease

1.7.1

Subversion of the host plasmin(ogen) activation system

Following host colonisation and evasion of early innate immune response, particularly
invasive GAS strains or subpopulations can penetrate deeper tissues within the host,
effectively transitioning from a mild to an invasive infection. The accumulation of host
plasmin activity on the GAS cell surface has been associated with the development of
invasive disease (Cole et al., 2006). Plasminogen circulates in human plasma as an
inactive zymogen, and is activated via cleavage by the host tissue-plasminogen
activator (tPA) or urokinase-plasminogen activator (uPA) to plasmin. Activated plasmin
is a highly potent serine protease capable of proteolysing multiple host ECM
components and fibrin blood clots (Plow et al., 1995). Subversion of the plasminogen
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system by GAS occurs via the non-enzymatic activation of plasminogen through direct
binding by secreted streptokinase (McArthur et al., 2012). Bacterial cell-surface
sequestration of plasmin(ogen), or the activated plasmin(ogen)-streptokinase complex
is mediated by GAS plasmin(ogen) receptors PAM, streptococcal surface enolase
(SEN) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Svensson et al.,
2002; Walker et al., 2005). Indirect plasmin(ogen) cell-surface sequestration also
occurs via the formation of a streptokinase-plasminogen-fibrinogen trimolecular
complex, which also retains plasmin activity and can be bound to the GAS cell-surface
through fibrinogen receptors such as Mrp (D'Costa and Boyle, 1998; Wang et al.,
1995). Activated human plasmin bound to the GAS cell-surface is capable of degrading
fibrin clots and opening a channel for GAS to invade sterile tissue sites and cause
invasive disease (Sun et al., 2004; Walker et al., 2005).
1.7.2

Two-component regulatory systems determining GAS virulence

Expression of GAS virulence determinants is regulated by individual transcription
factors and more broadly active regulatory systems, such as the multiple gene
regulator in group A streptococci (Mga) and RopB/Rgg (Chaussee et al., 2003;
Cunningham, 2000). GAS also encode twelve two-component gene regulatory
systems, of which several have been characterised, including sptRS, Ihk-Irr, and
covRS (Shelburne et al., 2005; Sitkiewicz and Musser, 2006; Sumby et al., 2006;
Voyich et al., 2004). The products of the covRS operon repress expression of multiple
virulence genes involved in resistance to innate immune responses and tissue
invasion, including ska (streptokinase), slo, the has operon, scpA, sda1, mac, spyCEP
and sic (Sumby et al., 2006). Conversely, mutations in covRS result in the upregulation of these factors, and abolish cysteine protease SpeB expression. It has been
shown that spontaneous covRS mutations acquired in vivo result in increased
resistance to killing by human PMNs by M1T1 GAS (Sumby et al., 2006) and that
concurrent loss of speB expression protects the secreted proteome, including immune35

modulating virulence factors of M1T1 GAS, from degradation (Aziz et al., 2004b).
Therefore, it has been proposed that mutation of the covRS system represents a
genetic trigger which enhances GAS innate immune resistance and invasive potential
(Walker et al., 2007).
1.7.3

Invasive disease initiation of serotype M1T1

The acquisition of covRS mutation in M1T1 GAS has been studied extensively, with
studies elucidating that the phage-encoded Sda D2 homologue, Sda1 is critical for the
selection of spontaneous covRS mutants during infection (Walker et al., 2007). In the
model proposed by Walker et al., infecting M1T1 GAS express SpeB during the early
stages of host colonisation, and attract neutrophils which release NETs to impede
bacterial dissemination (Fig. 1.9A). However, a subpopulation of GAS acquire a
mutation in covRS, resulting in the simultaneous up-regulation of secreted immune
modulating virulence factors including Sda1 and abolition of SpeB activity, sparing
these cell-surface and secreted virulence factors from degradation (Fig. 1.9A).
Pressure applied by NETS results in selection of the SpeB-negative phenotype due to
increased Sda1 activity, allowing the covRS-mutant subpopulation to proliferate and
acquire cell-surface plasmin activity through streptokinase-mediated plasminogen
activation and acquisition via GAS cell-surface receptors (Fig. 1.9C). Consequently,
M1T1 GAS selected for by this mechanism acquire a hypervirulent phenotype which
enables both evasion of the innate immune response and the initiation of invasive,
systemic diseases in the host (Fig. 1.9D). This model accounts for the virulence of the
invasive clone of serotype M1T1, however not for the virulence of isolates of other
serotypes which lack phage-encoded virulence factors such as Sda1. Recent work by
Maamary et al. demonstrates that mutations in covRS occur in a range of GAS
serotypes, and result in a unanimous increase in virulence and resistance to PMNkilling (Maamary et al., 2010). In corroboration, other ubiquitously distributed GAS
virulence factors such as M protein and capsule have been shown as critical for
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acquisition of covRS mutations (Cole et al., 2010). However, the ability of M1T1 GAS to
acquire covRS mutations more frequently may underlie the success of this globally
disseminated serotype relative to other GAS strains (Maamary et al., 2010; Maamary et
al., 2012). Mutation of M1T1 covRS upregulates a cohort of genes responsible for
innate immune resistance and initiation of invasive disease, but this increase in
virulence is counterbalanced by simultaneous detriment to colonisation ability, as
upregulation of capsule via covRS mutation impairs M1T1 GAS adherence to HEp-2
cells and biofilm formation (Hollands et al., 2010). Thus, while the molecular
mechanisms coordinating M1T1 GAS virulence and innate immune interactions have
been precisely described, further work is required to detail these aspects of non-M1T1
GAS pathogenesis.

Fig. 1.9 Transition of a mild to invasive infection by group A streptococcus (GAS). A)
GAS (blue) enter through a break in the epidermis and express cysteine protease SpeB (red)
to aid in host colonisation. Neutrophils are recruited to the site of infection and release
extracellular traps (NETs) which ensnare the bacteria. B) A subpopulation of GAS (green)
acquire a mutation in the covRS regulon, resulting in downregulation of SpeB and increased
activity of streptodornase 1 (Sda1). C) GAS covRS mutants with enhanced Sda1 activity are
able to degrade NETs, giving an advantage over the SpeB-expressing phenotype. D) Loss of
SpeB expression leads to the acquisition of cell surface plasmin activity, giving GAS enhanced
invasive propensity and potential for dissemination. Reproduced from Walker et al. (2007).
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1.8

Project aims

Resurgences in the rates of severe GAS diseases in urbanised areas emphasise the
importance of understanding the fundamental mechanisms by which GAS initiate
invasive infections. Whilst the molecular triggers for invasive disease initiation by the
M1T1 serotype, a serotype which is prevalent in urbanised areas, have been recently
uncovered, a dearth of knowledge remains regarding pathogenesis of serotypes from
areas with more diverse epidemiology of infection. Resistance to the innate immune
response is integral for the bacterium to survive and elicit severe infection. As such, indepth analysis of non-M1 GAS interactions with the innate immune effectors, such as
PMNs, will provide insight into the mechanisms that guide bacterial persistence and
host responses in a less urbanised context. The clinical bacteraemia isolate NS88.2
(emm98.1) was isolated from Australia’s Northern Territory, and exhibits virulent,
neutrophil resistant phenotypes that make it a suitable representative strain to model
emergent, virulent GAS isolates.
Thus, the specific aims of this study were to:


Conduct genomic screening analysis of the virulent GAS isolate NS88.2, to
identify virulence factors with putative roles in mediating PMN interactions.



Utilise this genomic sequence to assist transcriptomic and proteomic
interrogation of NS88.2 and support previous genomic analyses.



Isogenically delete candidate virulence factors from NS88.2 and characterise
the ability of mutant knock-out strains to resist innate immune killing.



Determine differential PMN responses to infection by both PMN-resistant and
PMN-sensitive GAS.

The results of this study describe in greater detail novel factors and pathways dictating
both pathogen- and host-oriented interactions in the non-M1T1 GAS background.
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CHAPTER 2: GENERAL MATERIALS AND METHODS

This chapter contains methods used during this project by the candidate. Other
methods used by co-authors for publications are detailed in the relevant research
chapters and are available in publications at the end of this thesis. Full details of all
general buffer components are listed in Appendix A.
2.1

Bacterial strains, plasmids and growth conditions

Bacterial strains and plasmids utilised in this study are listed in Table 2.1. Except
where otherwise noted, all GAS strains were routinely cultured at 37°C on solid horse
blood agar (HBA) (Oxoid, UK), Todd-Hewitt agar (THYA) (Difco, Australia) or in liquid
cultures of 1% (w/v) yeast-supplemented Todd-Hewitt broth (THY) (Difco, Australia).
GAS containing pDCerm or derivative constructs were cultured in static THY cultures
supplemented with 2 µg/ml erythromycin. Escherichia coli strains were cultured at 37°C
on solid lysogeny-broth (LB) agar or liquid LB supplemented with appropriate antibiotic.
2.2

Bacterial transformation

2.2.1

Preparation of electro-competent Escherichia coli

A single colony of each E. coli strain to be made competent was inoculated into 100 ml
of LB broth followed by subsequent overnight culture at 37°C with shaking at 200 rpm.
Each culture was expanded to 1 L of LB, and incubated at 37°C with shaking at 200
rpm until reaching OD600: 0.8. Cultures were harvested via centrifugation (4,650 x g, 10
min, 4°C) and supernatants decanted prior to resuspension in 200 ml of cold sterile
dH2O. Cell resuspensions were pelleted (6,690 x g, 10 min, 4°C), and the previous
washing step repeated twice with 100 ml of cold sterile H2O. After washing, cell pellets
were resuspended in 4 ml of cold sterile 10% glycerol and re-pelleted (3,020 x g, 10
min, 4°C). Supernatants were decanted, and sufficient cold sterile 10% glycerol used to
resuspend cell pellets prior to storage at -80°C
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Table 2.1 Bacterial strain and plasmids utilised in this study.
Bacterial strain
Features
or plasmid
Streptococcus pyogenes
NS88.2
Invasive blood isolate. emm98.1, emm pattern D, encodes an
inactivating point mutation in base number 1585 of the covS
gene.
NS88.2rep
NS88.2 derivative strain with the inactivating point mutation in
covS repaired to restore covRS functionality
NS88.2covS
NS88.2rep derivative strain with covS reverse complemented
by allelic exchange, re-inactivating covS
NS88.2 (eGFP)
NS88.2 derivative expressing eGFP via pDCerm
NS88.2rep
NS88.2rep derivative expressing eGFP via pDCerm
(eGFP)
NS88.2∆sclA
NS88.2 derivative with sclA replaced with cat via allelic
exchange
NS88.2∆gls24
NS88.2 derivative with gls24 replaced with cat via allelic
exchange
NS88.2∆sclA
NS88.2∆sclA derivative with the sclA deficiency
(pDC-sclA)
complemented via heterologous expression in pDCerm
NS88.2∆gls24 derivative with the gls24 deficiency
NS88.2∆gls24
(pDC-gls24)
complemented via heterologous expression in pDCerm
Escherichia coli
JM109
endA1 glnV44 thi-1 relA1 gyrA96 recA1 mcrB+ ∆(lac-proAB)
e14- [F' traD36 proAB+ lacIq lacZ∆M15]
M15 (pREP4)
His-tagged protein expression strain
DH5α
F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG
Φ80dlacZ∆M15 ∆(lacZYA-argF)U169 hsdR17(rK- mK+)
r
Tetr ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 supE44
XL10-Gold Kan
ultra-competent
thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB lacIqZ∆M15 Tn10
cells
(Tetr) Tn5 (Kanr) Amy]
F- mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacΧ74
TOP10
chemically
recA1 araD139 ∆(araleu) 7697 galU galK rpsL (StrR) endA1
competent cells
nupG
Plasmids
pPCR-Script
Apr, pUC origin, lac promoter, lacZ’, T7 promoter,
pQE-30
Apr, ColE1 origin, 6xHis affinity tag, T5 promoter, t0 and T1
transcriptional terminators
pCR2.1-TOPO
Apr, Kmr, pUC origin, lac promoter, lacZα, T7 transcription
promoter site.
r
pDCerm
Erm , phoZ, gram-positive origin of replication
pHY304-LIC
Ermr, Cmr, temperature sensitive replication protein repB,
ccdB encoded toxin
r
pHSG398
Cm , lacZ
pPCR-gls24
pQE-gls24
pCR-gls24
pCR-sclA
pDC-gls24
pDC-sclA
pHY-∆gls24
pHY-∆sclA

pPCR-Script derivative containing NS88.2 gls24 coding
sequence
pQE-30 derivative containing NS88.2 gls24 coding sequence
pCR2.1 derivative containing NS88.2 gls24 coding sequence
pCR2.1 derivative containing NS88.2 sclA coding sequence
pDCerm derivative containing NS88.2 gls24 coding sequence
pDCerm derivative containing NS88.2 sclA coding sequence
pHY304-LIC derivative containing a cat fusion with 250 bp
NS88.2 gls24 genomic flanking regions
pHY304-LIC derivative containing a cat fusion with 250 bp
NS88.2 sclA genomic flanking regions

Reference or
Source
Maamary et al.,
2010; McKay et
al., 2004
Maamary et al.,
2010
Maamary et al.,
2010
Ly et al., 2014
This study
This study
This study
This study
This study
Lab stock
Lab stock
Lab stock
Agilent, USA
Invitrogen, USA

Agilent, USA
Qiagen, USA
Qiagen, USA
Jeng et al. 2003
Cook et al. 2012
Takeshita et al.
1987
This study
This study
This study
This study
This study
This study
This study
This study
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2.2.2

Preparation of chemically-competent Escherichia coli

Single colonies of E. coli strains to be made competent were inoculated into 10 ml of
LB, and cultured overnight at 37°C. Starter cultures were inoculated into 225 ml of TSS
medium and grown to OD600: 0.3. Cultures were then cooled on ice for 10 min, and
centrifuged in pre-chilled sterile tubes (3000 x g, 10 min, 4°C). Excess media was
decanted and cell pellets resuspended in 5 ml of TSS medium, of which 200 µl aliquots
were snap frozen in liquid nitrogen and stored at -80°C.
2.2.3

Preparation of electro-competent GAS

Single colonies of S. pyogenes strains to be made competent were inoculated into 5 ml
of THY, and cultured overnight at 37°C. Two millilitre volumes of overnight cultures
were inoculated into pre-warmed 40 ml THY cultures and grown with gentle shaking to
OD600: ~0.25, after which cells were harvested by centrifugation (5000 x g, 10 min).
Excess media was decanted and cell pellets resuspended in 5 ml of cold sterile 0.625
M sucrose. Cells were pelleted (5000 x g, 10 min) and the previous washing step
repeated twice. Cell pellets were resuspended in 300 µl of cold sterile 0.625 M sucrose,
and 50 µl aliquots used immediately for transformations.
2.2.4

Transformation of electro-competent bacteria

Electro-competent bacteria were electroporated using a Bio-Rad Gene Pulser (BioRad, USA) according to the manufacturer’s instructions. Electro-competent E. coli
(2.2.1) were gently mixed on ice with approximately 10 ng of plasmid DNA and pulsed
at 2.5 kV, 25 µFD and 200 Ω, prior to transferral to 500 µl of LB media and incubated at
30°C (pHY304-LIC based vectors) or 37°C (all other constructs) for 1 h with shaking
before plating on selective LB media. Electro-competent GAS (2.2.3) were gently
mixed on ice with 1-2 µg of plasmid DNA and pulsed at 2.5 kV, 25 µFD and 200 Ω,
prior to resuspension in 500 µl of THY media containing 0.25 M sucrose and incubated
at 30°C or 37°C for 2 h without shaking before plating on selective THYA media.
41

2.2.5

Transformation of chemically-competent Escherichia coli

Chemically competent E. coli (2.2.2) were transformed by heat shock. Frozen cell
aliquots were slowly thawed on ice and incubated with DNA ligase reactions for 30 min.
Cell were subsequently heat shocked at 42ºC for 3 min, prior to dilution in 500 μl of LB
media and incubated at either 30ºC (pHY304-derived vectors) or 37ºC (all other
vectors) for 1 h. Cells were then plated onto LB media supplemented with appropriate
antibiotics to select transformant colonies.
2.3

DNA manipulations

2.3.1

Wizard Plus SV Genomic DNA extraction

GAS genomic DNA was prepared for routine PCR using a Wizard Plus SV Genomic
DNA extraction kit (Promega, USA) according to the manufacturer’s instructions. Single
GAS colonies were inoculated into 1 ml cultures of THY media with overnight
incubation at 37°C. Planktonic GAS cells were then collected (16,000 x g, 2 min) and
supernatants discarded, prior to resuspension in 480 µl of 50 mM EDTA, with 10 mg/ml
lysozyme added and samples incubated at 37°C for 60 min to promote bacterial cell
lysis. Cell nuclei and debris were pelleted (16,000 x g, 2 min), supernatants discarded,
and resulting pellets resuspended in 600 µl of nuclei lysis solution. Samples were
incubated at 80°C for 5 min, and cooled to room temperature before 3 µl of RNase
solution was added to lysates with mixing via inversion, prior to further incubation at
37°C for 60 min. A 200 µl volume of protein precipitation solution was added to the
RNase-treated cell lysate, mixed vigorously for 20 s and incubated on ice for 5 min
before centrifugation (16,000 x g, 3 min). Supernatants were transferred to clean 1.5 ml
microcentrifuge tubes containing 600 µl of room temperature isopropanol and mixed via
gentle inversion to precipitate purified genomic DNA. DNA was collected at 16,000 x g
for 2 min, supernatants gently decanted, and DNA pellets washed with 600 µl of room
temperature 70% ethanol. After washing, samples were centrifuged (16,000 x g, 2
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min), excess ethanol aspirated, DNA pellets completely air dried and resuspended in
100 µl of DNA Rehydration Solution overnight at room temperature. Aliquots of each
sample were taken and stored at -20°C.
2.3.2

Polymerase chain reaction (PCR) conditions

Amplification of cat, gls24 and sclA coding sequences; and the flanking regions of each
gene for cloning into sub-cloning and allelic exchange vectors was conducted using
polymerase chain reaction (PCR). All PCRs were carried out using an Eppendorf
Mastercycler thermal cycler (Eppendorf, Germany). PCRs for cloning were prepared in
0.2 ml PCR tubes with reaction mixtures consisting of: 2.5 U of PfuUltra II fusion
Hotstart proof-reading DNA polymerase (Agilent, USA), 1X PfuUltra II reaction buffer
(Agilent, USA), 250 µM of each dNTP, 1 µM forward primer, 1 µM reverse primer, 70
ng template DNA, with sterile Milli-Q water made up to a final volume of 20 µl. Routine
PCR screening of E. coli and GAS transformants for cloning and allelic exchange
mutagenesis was conducted with reaction mixtures consisting of: 2 U of Mango Taq
polymerase (Bioline, Australia), 1X Mango Taq reaction buffer (Bioline, Australia), 250
µM of each dNTP, 1 µM forward primer, 1 µM reverse primer, 2 mM MgCl2, and single
bacterial colonies used as template DNA in 10 µl reactions. The thermocycling
conditions for PCR were initiated with a denaturing step of 95°C for 2 min; followed by
30 cycles of 30 sec denaturation at 95°C, 30 sec annealing at 55-60°C (2-3°C below
the minimum melting temperature for each primer pair) and 1 min 30 sec elongation at
72°C; with a final elongation step of 72°C for 3 min followed by a 4 °C hold cycle.
Details of primer sequences used for all PCRs are given in Appendix B.
2.3.3

Wizard Plus SV Gel and PCR clean up purification

Excess nucleotides, primers and restriction enzymes from PCR reactions and
restriction enzyme digestions were removed using a Wizard Plus SV Gel and PCR
Clean-up system (Promega, USA) according to the manufacturer’s instructions.
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Agarose gel slices were mixed with membrane binding solution (10 µl to 10 mg
agarose) and heated to 65°C for 10 min, or until dissolving of the gel slice occurred.
PCR mixtures or molten gel slices mixed with an equal volume of membrane binding
solution were added to SV Minicolumns, incubated at room temperature for 1 min and
bound to column membranes by centrifugation (16,000 x g, 1 min). Flow-through was
then discarded and Minicolumn membranes washed twice with 700 µl of membrane
wash solution (16,000 x g for 1 min) and 500 µl of membrane wash solution (16,000 x
g, 5 min). Minicolumns were transferred to fresh microcentrifuge tubes and membranes
dried (16,000 x g, 2 min) prior to the addition of 30 µl of nuclease-free water and
incubation at room temperature for 1 min. DNA was eluted via centrifugation (16,000 x
g, 2 min) and DNA stored at -20°C.
2.3.4

pPCRScript cloning

Cloning of gls24 into qQE-30 for recombinant protein expression and purification was
facilitated via step-wise sub-cloning into pPCR-Script (Agilent, USA). Cloning into
pPCR-Script was initiated by PCR amplification using the proof-reading polymerase
PfuUltra II as described (2.3.2), after which PCR amplicons underwent blunt-end
ligation. Amounts of PCR products to be used in ligation reactions was calculated
according to the equation ng insert DNA = bp of insert DNA x 10 ng pPCR-Script/ 2961
bp pPCR-Script. Ligation mixtures therefore contained: 10 ng pPCR-Script, 1X pPCRScript reaction buffer, 0.5 µl of 10 mM rATP, 1.5 ng of gls24 blunt-ended PCR product,
1 µl of SrfI restriction enzyme, 1 µl T4 DNA ligase and distilled H2O to a final volume of
10 µl. Ligation mixtures were mixed gently and incubated at room temperature for 1 h,
followed by incubation at 65°C for 10 min and storage on ice. Following ligation,
recombinant plasmid DNA was transformed into XL10-Gold ultra-competent cells.
XL10-Gold cells were thawed on ice, prior to gently mixing 40 µl of competent cells with
1.6 µl β-mercaptoethanol. A 2 µl volume of each ligation reaction was then mixed with
competent cell aliquots and incubated on ice for 30 min. Each transformation mixture
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was heat pulsed in a 42°C water bath for 30 s, followed by incubation on ice for 2 min.
Transformation mixtures were then resuspended in 450 µl of pre-warmed LB media
and incubated at 37°C for 1 h with gentle shaking. Following incubation, cells were
plated onto solid LB media containing 1% (v/v) X-gal-IPTG and 100 µg/ml ampicillin,
and incubated overnight at 37°C. Resulting white transformant colonies were screened
for the presence of insert DNA via alkaline lysis and agarose gel electrophoresis
(Appendix C).
2.3.5

pCR2.1-TOPO cloning

Cloning of gls24 and sclA into pDCerm for complementation of gls24 and sclA deficient
GAS was facilitated via step-wise sub-cloning into pCR2.1-TOPO vector (Invitrogen,
USA). PCR amplification of gls24 and sclA was conducted using PfuUltra II polymerase
and specific primers (Appendix B), as previously described (2.3.2). Adenosine
overhangs were added to the 3’ ends of blunt-end PCR amplicons via treatment with 1
U of Taq polymerase at 72°C for 10 min. Cloning reactions were prepared with 0.5 - 4
µl of Taq treated PCR products, 1 µl of salt solution, 1 µl of pCR2.1-TOPO vector and
dH2O to 6 µl. Reaction mixtures were permitted to anneal for 30 min at room
temperature, prior to transformation of TOP10 chemically competent cells (Invitrogen,
USA). Two microlitre volumes of cloning reactions were added to 20 µl of chemically
competent cells, and incubated on ice for 30 min prior to heat shock at 42°C for 30 s.
Heat shocked cells were immediately transferred to ice, and diluted in 250 µl of SOC
medium prior to incubation at 37°C for 1 h with agitation. Transformant E. coli were
selected for on LB containing 100 µg/ml ampicillin overnight at 37°C, and resultant
colonies containing the gls24 or sclA insert were screened for by PCR and restriction
enzyme digestion (Appendix C).
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2.3.6

Restriction enzyme digestion

Sub-cloning vectors; pPCR-Script and pCR2.1-TOPO containing insert gls24 and sclA
genes, pQE-30 and pDCerm, were routinely subject to restriction enzyme digestion to
obtain double-stranded insert DNA with complementary single stranded overhangs
suitable for downstream ligation (Appendix C). Approximately 5 µg of pPCR-gls24 and
3 µg pQE-30 were digested in reactions containing 10 U of SmaI, 10 U of PaeI
restriction enzymes (Fermentas, Lithuania), in 1X Buffer B (Fermentas, Lithuania) with
dH2O to 30 µl at 30°C for 1 h, followed by 37°C for 1 h. Approximately 7 µg of pCRgls24, pCR-sclA and pDCerm were digested in reactions containing 20 U of XbaI and
10 U of EcoRI restriction enzymes (Fermentas, Lithuania), in 2X Tango buffer
(Fermentas, Lithuania) with dH2O added to 30 µl and incubated at 37°C for 1 h. In
restriction enzyme digests of cloning vectors (pQE-30 and pDCerm), 2 U of Fast AP
Thermosensitive Alkaline Phosphatase (Fermentas, Lithuania) was added to
dephosphorylate 3’-overhangs and prevent recircularisation during downstream
ligation. All digests were performed with appropriate single enzyme controls, after
which all reactions were heat inactivated at 75-85°C for 10 min as appropriate for each
enzyme, and digested DNA purified by Wizard Plus SV gel purification as previously
described (2.3.3).
2.3.7

Ligation conditions

Ligation of restriction enzyme digested inserts from sub-cloning vectors was conducted
using T4 ligase. Optimal ligation efficiency was obtained using a 3:1 (insert:vector)
molar ratio calculated from the equation ng insert DNA = (3/1)*[(bp of insert DNA x 70
ng vector DNA)/ bp of vector]. Ligation reactions therefore contained: 16-60 ng insert
DNA, 70 ng vector DNA, 1X T4 ligation buffer, 5 U T4 ligase with dH2O to 30 µl.
Reactions were incubated overnight at approximately 13°C and used to transform
chemically competent or electro-competent E. coli (2.2.4, 2.2.5).
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2.3.8

Ligation independent cloning (LIC)

Cloning of the chloramphenicol acetyltransferase (cat) gene into pHY304-LIC for
performing precise allelic exchange mutagenesis of gls24 and sclA was accomplished
via a Ligation Independent Cloning (LIC) strategy (Fig. 2.1). NS88.2 genomic DNA was
used as the template for PCRs amplifying 250 bp regions directly upstream and
downstream of gls24 and sclA, with each homology fragment modified via primer 5’
extensions to bear overlapping, complementary sequence to pHY304-LIC or cat
(Appendix B). The cat gene was PCR amplified from pHSG398, and pHY304-LIC
digested with the PmeI restriction enzyme. To enable DNA recombination, 200 ng of
PmeI treated pHY304 LIC, cat gene and homology fragments were treated with T4
polymerase in the presence of a deoxynucleotide (dTTP for pHY304-LIC and cat, dATP
for the homology fragments). T4 polymerase reaction mixtures contained: 200 ng of
template DNA, 6 U of T4 polymerase (New England Biolabs, USA), 1X NEBuffer 2
(New England Biolabs, USA), 5 mM of either dTTP or dATP, 5 mM DTT, 1 mg/ml BSA
and dH2O to 20 µl. T4 polymerase treatment resulted in the generation of 15-16 bp
single stranded overhangs at the end of each DNA fragment. The overhangs at the
ends of the pHY304-LIC were complementary to the 5’ overhang of the upstream
homology fragment and 3’ overhang of the downstream homology fragment. The
overhangs of the cat gene were complementary to the 3’ overhang of the upstream
homology fragment and the 5’ overhang of the downstream homology fragment. The
DNA fragments were mixed on ice and allowed to anneal for 30 min, prior to
transformation into chemically competent DH5α E. coli (2.2.5). The successful
construction of each LIC vector was confirmed by alkaline lysis of transformants and
sequencing analysis (Appendix C).
2.3.9

Plasmid extraction via alkaline lysis

E. coli transformant colonies were routinely screened for the presence of recombinant
plasmid DNA via alkaline lysis. Transformants were re-streaked onto appropriate
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selective LB media and incubated overnight at 37°C. A loopful of each transformant
was resuspended in 200 µl of cold Solution 1 and incubated for 5 min at room
temperature, followed by addition of 200 µl volume of fresh Solution 2, gentle mixing
via inversion and incubation for 5 min on ice. A 200 µl volume of Solution 3 was then
added, the samples mixed gently via inversion and incubated for a further 5 min on ice
before pelleting precipitated protein (16,000 x g, 10 min). Supernatants containing
plasmid DNA were carefully aspirated from each sample, added to 400 µl of room
temperature isopropanol and incubated for 10 min at room temperature to precipitate
DNA prior to centrifugation (16,000 x g, 5 min). DNA pellets were then washed with 1
ml of 70% ethanol (16,000 x g, 1 min) and the pellet air dried before resuspension in 40
µl of dH2O and size separation via agarose gel electrophoresis.

Fig. 2.1 Schematic of Ligation Independent Cloning (LIC) Strategy. pHY304-LIC based
knock-out vectors for allelic exchange were generated via LIC. Upstream and downstream
genomic regions flanking genes of interest and the cat gene were amplified by PCR from
NS88.2 genomic DNA (gDNA) and pHSG398. These amplicons and PmeI restriction digested
pHY304-LIC, were 3’-5’ exonuclease treated using T4 polymerase, generating complementary
single strand overhangs between pHY304-LIC vector, homology regions and the cat gene.
These fragments were combined, permitted to anneal and transformed into chemically
competent E. coli, generating intact vectors with in-frame gene fusions of the homology
regions to cat.
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2.3.10 Wizard Plus SV Mini-prep DNA purification
Plasmid DNA for use in restriction enzyme digestions, transformations and Sanger
DNA sequencing reactions was prepared using a Wizard Plus SV Mini-prep DNA
purification kit (Promega, USA) according to the manufacturer’s instructions. Each
strain undergoing plasmid extraction was struck out onto appropriate selective LB
media overnight at 37°C. A loopful of each strain was then resuspended in 250 µl of
cell resuspension solution with vigorous mixing. A 250 µl volume of cell lysis solution
was added to each sample and mixed four times via inversion, prior to adding 10 µl of
alkaline protease solution and mixing a further four times. Each sample was incubated
for 5 min at room temperature prior to adding 350 µl of neutralisation solution and
mixed four times via inversion. Cell lysates were cleared (16,000 x g, 10 min) and
loaded into silicone membranes, prior to binding DNA to the membrane (16,000 x g, 1
min). Flowthrough from each sample was discarded and the membrane columns
washed twice with 750 µl of column wash solution (16,000 x g, 1 min) and 250 µl of
column wash solution (16,000 x g for 5 min). Spin columns were then transferred to
fresh microcentrifuge tubes and dried (16,000 x g, 2 min), prior to transferral to a fresh
microcentrifuge tube. A 50 µl volume of nuclease free H2O was added to each spin
column and incubated at room temperature for 1 min, followed by elution of bound
plasmid DNA (16,000 x g, 2 min) and storage at -20°C.
2.3.11 Agarose gel electrophoresis
DNA samples were routinely size separated using 1% (w/v) agarose gels. DNA
samples were mixed with one fifth volume of DNA loading dye prior to being deposited
in each well. Agarose gels were electrophoresed using a Bio-Rad Power Pack (BioRad, USA) at 100 V for approximately 1 h in 1X TAE buffer. Following agarose gel
electrophoresis, agarose gels were stained in an excess volume of ethidium bromide
staining solution for 20 min with gentle agitation. Once sufficiently stained, gels were
destained in dH2O for 5 min followed by visualisation using a UVP EC3 bioilluminator
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with Gel HR/camera (UVP BioImaging Systems, USA). HyperLadder-1 (Bioline, USA)
DNA molecular size markers were used to estimate DNA size.
2.3.12 Ethanol precipitation of DNA
Concentration of DNA samples or removal of excess dye terminators prior to Sanger
capillary sequencing was conducted by ethanol precipitation. To each DNA sample, 2
M Sodium Citrate (pH 4.5) was added to a final concentration of 0.4 M. A 3.5 volume of
95% ethanol was subsequently added, samples inverted to mix and incubated on ice
for 20 min. DNA was pelleted via centrifugation (16,000 x g, 20 min) and supernatant
discarded. Each DNA pellet was then washed with 1 ml of 70% ethanol, centrifuged at
16,000 x g for 10 min and pellets air dried prior to resuspension in dH2O or storage at 20°C.
2.3.13 Sanger DNA sequencing
Routine confirmation of correct insert sequence of sub-cloning, expression and allelic
exchange vectors was conducted by chain terminating fluorescent dideoxynucleotide
sequencing (Sanger method). Sequencing reactions were prepared on ice with 200400 ng of plasmid DNA, 0.5 μl of BigDye v3.1 Ready Reaction Mix (Applied
Biosystems, USA), 1X sequencing buffer (Applied Biosystems, USA), 3.2 pmol
sequencing primer and dH2O to 10 μl. Sequencing reactions were then subjected to a
thermocycling program of an initial denaturation cycle of 96°C for 2 min; 25 cycles of
denaturation at 96°C for 30 s, primer annealing at 50°C for 20 s and elongation at 60°C
for 4 min; followed by a final extension cycle of 72°C for 1 min and a holding cycle of
4°C. Excess dye terminators were removed by ethanol precipitation as described
previously (2.3.12) and reactions read via capillary electrophoresis using an Applied
Biosystems 3130 Genetic Analyser (Applied Biosystems, USA). Electrophoragrams
were read and initial base calls assigned using Applied Biosystems Analysis software
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(Applied Biosystems, USA) with additional manual sequence curation and contig
assembly using Geneious Pro Trial v5.6 (Biomatters, New Zealand).
2.4

Allelic exchange mutagenesis

Isogenic deletion of gls24 and sclA from the NS88.2 genome was conducted via
precise allelic exchange of a cat gene fusion with the upstream and downstream gls24
and sclA homologous regions encoded in pHY-∆gls24 and pHY-∆sclA (Appendix C).
Electro-competent NS88.2 were transformed with 1 – 2 μg of allelic exchange vector
DNA as described previously (2.2.4) and transformants selected for at 30°C to permit
plasmid replication on THYA containing 2 μg/ml erythromycin (48 – 96 h incubation).
GAS transformants were PCR screened for the presence of the ermB gene and
inoculated into 3 ml liquid cultures of THY containing 2 μg/ml erythromycin overnight at
30°C. Post-incubation, cultures were diluted serially ten-fold onto THYA containing 2
μg/ml erythromycin and passaged overnight at the non-permissive plasmid replication
temperature of 37°C to encourage plasmid integration into the chromosome. Putative
GAS colonies with single cross-over allelic exchanges into the chromosome were
cultured overnight at 30°C in THY to allow for plasmid disintegration from the
chromosome, followed by serial dilution onto THYA in the absence of antibiotics and
overnight passage at 37°C, encouraging both single and double cross-over
homologous recombination events to occur. Single colonies from 37°C passages were
picked using sterile toothpicks and patched onto two individual THYA plates with and
without 2 μg/ml chloramphenicol. GAS colonies exhibiting chloramphenicol resistance
were PCR screened for the presence of cat and absence of ermB and the gene of
interest to confirm complete allelic exchange of gls24 or sclA with cat (Appendix C).
2.5

Sodium dodecyl sulphate-polyacrylamide gel electrophoresis

Protein samples were routinely separated via sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE). Samples were prepared by mixing with one fifth
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volume of protein cracking buffer and were boiled for 10 min to denature the proteins
and reduce disulphide linkages. Samples were then analysed by SDS-PAGE using a
PROTEAN Cell System (Bio-Rad, USA). Equivalent amounts of protein were loaded
and separated on 12% acrylamide gels at 185 V for ~45 min using a PowerPac 300
supply unit (Bio-Rad, USA) in 1X SDS-PAGE running buffer. Molecular sizes of
proteins were estimated using Unstained PageRuler Protein Ladder (Fermentas,
Lithuania). Visualisation of protein bands was conducted after staining the gel with an
excess volume of Coomassie Blue Rapid Stain overnight at room temperature with
gentle agitation. Background staining of gels was then removed using an excess
volume of Rapid Destain overnight with agitation and regular changing of destain
solution. Destained gels were scanned using a GS-800 calibrated densitometer (BioRad, USA).
2.6

Western transfer analysis

Detection of cleaved caspase-3 or actin in PMN lysates was conducted via transferral
of lysate samples separated by SDS-PAGE to a nitrocellulose membrane, with
subsequent chemiluminescent detection. Western transfers were routinely conducted
using a Mini Trans-Blot apparatus (Bio-Rad, USA). Cassettes were set up as shown in
Fig. 2.2, loaded into the gel tank, the tank filled with Western Transfer Buffer and
proteins transferred at 100 V for 1 h at 4°C with constant stirring to ensure even buffer
temperature and ion distribution. Post-transfer, membranes were blocked in PBST with
10% (w/v) skim milk powder (Difco, Australia) and incubated overnight at 4°C.
Following blocking, membranes were washed twice for 5 min in PBST and probed
using either mouse anti-caspase-3 antibody (Clone: 4-2-18, Biolegend, USA) diluted
1:1000 or polyclonal rabbit anti-actin antibodies (Sigma-Aldrich, USA) diluted 1:5000 in
PBST with 1% (w/v) skim milk powder (Difco, Australia). Primary antibodies were
incubated for 1 h with agitation at room temperature. Membranes were washed thrice
for 5 min in PBST and bound primary antibodies probed using either goat anti-rabbit
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IgG or goat anti-mouse IgG-horseradish peroxidise (HRP) conjugate antibodies (BioRad, USA) diluted 1:1000 in PBST containing 1% (w/v) skim milk powder, followed by
incubation for 1 h at room temperature. Excess secondary antibodies were washed
from the membrane thrice for 5 min with PBST, followed by a subsequent 1 X PBS
wash for 5 min. Bound antibodies were detected using Pierce SuperSignal West Pico
Chemiluminescence substrate (Thermo Scientific, USA) and Amersham Hyperfilm (GE
Healthcare, Sweden). Exposed X-ray films were scanned using a GS-800 calibrated
densitometer (Bio-Rad, USA).

Fig. 2.2 Schematic of the apparatus for Western blotting. All components were pre-soaked
in western transfer buffer prior to the loading of transfer apparatus. Transfers were conducted
with current applied from the acrylamide gel to the nitrocellulose membrane resulting in the
transfer of proteins to the membrane.

2.7

Protein purification

Recombinant His-tagged Gls24 protein was expressed within M15 (pREP4) E. coli and
purified by Nickel ion affinity chromatography (Appendix C). Single E. coli colonies
containing pQE-gls24 were inoculated into shaking 100 ml overnight cultures of liquid
LB media containing 100 μg/ml of ampicillin. The 100 ml culture was expanded to 1 L in
prewarmed LB media containing 50 ug/ml of ampicillin, and cultured with shaking to
OD600: >0.6. Upon reaching optical density, protein expression was induced via the
addition of 1 mM IPTG and 1 mM PMSF and cultures incubated for 4 h at 37°C with
shaking. Post-induction, cultures were pelleted via centrifugation (4000 x g, 20 min,
4°C) and stored at -20°C. Native cell lysis was conducted via thawing of the cell pellet
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on ice, followed by resuspension in 50 ml of ice cold native cell lysis buffer. Samples
were then incubated on ice for 20 min and lysed by cycling the sample approximately
10 times at 140,000 kPa, with interspersed cooling on ice, using an Avestin
EmulsiFlex-C5 Homogeniser (ATA Scientific, Australia).

Complete solubilisation of

protein was then encouraged via inverted mixing for 20 min at room temperature,
followed by sedimentation of insoluble material via centrifugation (12,000 x g, 20 min,
4°C) and filtration of the cleared lysate through 0.44 μm pore size filtration units
(Millipore, USA). Filtered cell lysate containing recombinant protein was bound to NiNTA resin via the addition of 2 ml 50% Ni-NTA resin in batch to lysate samples and
subsequently mixed via inversion at 4°C for 1 h. Resin slurry was then recovered in a
10 ml column and the resin bed washed with 10 column volumes of native wash buffer,
followed by elution in two 2 ml volumes of native elution buffer. Elution fractions
containing purified His-tagged protein were pooled and dialysed thrice against 2 L of 1
X PBS over 48 h.
2.8

SpeB degradation assays

SpeB protease activity was assayed as described in (Cole et al., 2006). Purified mature
SpeB protease (5 µg, Toxin Technologies, Australia) was mixed with 5 µg of purified
Gls24 or 25 µg of Casein (Sigma, USA), adjusted to a final volume of 25 µl with PBS
and incubated at 37°C for 3 h. Proteolysis of casein and Gls24 was determined by
SDS-PAGE analysis. Negative control assays containing casein, Gls24 or SpeB only
were also included.
2.9

Isolation of GAS supernatant protein

Single GAS colonies were inoculated into 3 ml of THBY and grown overnight with
parallel cultures containing 28 μM of cysteine protease inhibitor E64. Two millilitre
aliquots of starter cultures were used to inoculate 100 ml of THBY (± E64) and grown
overnight to early stationary phase (~20 h). Cultures were pelleted (5,400 x g, 15 min,
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4°C) and filtered using 0.22 μm pore-size filter units (Millipore, Ireland). Supernatant
proteins were precipitated via the addition of equal volumes of 10% trichloroacetic acid
(TCA), followed by incubation on ice for 20 min and centrifugation (11,000 x g, 15 min).
Supernatants were then discarded and protein pellets washed with an equal volume of
95% ethanol followed by centrifugation (11,000 x g, 5 min) and air drying. Protein
pellets were resuspended in a 1 ml volume of 100 mM Tris base (pH 7.6) and
transferred to fresh 2 ml microcentrifuge tubes, where supernatant proteins were TCAprecipitated as described above and resulting pellets stored at -20°C
2.10

Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE)

GAS culture supernatant proteins were separated via two-dimensional-polyacrylamide
gel electrophoresis (2D-PAGE) prior to mass spectrometry analysis. Supernatant
protein samples were resuspended in 500 μl Standard Sample Solubilisation (SSS)
buffer and sonicated at 14 W for 30 sec using a Microson ultrasonic liquid processor
XL2000 (Misonix, USA) followed by 15 sec of vortexing to facilitate complete
solubilisation of proteins. Sonication and vortexing steps were repeated a further three
times, with unsolubilised proteins pelleted by centrifugation (16,000 x g, 15 min), and
supernatants transferred to fresh 2 ml microcentrifuge tubes. Equal amounts of protein
were expanded to 250 µl with SSS buffer, 2 μl quantities of bromophenol blue solution
added to each sample, mixed thoroughly via gentle vortexing and pipetted along each
lane of the reswelling tray. IPG strips (11 cm, pH 4-7, Bio-Rad, USA) were placed gel
side down over each sample, and overlaid with 1 ml of paraffin oil to prevent matrix
desiccation. Strips were then allowed to rehydrate overnight at room temperature,
resulting in the uptake of supernatant proteins into the IPG gel matrices. Following
rehydration, electrode wicks (four per IPG strip) were equilibrated in Milli-Q prior
loading onto the electrodes of an isoelectric focussing (IEF) tray. Rehydrated IPG strips
were placed gel side down over the wicks, overlayed with 1 ml of paraffin oil and
focused using a Protean IEF Cell (Bio-Rad, USA) according to the following program:
55

100 V, 1 h; 300 V, 1 h; 600 V, 1 h; 1,000 V, 1 h; 2,000 V, 1 h; 4,000 V, 10 h with 100 V
hold. IPG strips were removed from the IEF cell and incubated with 3 ml of equilibration
buffer for 20 min with gentle rocking. Once equilibrated, strips were washed three times
with 1 X SDS-PAGE running buffer, placed between the glass plates on top of 12.5%
acrylamide gels and overlayed with 2 ml of molten 0.5% agarose in 1 X SDS-PAGE
running buffer. Marker paper soaked with 10 μl of PageRuler Prestained protein ladder
(Fermentas, Lithuania) was used as a molecular size marker. Gels were
electrophoresed in 1 X SDS-PAGE running buffer using a PowerPac (Bio-Rad, USA) at
90 V for ~21 h and stained for 48 h in an excess volume of colloidal Coomassie stain,
with destaining in colloidal Coomassie destain buffer.
2.11

Peptide mass fingerprinting analysis

To identify protein spots separated by 2D-PAGE, matrix-assisted laser desorption
ionisation time-of-flight mass spectrometry (MALDI-TOF MS) and peptide mass
fingerprinting (PMF) analyses were employed. 2D-PAGE gels were placed on a light
box and the spots of interest excised using a 200 μl pipette tip. The pipette tip was
rinsed thoroughly with 100% methanol between samples to prevent crosscontamination and the gel spots transferred to 96-well V-bottomed plates. Spots were
destained by the addition of 100 μl of Coomassie blue destain Buffer with shaking for 1
h at room temperature. Excess destain buffer was aspirated and gel pieces dried via
vacuum desiccation for 1.5 h. Proteins embedded in the gel were tryptically digested by
overlaying each gel spot with 133 ng of sequencing grade modified trypsin (Promega,
USA) and incubating the plate for 1 h at 4°C with gentle shaking. Excess trypsin was
aspirated and discarded, followed by the release of digested peptides in 20 μl of 50
mM NH4HCO3 (pH 7.8) overnight at 37°C with gentle shaking. Shimadzu MALDI-TOF
MS target plates were prepared by thorough rinsing with methanol and were air-dried
prior to sample loading. Each sample well was thinly layered with mass spectrometry
matrix by pipetting a 2 μl volume of matrix on and off the well. A 0.7 μl volume of
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tryptically digested protein was then added and overlaid with 0.5 μl of mass
spectrometry matrix containing 0.25 pM of MALDI-TOF calibration standards
(Angiotensin, 1046.5423 Da; Pro14-Arg, 1533.8582 Da; Adrenocorticotropic hormone
fragment, 2465.1981 Da). Mass spectra were generated using an AXIMA Confidence
MALDI-TOF MS (Shimadzu Biotech, USA). Spectra were analysed using Shimadzu
Biotech Launchpad version 2.8.3 (Kratos Analytical Ltd, USA). The mass/charge peaks
corresponding to tryptically digested proteins were used as the search query for
interrogation of a custom Mascot database provided by the Australian Computational
Proteomics Facility (http://www.apcf.edu.au). This database was constructed using a
multiple-entry FASTA file of protein coding sequence exported from the NS88.2
genome draft subject to theoretical tryptic digestion, giving a indexed catalogue of
mass/charge values for each protein (Chapter 3). Positive identification of proteins was
based upon the highest number of experimental peptides from MALDI-TOF spectra
correlating with peptide masses generated from theoretical tryptic digestion of
translated GAS genomic data. As additional confirmation, mass spectral data was also
searched

using

the

public

Mascot

database

available

via

Matrix

Science

(http://www.matrixscience.com). A minimum of two experimental peptide matches was
required for positive identification of each protein. A representative MALDI-TOF
spectrum and results from Matrix Science PMF are presented in Appendix D.
2.12

Whole blood growth kinetics

Estimation of GAS ability to survive and replicate in whole blood was conducted via the
Lancefield method as described previously (Humtsoe et al., 2005). Venous blood from
healthy donors was collected and inoculated with a one-tenth volume of midlogarithmic (OD600: 0.4) phase GAS culture and incubated at 37°C for 3 h with gentle
agitation on a rotating mixer. Fold growth was calculated as resultant CFU/ml after 3 h
over initial CFU/ml. All individual assays were conducted in triplicate, with a minimum
of 3 donors for calculation of growth kinetics for each strain assayed.
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2.13

Hyaluronic acid capsule determination

Measurement of hyaluronic capsule production by the NS88.2 strains was conducted
as previously described in (Schrager et al., 1996). Two millilitre overnight GAS cultures
were inoculated into 25 ml of THBY and grown to OD600: 0.5. Ten millilitre volumes of
mid-logarithmic phase cultures were sedimented (6000 x g, 10 min) and supernatants
discarded prior to resuspension of GAS cell pellets in 500 µl sterile dH2O.
Determination of colony forming units (CFU) per ml was conducted by serial dilution of
the GAS cell resuspension on THYA with subsequent overnight incubation. Hyaluronic
acid capsule was released by shaking the remaining culture with 1 ml of chloroform for
5 min. Aqueous and organic solvent phases were separated by centrifugation (16,000 x
g, 10 min) and the aqueous phase containing hyaluronic acid capsule harvested.
Capsule extracts were serially-diluted in sterile dH2O and stained using Stains-all
solution, prior to spectrophotometric reading at A640 using a SpectraMax 250 microtitre
plate reader (Molecular Devices, USA). Amounts of hyaluronic acid capsule were
interpolated from a standard curve of hyaluronic acid standards against absorbance
and the amount of hyaluronic acid of each strain expressed as femtograms per CFU
(fg/CFU).
2.14

RNA extraction from GAS

RNA from mid-logarithmic phase GAS cultures in THY or blood were isolated using an
RNeasy minikit (Qiagen, Germany) essentially as per the manufacturer’s instructions.
Single colonies of GAS were inoculated into 5 ml of THY media with subsequent
overnight incubation at 37°C. One millilitre of starter cultures were used to subinoculate
into 40 ml of THY and grown to OD600: 0.4. Ten millilitres of GAS culture was pelleted
via centrifugation (5000 x g, 10 min) and resuspended into 600 µl of RLT buffer
containing β-mercaptoethanol for immediate RNA extraction. For RNA extracted from
GAS blood cultures, 10 ml of mid-logarithmic phase GAS cultures were resuspended in
200 µl of sterile 1X PBS, inoculated into 1.8 ml of freshly drawn blood and incubated for
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1 h at 37°C with gentle agitation. Blood cultures were hypotonically lysed using 40 ml of
sterile Milli-Q and GAS harvested via centrifugation (7000 x g, 5 min) before being
resuspended into 600 µl of RLT buffer containing 6 µl of β-mercaptoethanol. Bacteria
from THY or blood cultures were homogenised using 0.1 mm silicon bead
homogenisation vials shaken twice at 10 m/s for 45 s using a FastPrep-24
homogeniser (MP Biomedical, USA). Post-homogenisation, RNA samples were
transferred to 1.5 ml microcentrifuge tubes containing 300 µl of 70% ethanol, mixed
thoroughly and RNA bound to the membranes of RNeasy spin columns via
centrifugation (14,000 x g, 15 s). Column membranes were washed with 350 µl
volumes of RW1 buffer (14,000 x g, 15 s), flow through discarded and the RNA DNase
treated on the RNeasy column with 10 µl of DNase I solution and 70 µl of RDD buffer
for 15 min at room temperature. DNase protein was removed via washing with 350 µl of
RW1 buffer via centrifugation (14,000 x g, 15 s). RNeasy spin columns were then
washed twice with 500 µl of RPE buffer via centrifugation (14,000 x g, 15 s and 2 min)
and a further time without buffer to eliminate ethanol carry-over (14,000 x g, 1 min).
RNA samples were eluted from RNeasy columns using 40 µl of RNase-free water
(14,000 x g, 2 min). Samples were then subjected to a second round of DNase
treatment in solution using 2.5 µl of DNase I in 10 µl of RDD buffer diluted with 55 µl of
RNase free water for 10 min at 22°C. Post-DNase treatment, RNA clean up was
initiated by the addition of 350 µl of RLT buffer, followed by 250 µl of absolute ethanol
and transferral of RNA samples to fresh RNeasy spin columns with RNA bound via
subsequent centrifugation (14,000 x g, 15 s). RNeasy spin columns were then washed
twice with 500 µl of RPE buffer via centrifugation as previously (14,000 x g, 15 s and 2
min) and a further time without buffer to eliminate ethanol carry-over (14,000 x g, 1
min). RNA samples were eluted from RNeasy columns using 40 µl of RNase-free water
(14,000 x g, 2 min).
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2.15

qPCR analysis of GAS gene expression

Purified GAS RNA was prepared for quantitative PCR analysis by conversion to cDNA
using a Tetro cDNA Synthesis kit (Bioline, UK). cDNA synthesis reactions contained 1 2 µg of GAS RNA, 1X RT buffer, 1 µl random hexamer primers, 1 µl Ribosafe RNase
inhibitor, 200 U Tetro Reverse Transcriptase, 0.5 mM dNTPs and DEPC-treated water
to 20 µl. Reactions were incubated for 10 min at 25ºC, followed by 45ºC for 60 min and
85ºC for 10 min. NS88.2 transcripts were quantified by qPCR using a SensiFAST
SYBR No-Rox kit (Bioline, UK). qPCR reactions contained 1X SensiFAST reaction
buffer, 0.5 µM forward and reverse primers, 20 ng of reverse transcribed GAS total
RNA and DEPC-treated water to 15 µl. Reactions were read on a LightCycler 480
instrument (Roche, Switzerland) using a 2-step thermocycling protocol of 95ºC for 2
min, followed by 40 cycles of 95º for 5 s and 60ºC for 30 s. Melt curve analysis was
performed following amplification of each sample to confirm generation of single
amplicons via continuous fluorescent acquisition from 55ºC to 95ºC. The absence of
contaminating chromosomal DNA in RNA samples was confirmed via standard PCR
analysis of purified RNA samples. Fold changes in expression were normalised
according to amplification efficiency for each gene as described (Pfaffl, 2001), and to
the house-keeping gene proS, the expression of which does not vary with covS
mutation or growth cycle (Graham et al., 2002). Primer sequences for each gene
analysed are listed in Appendix B. Representative melt curves and efficiency
calculations for each primer are shown in Appendix E.
2.16

Human polymorphonuclear leukocyte assays

2.16.1 Ethics statement
Permission to collect human blood under informed consent was approved by the
University of Wollongong Human Ethics Committee protocol number HE08/250.
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2.16.2 Preparation of human polymorphonuclear leukocytes
Human PMNs were purified from peripheral venous blood for use in PMN killing assays
and other PMN-GAS association assays. Volumes of PolyMorphPrep (Axis-Shield,
Norway) equal to the volume of blood taken were brought to room temperature as 5 ml
aliquots in 15 ml centrifuge tubes. Blood was taken via venepuncture from healthy
consenting donors into sterile tubes containing sodium citrate to a final concentration of
10 µM or heparin coated silicon beads as an anti-coagulant. Drawn blood was allowed
to cool to room temperature, 5 ml of blood overlaid onto 5 ml of PolyMorphPrep and
centrifuged at 500 x g for 30 min at room temperature without deceleration brakes
applied. Cleared plasma was aspirated from each centrifuge tube and complement
inactivated via heating at 55°C, incubation on ice for 30 min and centrifugation at 5000
x g to remove precipitate. Contaminating mononuclear leukocytes fractions from each
centrifuge tube were removed via aspiration and the PMN fraction collected into a
sterile 50 ml centrifuge tube. Isolated PMNs were equilibrated in 50 ml of sterile 1X
PBS, pelleted (380 x g, 10 min) and the supernatant gently decanted. Contaminating
erythrocytes in the PMN fraction were removed via hypotonic lysis in ~5 ml of sterile
Milli-Q water for approximately 20 s prior to restoration of isomolarity via addition of 45
ml of sterile 1X PBS. PMNs were pelleted (380 x g, 10 min) and the supernatant
decanted to remove lysed cellular debris. Isolated PMNs were resuspended in 0.5 ml of
cold Rosewell Park Memorial Institute (RPMI) media supplemented with 2% heatinactivated human plasma until use. Cell counts were performed with an equal volume
of Trypan blue to ascertain viable cells (>99% for all experiments).
2.16.3 In vitro infection of human PMNs with GAS
GAS cultures were routinely prepared for in vitro human PMN infection via growth to
mid-logarithmic phase (OD600: 0.4), washing twice with sterile 1X PBS and dilution to
the required inoculum in RPMI containing 2% heat-inactivated human plasma. Human
PMNs were purified as described previously (2.16.1), seeded into the wells of either
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tissue culture treated sterile 96-well (GAS killing, phagocytosis, cytotoxicity, ψM
depolarisation assays) or 24-well plates (double immunofluorecence, TUNEL,
microarray and western blot assays) (Greiner bio-one, Germany) and GAS added to
the appropriate multiplicity of infection (MOI) (PMNs:GAS). PMNs were brought into
close proximity with GAS via centrifugation (380 x g, 8 min, 4°C) prior to incubation at
37°C in 5% CO2.
2.16.4 PMN bactericidal assay
Measurement of GAS resistance to PMN-mediated killing in vitro was conducted
essentially as previously (Hollands et al., 2008). In vitro infection of 2 x 105 PMNs with
2 x 104 GAS CFU was conducted as described above (2.16.2). After 30 min incubation,
PMNs were hypotonically lysed and surviving GAS enumerated via serial dilution and
overnight incubation on THYA. GAS survival was calculated as a percentage of GAS
surviving following PMN incubation compared with growth controls incubated without
PMNs.
2.16.5 Phagocytosis of GAS
To measure GAS uptake by PMNs, 5 x 105 PMNs were infected with 5 x 106 CFU of
eGFP expressing GAS (2.16.2) and incubated for varying times (5, 40, 80, 120 min) or
for 40 min at varying MOIs (1:5, 1:10, 1:20, 1:40). Post-incubation, assays were
transferred to FACS tubes, resuspended in 1 ml PBS and pelleted (380 x g, 8 min,
4ºC), prior to resuspension in 500 μl 1X PBS containing 5 mM sodium azide and 5
mg/ml BSA. Association of GAS with PMNs was measured using an LSRII (BD
Biosciences, USA) flow cytometer. A single gate was used to exclude debris, free GAS
cells and isolate PMNs (Appendix F). Association of fluorescent GAS with PMNs was
calculated as the percentage of PMNs with GAS eGFP fluorescence (510_20+
population). The relative quantity of GAS associated with PMNs was estimated by the
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mean fluorescence intensity (MFI) of eGFP positive PMNs. Data were analysed using
Flowjo (Treestar, USA)
2.16.6 Double immunofluorescence microscopy
Visualisation

of

PMN

phagocytosis

of

GAS

was

conducted

by

double

immunofluorescence microscopy as described previously (Goldmann et al., 2004).
Sterile coverslips were prepared in 24 well tissue culture plates and covered with 200
µl 10% Poly-L-lysine solution for 30 min at 37°C. Post-incubation, excess Poly-L-lysine
solution was aspirated and coverslips rinsed twice with sterile 1X PBS before being
allowed to dry. 1 x 106 PMNs were purified as previously described, and infected with 1
x 107 CFU of GAS (2.16.2). Post-incubation, assays were fixed with 4%
paraformaldehyde. Coverslips were then rinsed twice with 1X PBS, and non-specific
antibody binding of GAS was blocked using 1X PBS with 10% FCS for 45 min at room
temperature, and coverslips rinsed twice with 1X PBS. Extracellular GAS were labelled
with polyclonal rabbit anti-GAS antiserum (kindly provided by M. Rohde) at a dilution of
1:300 in 1X PBS containing 10% FCS for 45 min at room temperature. After primary
labelling, coverslips were rinsed twice with 1X PBS containing 10% FCS and goat antirabbit IgG Alexa 488 conjugate antibody (Dako, Denmark) diluted 1:300 in 1X PBS
containing 10% FCS added for 45 min at room temperature. Coverslips were then
rinsed twice with 1X PBS containing 10% FCS and PMN membranes permeabilised
with 0.1% Triton-X 100 (v/v) in 1X PBS for 5 min at room temperature. Coverslips were
then rinsed thrice with 1X PBS, and intracellular and extracellular GAS labelled with
polyclonal rabbit anti-GAS antiserum at a dilution of 1:150 in 1X PBS containing 10%
FCS for 45 min at room temperature. Coverslips were then rinsed twice with 1X PBS
containing 10% FCS and secondary goat anti-rabbit IgG Alexa 568 conjugate (Dako,
Denmark) added at a dilution of 1:400 in 1X PBS containing 10% FCS for 1 h at room
temperature. Coverslips were then rinsed twice with 1X PBS. A 5 µl volume of Prolong
Gold mounting medium (Invitrogen, USA) containing DAPI as a PMN nuclear
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counterstain was used to mount coverslips, then sealed with nail polish and visualised
using an Axio Observer inverted microscope (Zeiss microscopy, Germany).
2.16.7 Reactive oxygen species production
Kinetic measurement of PMN ROS production was conducted essentially as previously
(Kobayashi et al., 2003a). Purified PMNs were loaded with 25 µM of dichlorofluorescein
(DCF, Molecular Probes) for 40 min in the dark at room temperature, prior to infection
of 5 x 105 PMNs with 5 x 106 GAS CFU (2.16.2) in a black-walled microtitre plate. PMN
ROS production was measured spectrophotometrically (λex: 488 nm, λemm: 515 nm) at
37ºC using a POLARstar Omega fluorescent plate reader (BMG Labtech, USA).
2.16.8 GAS-induced cytotoxicity
PMN cytotoxicity was assessed essentially as previously (Goldmann et al., 2009).
Briefly, 2 x 105 PMNs were infected with 2 x 106 GAS CFU (2.16.2) and incubated for
varying time points, following which 50 µl aliquots of cell supernatants were sampled
and the lactate D-hydrogenase (LDH) concentration measured using the CytoTox 96 kit
(Promega) according to the manufacturer’s instructions. Cytotoxicity was calculated as
LDH release induced by either GAS strain over maximum LDH release (total LDH from
lysed uninfected cells) minus spontaneous release of LDH from uninfected cells.
2.16.9 Western blot of cleaved caspase-3
Caspase-3 cleavage was detected via western blotting of cell lysates from uninfected
and GAS-infected PMNs. In vitro infection of 2 x 106 PMNs with 2 x 107 GAS CFU was
conducted as previously (2.16.2). Western blotting of caspase-3 and actin protein was
conducted as previously (2.6).
2.16.10 TUNEL staining of purified PMNs
Assessment of apoptosis induced nuclear DNA fragmentation was measured using the
DEADend fluorometric TUNEL kit (Promega, USA) instructions for suspension cells. In
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vitro infection of 2 x 106 PMNs with 2 x 107 GAS CFU was conducted as previously
(2.16.2). Post-incubation, assays were transferred to FACS tubes, resuspended in 1 ml
PBS with 1% BSA and pelleted (380 x g, 10 min). Supernatant was discarded, and
cells fixed in 1 ml 4% paraformaldehyde for 30 min on ice. Cells were subsequently
washed with 2 ml of PBS (380 x g, 10 min) and stored overnight in 2 ml 70% ethanol at
-20ºC. After overnight incubation, cells were pelleted (380 x g, 10 min), ethanol
aspirated and washed with 1 ml of PBS (380 x g, 10 min). Samples were then
transferred to 1.5 ml centrifuge tubes, and incubated for 5 min in 80 μl equilibration
buffer. Cells were pelleted (400 x g, 10 min), buffer aspirated and samples incubated in
50 μl incubation buffer containing fluorescein-conjugated nucleotide mix and
deoxynucleotidyl transferase enzyme for 90 min at 37ºC in the dark. Reactions were
stopped via the addition of 1 ml 20 mM EDTA and samples pelleted (400 x g, 10 min).
Samples were then permeabilised using 1 ml 0.1% Triton-X 100 in PBS with 5 mg/ml
BSA, pelleted (400 x g, 10 min) and finally resuspended in 0.5 ml PBS, transferred to
FACS tubes and read using a LSRII flow cytometer (BD Bioscience, USA). A single
gate was used to remove debris, and apoptotic cells with incorporated fluorescein
(515_20+) were quantified (Appendix F). Data were analysed using Flowjo (Treestar,
USA)
2.16.11 Estimation of PMN mitochondrial membrane potential (Ψm)
Depolarisation of mitochondrial membranes of infected PMNs was estimated as
previously (Goldmann et al., 2009). Purified PMNs were loaded with 5 µM of 3,3’Dihexyloxacarbocyanine [DiOC6(3)] iodide for 20 min at room temperature prior to
infection of 5 x 105 PMNs with 5 x 107 GAS CFU (2.16.2) for 2 h. Perturbation of Ψm
was indicated as a loss of DiOC6(3) fluorescence (FL1 channel) compared to time 0
uninfected PMNs as determined using a FACSCalibur flow cytometer (Appendix F) (BD
Bioscience, USA). Data were analysed using Flowjo (Treestar, USA)
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2.17

Animal infection studies

2.17.1 Ethics statement
All animal use and procedures were approved by the University of Wollongong Animal
Ethics Committee protocol numbers AE11/09 and AE12/05.
2.17.1 Subcutaneous GAS challenge
Subcutaneous GAS challenge of C57BL/6 mice has been described previously
(Maamary et al., 2010). Mid-logarithmic GAS cultures were prepared in cold sterile
0.7% (w/v) NaCl at an inoculum of 9 x 108 CFU/100 μl. For each strain, 10 gender
matched C57BL/6 wild-type mice were prepared for infection via shaving and
application of depilatory cream to the rear right flank. Mice were anaesthetised via
isoflurane inhalation and GAS injections given in 100 µl subcutaneously to the shaven
flank. Estimation of GAS virulence was determined by observation of mouse mortality
over a 10-day period post-injection.
2.17.2 Intradermal phagocytosis of GAS and GAS survival
Estimation of GAS survival in vivo and GAS interaction with murine PMNs were
conducted by the method of (Ly et al., 2014). C57BL/6 mice were mice were prepared
for infection via shaving and application of depilatory cream to the rear left and right
flanks. Mice were then anaesthetised via isoflurane inhalation and 2 x 107 CFU of midlogarithmic phase eGFP expressing GAS were injected intradermally into the shaven
flanks prior to incubation for 6 h. Mice were subsequently euthanised via CO2
asphyxiation and the sites of injection lavaged with two 1 ml quantities of sterile 0.7%
saline. Lavage fluid was adjusted to a fixed volume and bacterial survival estimated via
serial dilution of lavage fluid in dH2O, plating out and enumeration of recovered
bacteria after overnight incubation. Survival was calculated as [recovered GAS
CFU/CFU of inoculum]*100%. Remaining lavage fluid was washed once with sterile
PBS, labelled with 0.2 μg rat anti-mouse Ly6-G PE-conjugated IgG (clone: 1A8,
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Biolegend, USA) for 20 min in the dark, and murine PMN (575_26+) phagocytosis of
GAS assessed as previously using a LSRII flow cytometer (Appendix F) (2.16.4). Data
were analysed using Flowjo (Treestar, USA)
2.17.3 Immunohistochemistry and histology
Immunohistochemical determination of murine PMN apoptosis and inflammation was
conducted via bilateral injection of 5 x 107 GAS CFU into the dermis of C57BL/6 mice
as previously (2.17.2). Infected murine dermal tissue was harvested 24 h post-infection
using a 12 mm biopsy punch and fixed in ice cold neutral buffered formalin for 3 h.
Tissue processing was conducted using an ASP200 automated vacuum tissue
processor (Leica, Germany) using the protocol listed in Table 2.2, and tissue biopsies
embedded in paraffin using a EG1150 paraffin embedding station (Leica, Germany).

Table 2.2 Automated tissue processing protocol.

Solution

Time (h.min)

1. Formalin
2. 70% ethanol
3. 90% ethanol
4. 100% ethanol
5. 100% ethanol
6. 100% ethanol
7. 100% ethanol
8. Xylene
9. Xylene
10. Xylene
11. Paraffin
12. Paraffin
13. Paraffin

00.05
00.10
00.10
00.20
00.20
00.30
00.45
00.20
00.30
00.45
00.20
00.30
00.45

Temperature (ºC)
37
37
37
37
37
37
37
37
37
37
65
65
65

Paraffin embedded tissue blocks were sectioned (5 μm thickness) using a microtome
(Leica, Germany). Sections were regressively haematoxylin and eosin (H&E) stained
using the protocol listed in Table 2.3. Immunofluorescent identification of apoptotic
murine cells was conducted by deparaffinising tissue sections with two xylene washes
(5 min each), rehydrating sections using a graded series of ethanol (100%, 5 min;
100%, 95%, 85%, 70%, 50%, 3 min each) and washing in 0.85% NaCl (5 min).
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Enzymatic antigen retrieval was conducted using 20 μg/ml proteinase K in PBS for 10
min at room temperature, followed by identification of apoptotic cells using the
DEADend fluorometric TUNEL kit (Promega, USA) instructions for paraffin embedded
tissues. Slides were covered with 100 μl of equilibration buffer for 10 min, followed by
aspiration of equilibration buffer and treatment with 50 μl incubation buffer containing
fluorescein-conjugated nucleotide mix and deoxynucleotidyl transferase enzyme for 60
min at 37ºC in the dark. Slides were washed in 2X SSC buffer (15 min), followed by
washing twice in PBS (5 min each). Coverslips were then mounted on samples using
Slowfade gold mounting medium (Invitrogen, USA) and sealed with nail polish.
Analysis of cells was conducted using a TCS SP5 confocal microscope (Leica,
Germany).

Table 2.3 Haematoxylin and eosin (H&E) staining protocol.

Solution

Time (min.s)

1. Xylene
2. Xylene
3. 100% ethanol
4. 100% ethanol
5. Water bath
6. Harris haematoxylin
7. Water bath
8. Acid alcohol
9. Water bath
10. Scotts blueing solution
11. Water bath
12. 1% aqueous eosin
13. 100% ethanol
14. 100% ethanol
15. Xylene
16. Xylene

1.30
1.00
1.30
0.10
1.00
2.00
2.00
0.01
1.00
1.00
1.00
0.20
1.00
0.45
0.10
1.00
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CHAPTER 3: ASSEMBLY AND ANALYSIS OF THE NS88.2 DRAFT GENOME
SEQUENCE

A part of this work has been published in FASEB J.
Reference:
James A. Tsatsaronis, Andrew Hollands, Jason N. Cole, Peter G. Maamary, Christine
M. Gillen, Nouri L. Ben Zakour, Malak Kotb, Victor Nizet, Scott A. Beatson, Mark J.
Walker, Martina L. Sanderson-Smith (2013). Streptococcal collagen-like protein A and
general stress protein 24 are immuno-modulating virulence factors of group A
Streptococcus. FASEB J. 7: 2633-43.
3.1

Introduction

Recent increases in the incidences of life-threatening invasive GAS infections highlight
the need to identify bacterial factors that explain this epidemic behaviour. Extensive
research has focused on GAS serotypes associated with outbreaks in urbanised
regions (Kansal et al., 2010; Sumby et al., 2005). In contrast, comparatively few studies
have focused on disparate GAS strains originating from less developed areas. In many
cases, rates of severe GAS diseases from these areas far exceed those observed in
urban centres (Carapetis et al., 1996). The diversity of GAS strains isolated from
regions of endemic GAS disease also prompts greater interest into the mechanisms
underlying this epidemiology.
Genomic sequencing and comparative bioinformatics has enabled high-throughput
screening of M2, M4, M6, M12 and M28 GAS strains (Musser and Shelburne, 2009).
These techniques have identified genetic features that distinguish virulent subclones of
these strains from closely related, avirulent strains (Beres et al., 2006; Green et al.,
2005). Such features, which include the acquisition of prophages, direct recombination
of core chromosomal elements between GAS serotypes and from other streptococcal
species, have bestowed recipient strains with enhanced virulence capacity or disease
predilection (Green et al., 2005; Sumby et al., 2005). Currently, genomic research has
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focused exclusively on GAS serotypes which are more prevalent in developed
countries such as M1, M3, M12 and M28 (Musser and Shelburne, 2009). Whilst these
serotypes are frequently isolated from severe infections in more developed regions,
and/or are associated with distinct disease pathologies, the majority of GAS infections
nonetheless occur in developing areas (Carapetis et al., 2005). Furthermore, prior to
2010 no representative emm-pattern D GAS (skin tropic) isolate had undergone wholegenome sequencing (Musser and Shelburne, 2009; Smeesters et al., 2010). Since
then, only a single study has described whole-genomic analysis of an emm-pattern D
isolate (Bessen et al., 2011). This highlights the underrepresented nature of GAS
strains from developing regions in genomic research.
Whole-genome shotgun sequencing, facilitated by next-generation sequencing (NGS)
technologies, represents a viable method to use in the rapid and comprehensive
genetic characterisation of candidate strains which display remarkable disease
propensity. The clinical GAS isolate NS88.2 (emm98.1, emm-pattern D) is highlyencapsulated, acquires cell-surface plasmin activity, is resistant to killing by human
neutrophils and is hypervirulent in a humanised plasminogen mouse model (Maamary
et al., 2010; Sanderson-Smith et al., 2008). As such, NS88.2 exhibits a virulent
phenotype suitable to use as a model strain for interrogative genomic analyses. As
such, we utilised whole-genome shotgun sequencing and comparative bioinformatics to
assist in identifying virulence factors that distinguish the neutrophil resistant GAS
isolate NS88.2 from other GAS serotypes.
3.2

Results

3.2.1

Assembly of NS88.2 draft genome

Genomic sequence analysis of the NS88.2 strain was instigated via the generation of a
genomic sequence draft. RNA-free, genomic NS88.2 DNA was isolated from overnight
liquid culture; genomic fragment libraries constructed for whole-genome shotgun
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sequencing at the Australian Genome Research Facility, and sequenced using a
Genome Analyser II instrument (Illumina, USA). A total of 1,857,922 75-bp read pairs
were generated, giving estimated genome coverage of approximately 75X, based upon
an average genome size of 1.85 Mb according to other fully sequenced GAS.
To facilitate screening for potential NS88.2 virulence determinants and novel nucleotide
sequence, read pairs were assembled de novo using Velvet 1.0.13, a de Brujin graphbased assembly algorithm designed for short-read sequences (Zerbino and Birney,
2008). Iterative refinement of the -hash_length argument (kmer value) was
conducted, utilising genome draft length, contig n50 (a metric describing the length for
which the collection of all contigs of that length or longer contains at least half of the
sum of the lengths of the contigs), number of nodes (contigs) and maximum contig
length as approximate indicators of assembly quality (Fig. 3.1). A kmer value of 31 was
selected, as this value produced the longest relative genome and max contig length
and a lower relative number of nodes (Fig. 3.1). As such the following Velveth
command was used for sequence hashing.
./velveth

NS882gen

31

–fastq

–shortPaired

–

NS882/s_1_1_sequence.txt NS882/s_1_2_sequence.txt

Fig 3.1 Optimisation of kmer value for velveth hashing of NS88.2 read pairs. Iterative
refinement of the kmer value for velveth was conducted to optimise several draft genome
parameters including number of nodes, genome length (nt), contig n50 (nt) and maximum
contig length (nt). The optimum kmer value of 31 is indicated.
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A similar approach was taken for de Brujin graph construction, error removal and
repeat resolution, whereby iterative refinement of the -cov_cutoff argument was
used to remove low coverage nodes after assembly (Fig 3.2). As such a cov_cutoff value of 6 was chosen, resulting in the following command being used
for the second step of de novo genome assembly.
./velvetg NS882gen –exp_cov 70 –read_trkg yes –cov_cutoff 6 –
ins_length 300
Using this approach, a 1,731,197 bp genome draft of NS88.2 was generated, with 73fold average sequence coverage over 482 nodes, an n50 score of 14,205 bp and max
contig length of 63,219 bp. Nodes shorter than 100 bp were then manually removed
from the draft to reduce background noise in later homology searches, resulting in a
scaffold of 298 nodes over 1,727,974 bp.

Fig. 3.2 Optimisation of coverage cutoff (-cov_cuttoff) for velvetg de Brujin graph
generation, error removal and repeat resolution. Iterative refinement of the -cov_cutoff
value for velvetg was conducted to optimise several draft genome parameters including
number of nodes, genome length (nt), contig n50 (nt) and maximum contig length (nt). The
optimum –cov_cutoff value of 6 is indicated.

The unordered scaffold was used to calculate genomic distances between the NS88.2
draft genome sequence and publically available fully sequenced genomes, as given by
DNA maximal unique matches indices (MUMi) (Deloger et al., 2009), calculated using
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MUMmer3 (Kurtz et al., 2004) (Table 3.1). The GAS genome with the lowest MUMi
ratio

(indicating

closest

sequence

similarity),

MGAS315

(accession

number:

NC_004070), was then used as the reference for reordering the nodes using the contig
mover tool of Mauve (Darling et al., 2004). These contigs were concatenated and
submitted to the RAST server (http://rast.nmpdr.org) (Aziz et al., 2008) for automated
annotation, wherein open reading frames (ORFs) were called using the built in
Glimmer3 algorithm (Delcher et al., 2007), and putative protein function for each ORF
assigned from FIGfam subsystem families (Meyer et al., 2009). Manual curation and
analysis of the draft genome was conducted using Artemis 12.0 (Rutherford et al.,
2000) and read coverage mapped using BAMview (Carver et al., 2010).
Table 3.1 DNA maximal unique match indices (MUMi) calculated between the NS88.2 draft
scaffold and fully sequenced GAS genomes.

Genbank
Accession number
NC_002737

MUMi
ratio
0.2955

MGAS5005 (M1)

NC_007297

0.2960

MGAS10270 (M2)

NC_008022

0.3217

MGAS315 (M3)

NC_004070

0.2685

SSI-1 (M3)

NC_004606

0.2690

MGAS10750 (M4)

NC_008024

0.3201

MGAS10394 (M6)

NC_006086

0.3384

Manfredo (M5)

NC_009332

0.2870

MGAS2096 (M12)

NC_008023

0.3183

MGAS9469 (M12)

NC_008021

0.3052

MGAS8232 (M18)

NC_003485

0.3220

MGAS6180 (M28)

NC_007296

0.3005

NZ131 (M49)

NC_011375

0.3129

Strain (Serotype)
SF370 (M1)
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3.2.2

General features of the NS88.2 genome

The NS88.2 draft genome consists of a single circular chromosome with a sequence
length of 1.7 Mbp, G +C content of 39.35% and estimated 1659 protein coding
sequences (CDS), which account for 86.3% of the genome. The NS88.2 genome
encodes many previously characterised virulence factors, including streptolysin O (slo),
Mac-1-like protein (mac), SmeZ, cysteine protease SpeB and C5a peptidase (scpA),
though not streptococcal inhibitor of complement nor serum opacity factor, as expected
for an emm pattern D GAS isolate. Relatedness to other GAS was determined by multilocus sequence typing (MLST). The NS88.2 glucokinase (gki), glutamine transporter
protein (glnQ), glutamate racemase (murI), DNA mismatch repair protein (mutS),
transketolase (recP), xanthine phosphoriboyl transferase (xpt) and acetyl-CaA
acetyltransferase (yiqL) gene sequences were used to interrogate the MLST database
(http://spyogenes.mlst.net). These sequence data gave the following sequence types:
gki, 16; glnQ, 2; murI, 8; mutS, 3; recP, 2; xpt, 3, yiqL, 2; corresponding to a MLST
sequence type (ST) of 205. The relative abundances of sequence types and
connectedness of ST 205 to other GAS MLST types was then visualised using the
eBURST v3 tool (http://eburst.mlst.net) (Fig. 3.3). A population snapshot representing
all 602 known STs from 2343 typed isolates in the MLST database illustrates the
disparate evolutionary pathways that GAS appears to have undergone, demonstrated
by few single locus variations (SLV) which link separate ST clusters together (Fig. 3.3).
ST205 is connected by a SLV in gki to ST340, a founder for a small cluster of STs
primarily comprising emm53 GAS isolates.
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Comparison of NS88.2 FCT and MGA loci
Group A Streptococci carry a pathogenicity island known as the Fibronectin,

Fig. 3.3 Population snapshot of all 2343 GAS isolates in the MLST database. Each circle
represents a single ST, with the relative abundance of each ST indicated by the size of each
circle. Circles connected by lines are separated by a single variation in one of the seven loci
used to group STs together. Blue circles represent putative founders for each cluster, with subfounders coloured yellow. ST 205 (NS88.2 strain, indicated in red) and other STs representing
clinically prevalent emm-types; 28 (emm1), 52 (emm28), 36 (emm12), 39 (emm4), 15 (emm3),
176 (emm58), 63 (emm77), 340 (emm53); are indicated.

3.2.3

BLAST comparison of NS88.2 to other fully sequenced GAS genomes

Identification of novel NS88.2 genomic sequence and genes was conducted by whole
genome BLAST analysis and comparison to other fully sequenced GAS genomes
using the BLAST Ring Image Generator (BRIG) (Fig. 3.4) (Alikhan et al., 2011). The
majority of genetic variation (nucleotide sequence identity <80%) was localised to a
prophage-like region situated between base pairs 908,594 – 939,872. Closer
inspection of the core NS88.2 genome (excluding exogenous prophage-like sequence)
showed high similarity between NS88.2 and other GAS genomes, excepting the
NS88.2 MGA and FCT loci. Manual curation of BLAST results identified several genes
containing regions of variation with <80% sequence identity to all other fully sequenced
GAS genomes, including streptococcal collagen-like protein A, streptococcal collagenlike protein B, M protein and extra-cellular protein factor (Appendix G).
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Fig. 3.4 Genome-wide BLAST comparison of the NS88.2 draft genome to publicly
available fully sequenced GAS genomes. Rings are annotated from outermost to innermost.
Location of the variable fibronectin-binding, collagen-binding, T antigen (FCT) locus and MGA
regulatory region (ring 1). Coloured blocks denoting BLAST matches of 80% - 100% nucleotide
identity between NS88.2 and query genomes (rings 2 - 11; Genbank accession numbers are
indicated in parentheses): NZ131 (NC_011375), MGAS6180 (NC_007296), MGAS8232
(NC_003485), MGAS9469 (NC_008021) and MGAS2096 (NC_008023), MGAS10394
(NC_006086), Manfredo (NC_009332), MGAS10750 (NC_008024), SSI-1 (NC_004606) and
MGAS315 (NC_004070), MGAS10270 (NC_008022), MGAS5005 (NC_007297) and SF370
(NC_002737). Mapping coverage, red bars denote <200 fold coverage, blue bars denote >200
fold coverage (ring 12). Guanine and cytosine deviation (ring 13). Percent guanine and
cytosine content (ring 14). NS88.2 genome draft concatenated backbone in kilo base pairs
(kbp, ring 15).

3.2.4

Comparison of the NS88.2 FCT and MGA loci

GAS genomes are known to contain a Fibrinogen, Collagen and T-antigen (FCT) locus
that contains genes responsible for the assembly of a pilus structure (Mora et al.,
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2005). GAS pili are responsible for adherence to the host cells and binding of host
ECM components (Falugi et al., 2008; Manetti et al., 2007). Classification of the
NS88.2 FCT locus by the previously established FCT typing scheme corresponds to
FCT-3, which encode a collagen-binding protein Cpa and fibronectin-binding protein
PrtF2 (Kratovac et al., 2007). Comparison of the NS88.2 FCT sequence to other GAS
was conducted via BLASTn analysis and visualised using EasyFIG (Sullivan et al.,
2011) (Figure 3.4A). As expected, the NS88.2 FCT locus showed the highest sequence
identity with FCT-3 loci from other fully sequenced GAS strains (SSI-1, Manfredo,
MGAS8232 and NZ131) and low identity to strains bearing FCT types 1 (MGAS10394),
2 (SF370), 4 (MGAS6180) and 5 (MGAS10750) (Fig. 3.5A). Two genes comprising the
NS88.2 cpa and fctA also exhibited variability relative to other FCT type 3 GAS (SSI-1,
Manfredo, MGAS8232 and NZ131) as has been previously described (Kratovac et al.,
2007).
GAS express multiple anti-phagocytic virulence factors, many of which are encoded
within or regulated by the Multiple Gene regulator in group A Streptococci (MGA) locus
(Hollingshead et al., 1993). This region encodes the well-characterised M protein
(emm), in addition to M-like proteins (enn and mrp) and C5a peptidase (scpA). As an
emm-pattern D isolate, NS88.2 encodes both the plasminogen-binding M protein-like
protein, Prp, and two M-family proteins, Enn and Mrp in the MGA regulon (McKay et
al., 2004). Comparison of the NS88.2 MGA region to other GAS was conducted by
BLASTn analysis and visualised as previously (Fig. 3.4B). These data indicated high
sequence identity between NS88.2 scpA, mga, isp and the irk-irr operon to other GAS,
but limited homology between NS88.2 emm, and where present, enn and mrp in other
GAS (Fig. 3.5B). These data support current understanding of the hypervariable nature
of GAS M and M-like proteins.
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A

B

Fig. 3.5 Comparison of the NS88.2 FCT and MGA loci to other GAS strains. The NS88.2
FCT (A) and MGA (B) loci were compared with those of other GAS strains via BLASTn
analysis and shaded by percent sequence identity. A Brown, hsp33 and M1_0136 FCT locus
flanking genes; red, transcriptional regulators (nra, rofA, msmR); magenta, surface exposed
proteins (fctA. fctB); yellow, genes encoding fibronectin binding proteins (prtF1, prtF2, fbaB);
green, cpa collagen-binding protein; cyan, sortases (srtC1, srtC2, srtB); blue, lepA signal
peptidase; white, other ORFs. B Red, scpA C5a peptidase; orange, sic streptococcal
inhibitor of complement; cyan, isp immunogenic secreted protein; magenta, irk-irr twocomponent regulator; yellow, mga and mga-associated protein; green, emm streptococcal M
protein; blue, mrp M protein-related protein; brown, enn M-like protein. Genes are displayed
as 5’-3’ left to right, with arrows indicating gene direction. Nucleotide scale bars are drawn to
the sizes indicated in base pairs (bp) and BLASTn sequence identify (Blast seq. ID %) are
shaded as indicated.
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3.2.5

Analysis of NS88.2 prophage-like sequence

Bacterial outbreaks and variations in virulence capacity are often driven by lateral gene
transfer of novel genes that bestow antibiotic resistance or additional survivability within
the host. In GAS, the acquisition of exogenous DNA is primarily mediated via
bacteriophages, which have been previously associated with GAS epidemics and
acquisition of novel virulence factors, such as sda1 in M1T1 GAS (Maamary et al.,
2012). The NS88.2 draft genome contains at least one lysogenised prophage-like
element, with many contigs containing putative phage genes situated between base
pairs 908,594 – 939,872. Manual interrogation of this region (Appendix G) identified the
presence of a paratox (prx) gene in this region. Particular prx alleles have been
previously shown to be genetically associated with specific phage-encoded toxins,
such as speA2 and sda1 (Aziz et al., 2005). Analysis of the genes flanking prx showed
that a streptococcal pyrogenic exotoxin L (speL) is encoded adjacent to prx, which has
been previously associated with M89 isolates and is reported to bind mammalian MHC
class II molecules in a Zn-dependent manner (Proft et al., 2003).
As an additional screen for the presence of known phage-encoded virulence factors
unable to be assembled via the previously described pipeline, a read pair mapping
approach was applied. This method involved construction of a pan-prophage sequence
using the already defined prophage-like elements from fully sequenced GAS, and using
Maq software (http://maq.sourceforge.net), mapped the original raw read pairs from
NS88.2 Illumina sequencing to the concatenated phage sequence and visualised the
stacked reads using BAMview. Manual interrogation of this sequence showed that
mapped reads were primarily situated on nodes containing putative phage structural
genes, phage integrases, AttL and AttR integration sites and the previously described
prx and speL genes (Appendix G).
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3.2.6

Secretion signal peptide and cell-surface anchor prediction

To identify genes encoding secreted proteins, protein coding sequences from NS88.2
were

interrogated

using

the

SignalP

4.1

algorithm

(http://www.cbs.dtu.dk/services/SignalP/) (Bendtsen et al., 2004) using the gram-positive
bacteria option and default D-cutoff values. By this approach, 190 genes encoding
proteins with putative secretion signal peptides were identified, including genes
encoding previously characterised secreted virulence factors such as streptolysin O,
streptolysin S and streptokinase (Appendix G). Cell-surface bound proteins were also
bioinformatically predicted via the hmmsearch function of the hmmer3 package
(http://hmmer.janelia.org/). Analysis using hidden Markov model for Gram-positive
anchor motifs identified 10 genes encoding putative cell-surface anchored proteins,
including NS88.2 M protein, M-like proteins and streptococcal collagen-like protein A
(Appendix G).
3.3

Discussion

The methods by which bacterial phenotypes are analysed have evolved over the last
decade to harness the technologies that are now available. Whole-genome shotgun
sequencing offers a rapid and comprehensive approach to genetically screen bacteria,
and characterise their evolution and acquisition of novel genetic content (Parkhill and
Wren, 2011). More so, NGS technologies such as Illumina’s sequencing by synthesis,
454 Life Science’s pyrosequencing or Applied Biosystem’s SOLiD sequencing method,
produce a profusion of data that enables comprehensive, genomic based screening
approaches to be undertaken (Metzker, 2010). In this study, we utilised Illumina based
sequencing technology to assemble a draft genome sequence of the hypervirulent
NS88.2 GAS isolate. The construction of this sequence permitted calculation of
relatedness to other GAS, secreted and cell-surface protein prediction, in-depth
analysis of prophage-like elements and whole genome sequence comparison between
NS88.2 and other fully sequenced GAS.
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Analysis of other fully sequenced GAS reveals that the GAS core genome (excluding
all prophage-like material and other exogenous genetic elements) is highly conserved,
whereas variation in these genetic elements may account for up to 10% of the genome
(Musser and Shelburne, 2009). The source of this variation is primarily from the
integration of prophage elements, which are responsible for intra- and inter-serotype
circulation of GAS virulence factors (Aziz et al., 2005; Beres et al., 2002; Nakagawa et
al., 2003). Analysis of NS88.2 prophage-like sequence did not elucidate any factors
that have obvious roles in bestowing resistance to neutrophil killing. However, read
coverage of this region was also lower than in more conserved areas, and a more
targeted approach to sequencing and analysing NS88.2 prophage-like material may be
necessary to fully deconvolute the number, position and content of NS88.2 prophages.
Other individual, non-phage related genes in the NS88.2 genome also display
divergence from other fully sequenced GAS (Fig. 3.5). Some of these genes, including
emm, mrp and enn, encode proteins with secretion signal peptides, cell-wall surface
anchors and have known anti-phagocytic roles in pathogenesis (Horstmann et al.,
1988; Podbielski et al., 1994), and support putative roles for other genes in mediating
host-pathogen interactions.
Several recent studies have employed large scale, high-throughput sequencing to
characterise GAS epidemics (Beres et al., 2010; Fittipaldi et al., 2012; Shea et al.,
2011). Such analyses greatly enhance our knowledge of GAS genome biology, with the
addition of 396 M3 genomes and 601 M59 genomes to genome databases (Fittipaldi et
al., 2012; Shea et al., 2011). The ability to rapidly sequence and analyse epidemic
strains

(<10

days

from

strain

isolation

to

full-genome

sequencing),

and

comprehensively characterise their genetic makeup through comparative genomics
and single nucleotide polymorphism (SNP) profiling, allows the precise evolution of
epidemics to be traced (Fittipaldi et al., 2012; Maamary et al., 2012; Tse et al., 2012).
These approaches can also be applied within smaller clinical scenarios to determine
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causal bacterial clones, and thus make more informed inferences regarding sources of
bacterial transmission within hospitals (Ben Zakour et al., 2012; Walker and Beatson,
2012).
Full genome shotgun sequencing of NS88.2 will enable other systematic analyses of
this isolate, to comprehensively define the complete genomic, transcriptional and
proteomic factors which underlie the virulent and immuno-modulating qualities it
exhibits.
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CHAPTER 4: STREPTOCOCCAL COLLAGEN-LIKE PROTEIN A AND GENERAL
STRESS PROTEIN 24 ARE IMMUNO-MODULATING VIRULENCE FACTORS OF
GROUP A STREPTOCOCCUS

A major part of this work has been published in FASEB J and is formatted accordingly.
Reference:
James A. Tsatsaronis, Andrew Hollands, Jason N. Cole, Peter G. Maamary, Christine
M. Gillen, Nouri L. Ben Zakour, Malak Kotb, Victor Nizet, Scott A. Beatson, Mark J.
Walker, Martina L. Sanderson-Smith (2013). Streptococcal collagen-like protein A and
general stress protein 24 are immuno-modulating virulence factors of group A
Streptococcus. FASEB J. 7: 2633-43.
4.1

Abstract

In Western countries, invasive infections caused by M1T1 serotype group A
Streptococcus (GAS) are epidemiologically linked to mutations in the control of
virulence regulatory two-component operon (covRS). In indigenous communities and
developing countries, severe GAS disease is associated with genetically diverse nonM1T1 GAS serotypes. Hypervirulent M1T1 covRS mutant strains arise through
selection by human polymorphonuclear cells for increased expression of GAS virulence
factors such as the DNase Sda1, which promotes neutrophil resistance. The GAS
bacteraemia isolate NS88.2 (emm 98.1), is a covS mutant that exhibits a hypervirulent
phenotype and neutrophil resistance, yet lacks the phage-encoded Sda1. Here, we
have employed a comprehensive systems biology approach to identify NS88.2
virulence determinants that enhance neutrophil resistance in the non-M1T1 GAS
genetic background. Using this approach, we have identified streptococcal collagenlike protein A and general stress protein 24 proteins as NS88.2 determinants that
contribute to survival in whole blood and neutrophil resistance in non-M1T1 GAS. This
study has revealed new factors that contribute to GAS pathogenicity that may play
important roles in resisting innate immune defences and the development of human
invasive infections.
83

4.2

Introduction

Streptococcus pyogenes (group A Streptococcus, GAS) infection is responsible for
human mortality and morbidity on a global scale. Severe disease pathologies caused
by GAS include acute suppurative invasive conditions such as bacteraemia,
streptococcal toxic shock-like syndrome (STSS), and necrotising fasciitis, as well as
post-infectious immune-mediated sequelae in the form of acute rheumatic fever and
glomerulonephritis (Cole et al., 2011). Epidemiologically, severe GAS infections in
developed countries are dominated by a handful of serotypes (Schwartz et al., 1990).
Notably, the well-characterised M1T1 GAS clone is frequently isolated from invasive
infection (Chatellier et al., 2000). A resurgence in the rates of severe GAS disease over
the last three decades has been paralleled by the global emergence of clonal
hypervirulent M1T1 and M3 isolates (Ikebe et al., 2002; Sharkawy et al., 2002). In
contrast, diverse GAS serotypes are endemic in indigenous and developing
communities, where no serotype predominates (Carapetis et al., 1999). Necrotising
fasciitis isolates from tropical northern Australia exhibit emm diversity, and serotypes
that monopolise disease epidemiology in the Western hemisphere are seldom
encountered (Hassell et al., 2004). Thus isolates from indigenous and developing
areas make ideal model organisms for the study of emergent, invasive GAS strains.
Multiple factors appear to underlie the pandemic spread of M1T1, including the recent
acquisition of phage-encoded virulence factors that dampen innate immune responses
(Aziz and Kotb, 2008; Sumby et al., 2005). Bacteriophage-encoded deoxyribonuclease
Sda1 enables M1T1 GAS to degrade neutrophil extracellular traps (NETs) (Buchanan
et al., 2006), and the transfer of Sda1 to M1T1 provides a selective trigger for acquiring
mutations in the control of virulence covRS regulator (Walker et al., 2007). Certain
mutations of covRS result in the up-regulation of many GAS virulence factor genes
including sda1 and those encoding streptolysin O and hyaluronic acid capsule (Aziz et
al., 2010; Kansal et al., 2010; Sumby et al., 2006). Furthermore, expression of the
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broad spectrum cysteine protease SpeB is also abrogated as a result of covRS
mutation, preserving the integrity of many GAS virulence proteins (Aziz et al., 2004b)
and allowing the pathogen to acquire cell-surface plasmin activity capable of degrading
fibrin clots which impede bacterial dissemination (Cole et al., 2006). Thus, the in vivo
selection for GAS covRS mutants by the host innate immune system inadvertently
initiates a permanent genetic switch to a hypervirulent phenotype, capable of resisting
neutrophil-mediated killing and subverting the host plasminogen activation system for
systemic infection (Cole et al., 2011).
The mechanisms coordinating the virulence of non-M1T1 GAS are less defined. It has
recently been shown that mutation of covRS in a range of GAS M-types results in a
genetic switch analogous to that seen in M1T1 (Maamary et al., 2010), and that GAS of
divergent M-types with mutations in covRS and/or the regulatory ropB gene are
frequently isolated from STSS patients (Ikebe et al., 2010). However, the mechanisms
underlying the hypervirulent phenotype in the absence of the bacteriophage encoded
DNase Sda1 are yet to be characterised. The clinical isolate NS88.2 (emm98.1)
encodes a mutated covS gene, is highly-encapsulated, acquires cell-surface plasmin
activity, is resistant to killing by human neutrophils and is hypervirulent in a humanised
plasminogen mouse model (Maamary et al., 2010; Sanderson-Smith et al., 2008).
Here, we apply a comprehensive systems biology approach to analyse this
representative non-M1 isolate, in order to identify virulence determinants contributing to
GAS neutrophil resistance, leading to invasive infection in the absence of sda1.
4.3

Materials and methods

4.3.1

Ethics statement

Permission to collect human blood under informed consent was approved by the UCSD
Human Research Protections Program and the University of Wollongong Human Ethics
Committee. All animal use and procedures were approved by the UCSD Institutional
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Animal Care and Use Committee and the University of Wollongong Animal Ethics
Committee.
4.3.2

Biofilm formation

Measurement of biofilm formation on polystyrene essentially as previously described
(Hollands et al., 2010). Briefly, 12 individual wells of a tissue culture treated 96-well
microtitre plate were inoculated with 150 µl of overnight culture diluted 1:100 in THB
and incubated for 24 h at 37°C. Plates were washed with sterile phosphate-buffered
saline (PBS), and cells were fixed with 4% paraformaldehyde. Wells were stained with
0.2% crystal violet, extracted in ethanol/acetone (80:20), and assayed for crystal violet
absorbance at 595 nm for biofilm quantification.
4.3.3

Epithelial cell adherence and invasion assay

Assays measuring the adherence of GAS to human keratinocyte cells (HaCaT) were
performed as previously described (Hollands et al., 2010). Mid-logarithmic phase GAS
(2 x 106 CFU) were added to HaCaT cells (2 x 105 cells) in the wells of a 24 well plate,
centrifuged for 10 min at 500 x g and incubated at 37°C in 5% CO2. For adherence
assays, plates were incubated for 30 min prior to washing with PBS with subsequent
release and lysing of cells. Bacteria were serially diluted and plated on THYA for
enumeration. For invasion assays, plates were incubated for 2 h. Plates were then
washed as previously described and treated with gentamicin and penicillin G. Plates
were then incubated for a further 2 h, prior to washing and treating as described above.
Bacterial adherence and invasion was calculated as a percentage of the original
inoculum. Statistical significance was determined using one-way ANOVA with the
Tukey post-hoc test.
4.3.4

Murine skin adherence assay

Adherence of GAS to mice flank was assessed in vivo as previously conducted
(Hollands et al., 2010). Mid-logarithmic phase GAS culture (2 x 105 CFU) was spotted
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onto THYA plates, air-dried and agar disks containing the bacteria excised using a
biopsy punch. Bacterial agar disks were affixed to a total of 10 CD1 mice, each with 3
disks (one each of the wild type NS88.2, NS88.2rep and NS88.2covS). After 1 h, the
mice were euthanised and skin under the bacterial disks was excised. Tissue was
thoroughly washed with sterile PBS to remove non-adherent bacteria prior to
homogenisation. Homogenate was serially diluted in sterile PBS and plated on THYA
for enumeration. Bacterial adherence was calculated as a percentage of the original
inoculum. Statistical significance was determined using one-way ANOVA with the
Tukey post-hoc test.
4.3.5

Transcriptional Microarray

The oligonucleotide microarray used in this study and the method for in vitro
transcriptional microarray has been described previously (Maamary et al., 2010). Midlogarithmic phase GAS cultures were grown in THBY and RNA extracted using the
RNeasy Mini Kit (Qiagen, Germany). RNA was DNase-treated and converted to
dendrimer-labeled cDNA using the Genisphere 3DNA Array 900MPX Kit according the
manufacturer’s guidelines. Dendrimer-labeled cDNA was hybridised to the array and
labelled with Alexa Fluor 546 or Alexa Fluor 647. Sliders were scanned with a GenePix
4000B scanner (Molecular Devices, USA) and images processed using GenePixPro
4.0 software (Molecular Devices, USA). Transcriptional analyses were performed with
GeneSpring GX 10 (Agilent, USA). All transcriptional microarray data were submitted to
the NCBI Gene Expression Omnibus (GEO) according to the MIAME standards (GEO
accession No. GSE23825).
4.3.6

NET Degradation

Visualisation of NET degradation was conducted as previously (Buchanan et al., 2006).
Human neutrophils were purified from venous blood using a PolyMorphPrep kit (AxisShield, Norway) as per the manufacturer’s instructions and seeded at 2 x 105 cells per
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well in 96-well plates. GAS were added to the wells at a multiplicity of infection of 1:100
(GAS:neutrophils) and Sytox Orange (Invitrogen, USA) added at a final concentration
of 0.1 µM. Cells were visualised without fixation or washing using a Zeiss Axiovert 100
inverted microscope with appropriate fluorescent filters, and images captured with a
CCD camera. For quantification, NETs were enumerated for each treatment by
counting one transect after staining from 3 independent wells; a NET was defined as a
discrete area of bright orange fluorescence larger than the size of a neutrophil.
Statistical significance was determined using one-way ANOVA with the Tukey post-hoc
test.
4.4

Results

4.4.1

Reduction of NS88.2 colonisation potential due to covS mutation

Similar to the globally disseminated M1T1 GAS, mutation of covS in non-M1T1 GAS
results in a hypervirulent, neutrophil resistant phenotype (Maamary et al., 2010). Such
mutations in the M1T1 background have come with a potential fitness cost, as the covS
mutant displays reduced capacity for biofilm formation and epithelial adherence and
invasion (Hollands et al., 2010). To determine whether this phenomenon occurred in
the non-M1T1 background, clinical covS mutant GAS isolate NS88.2 (emm98.1) from a
case of severe bacteraemia in Australia’s Northern Territory (McKay et al., 2004) was
compared to isogenic derivative strains with the covS mutation repaired (NS88.2rep)
and the covS regulator returned to non-functionality via reverse complementation
(NS88.2covS) (Maamary et al., 2010). Restoration of functional covS in NS88.2rep
resulted in a significant increase in biofilm formation compared to the wild-type NS88.2
or the reverse complemented mutant NS88.2covS, which each express truncated
CovS (P < 0.001) (Fig. 4.1A). A similar result was observed with respect to the ability of
the NS88.2 strains to adhere to and invade epithelial cells. The intact covS NS88.2rep
strain showed a significant increase in adherence to and invasion of the HaCaT
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keratinocyte cell line over the covS mutant NS88.2 and NS88.2covS strains (P < 0.001)
(Fig. 4.1B). This in vitro data was further corroborated by in vivo assays, as adhesion to
live mouse skin was also compromised by covS mutation in NS88.2 and NS88.2covS
(P < 0.01) (Fig. 4.1C).

Fig. 4.1 Reduction of colonisation propensity due to covS inactivation in NS88.2. A
Biofilm formation of covS inactive strains NS88.2 and NS88.2covS and covS intact strain
NS88.2rep. B Adherence and invasion of HaCaT human keratinocytes by NS88.2, NS88.2rep
and NS88.2covS. C Adherence of NS88.2, NS88.2rep and NS88.2covS to live mouse flanks.
Panels B and C are expressed as a percentage of adherent/invasive bacteria of the original
inoculum. Values shown for panels A and B are means ± standard deviations. *** indicates P <
0.001, ** indicates P < 0.01.
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4.4.2

NS88.2 neutrophil resistance does not require neutrophil extracellular trap

degradation
NS88.2 is highly resistant to neutrophil killing (Maamary et al., 2010); however PCR
and genomic screening indicates that NS88.2 does not contain the sda1 gene (Chapter
3). The ability of NS88.2 and the isogenic covS derivative mutants NS88.2rep and
complemented mutant NS88.2covS to degrade NETs was examined. We observed no
significant differences in NET degradation between NS88.2, the NS88.2 derivative
strains or 5448∆sda1, an M1T1 GAS strain with sda1 deleted via precise allelic
exchange (Fig. 4.2). In contrast, the covRS mutant animal-passaged 5448AP strain
exhibited significantly higher NET degradation in comparison to all of the NS88.2
strains and 5448∆sda1 (P < 0.001). We conclude that in the absence of Sda1, other
virulence factors play a role in NS88.2 neutrophil resistance. To test this hypothesis,
we undertook a systems biology approach to identify virulence determinants
contributing to neutrophil resistance in this genetic background.

Fig. 4.2 GAS mediated degradation of extracellular neutrophil DNA NETs. NET
degradation by GAS strains NS88.2, NS88.2rep and NS88.2covS and M1T1 GAS strains
5448AP (animal passaged 5448 encoding a truncated covS protein) and 5448∆sda1 (a 5448
derivative with sda1 isogenically deleted). Values shown are means ± standard deviations. ***
indicates P < 0.001.
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4.4.3

Screening of the NS88.2 secretome

GAS secrete many proteins which play immune-modulating roles during infection.
Screening of the NS88.2, NS88.2rep and NS88.2covS supernatant protein fractions
was conducted via two-dimensional electrophoresis to experimentally confirm the
surface exposure of putatively secreted proteins (Fig. 4.3). To analyse peptide mass
fingerprinting data, we used CDS data from the NS88.2 draft genome sequence
(Chapter 3), and formatted this information as a database which could be interrogated
by the Mascot search engine (2.11) (Perkins et al., 1999). Multiple putatively
cytoplasmic proteins were detected in the supernatant, as has been noted previously
(Lei et al., 2000). Notably, of the 42 supernatant proteins identified (Table 4.1), SclA
and general stress protein 24 (Gls24) were both found in the supernatants of NS88.2
and NS88.2covS, but not in NS88.2rep. As with M1T1 GAS (Aziz et al., 2004b),
expression of cysteine protease SpeB resulted in the degradation of much of the
NS88.2rep secretome, including Gls24 and SclA, when grown in the absence of
cysteine protease inhibitor E64 (data not shown).

Fig. 4.3 Screening of the NS88.2 secretome. Secreted proteomic profiles of A NS88.2, B
NS88.2rep and C NS88.2covS. Proteins identified via MALDI-TOF MS are indicated with
numbered arrows (Table 4.1). Molecular masses of marker proteins (expressed as kilo Daltons,
kDa) and approximate isoelectric point (pI) values of each gel are indicated. Results shown are
representative of duplicate gels from two independent protein isolations.

91

Table 4.1 List of proteins identified in the supernatant of NS88.2, NS88.2rep and
NS88.2covS.

Protein

pI

a

Size
(kDa)

Peptide
b
Match

Coverage
22

1

Translation elongation factor G

4.83

76.5

9

2

Transketolase

4.98

71.4

3

6

3

Chaperone protein DnaK

4.62

64.9

8

19

4

Cell division trigger factor

4.48

47.1

3

16

5

Heat shock protein 60 family chaperone GroEL

4.75

42.1

8

32

6

Collagen-like surface protein A

5.39

32.2

3

13

7

Immunogenic secreted protein

5.42

54.1

4

10

8

Group B streptococcal surface immunogenic protein

4.62

40.8

4

18

9

Enolase

4.80

47.3

12

41

10

Pyruvate kinase

4.96

54.5

10

24

11

Xaa-His dipeptidase

4.87

51.3

6

19

12

SSU ribosomal protein S1p

4.90

43.8

7

20

13

Translation elongation factor Tu

4.89

43.9

9

36

14

Non-phosphorylating glyceraldehyde-3-phosphate
dehydrogenase

5.06

50.4

6

19

15

Arginine deiminase

4.99

46.3

6

18

16

Phosphoglycerate kinase

4.82

42.1

11

42

17

Translation elongation factor Ts

4.86

37.3

7

28

18

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)

5.34

35.9

5

15

19

L-lactate dehydrogenase

5.14

35.3

5

22

20

Phosphate acetyltransferase

4.85

35.9

4

15

21

6-phosphofructokinase

5.34

35.7

4

11

22

Manganese-dependent inorganic pyrophosphatase

4.47

33.9

4

20

23

Fructose-bisphosphate aldolase class II

4.98

31.2

5

32

24

Protein serine/threonine phosphatase PrpC

4.60

27

5

31

25

Adenylate kinase

4.74

23.7

4

29

26

Translation elongation factor P

4.85

20.4

4

27

27

Manganese superoxide dismutase

4.87

22.7

6

45

28

Phosphoglycerate mutase

5.10

26

7

41

29

Ribosomal subunit interface protein

4.45

21.1

4

34

30

Peptidoglycan hydrolase, Autolysin2

4.66

25.5

4

31

31

Alkyl hydroperoxide reductase protein C

4.65

20.5

3

22

32

Sortase A, LPXTG specific

9.17

27.7

5

18

33

Transcription elongation factor GreA

4.67

17.6

3

31

34

General stress protein, Gls24 family

4.93

12.6

5

50

35

Peptide deformylase

5.50

22.9

3

22

36

Streptodornase B; Mitogenic factor 1

8.61

28.7

6

33

37

Triosephosphate isomerase

4.57

26.6

6

33

38

Ribosome recycling factor

5.58

20.6

4

22

39

Streptokinase

5.58

50.2

9

28

40

Secreted antigen GbpB/SagA/PcsB, putative peptidoglycan
hydrolase

8.42

42

3

15

41

Streptococcal pyrogenic exotoxin B (SpeB)

8.76

43.2

8

28

42

M1_SPy_1686

4.40

12.6

2

24

c

a

Isoelectric point calculated using Expasy compute pI/Mw tool
Number of tryptic peptides from mass spectrum matched to theoretical tryptic digest of protein
sequence
c
Percentage coverage of protein sequence covered by Peptide Matches
b
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4.4.4

Expression of the NS88.2 transcriptome

The covRS operon has been shown to control ~10-15% of the GAS genome, including
many genes which have proven or putative roles in host-pathogen interactions (Sumby
et al., 2006). We subjected the parental NS88.2 strain bearing a mutated covS gene
and the derivative NS88.2rep with intact covS to transcriptional microarray analysis
during mid-logarithmic phase growth (Appendix H). Comparison of the transcriptional
profile of NS88.2 to NS88.2rep showed significant de-repression of many virulence
genes associated with resistance to innate immune responses, including emm, scpA,
slo and the hyaluronic acid capsule biosynthesis genes hasA and hasB (Fig. 4.4). The
sclA gene was also found to be highly up-regulated in NS88.2 compared with
NS88.2rep. A putative antibiotic resistance gene norA, and speB were found to be
repressed in NS88.2 as a result of covS mutation, in accordance with previous studies
(Maamary et al., 2010; Sumby et al., 2006).

Fig. 4.4 Differential regulation of genes between the parental NS88.2 wild-type strain,
which contains a covS inactivating mutation and derivative NS88.2rep which encodes a
functional covS gene. Selected genes are significantly differentially expressed (P < 0.05).

To validate the microarray data, a panel of five genes was chosen for interrogation
using quantitative real-time PCR analysis (Fig. 4.5A). The strong up-regulation of the
emm, sclA and hasA genes, and down-regulation of speB in wild-type NS88.2 relative
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to the NS88.2rep strain were found to be consistent with the microarray analysis. In
addition, expression of the gls24 gene was analysed and did not show significant
differences in regulation between the two covS variants. However, 2D-PAGE data
described previously (Fig. 4.5) and in vitro assays utilising purified Gls24 protein
suggest that expression of Gls24 may be regulated at the protein level via SpeBmediated degradation (Fig. 4.6). Exposure of GAS to whole blood is likely to play an
important role in the regulation of GAS genes during infection, and gene expression
levels were also investigated following 1 h incubation in sanguis (Fig. 4.5B). Transcripts
were quantified relative to the proS housekeeping gene, and the relative transcript
abundance between NS88.2 and NS88.2rep cultured in THY and cultured in blood was
estimated. Growth of NS88.2 and NS88.2rep in blood resulted in a significant (P <
0.001) up-regulation of gls24 expression relative to growth of the same strains in THY.
Other NS88.2 genes (sclA, emm) also displayed increased expression in response to
exposure to blood, whilst speB showed consistent down-regulation in response to
growth in whole blood and covS mutation.

Fig. 4.5 SclA and Gls24 are up-regulated in response to growth in whole blood. A
Quantitative real-time PCR analysis of NS88.2 genes during mid-logarithmic phase growth.
Fold-change in expression between NS88.2 relative to NS88.2rep is indicated. B Quantitative
real-time PCR analysis of NS88.2 genes during mid-logarithmic phase growth in THY or after 1
h incubation in whole blood. Transcript abundance is expressed relative to the house-keeping
gene proS. *** indicates P < 0.001.
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Fig. 4.6 Gls24 protein is degraded by GAS cysteine protease SpeB in vitro. Lane 1: SpeB
and Casein; Lane 2: SpeB and Gls24; Lane 3: Casein; Lane 4: Gls24; Lane 5: SpeB.
Molecular weight markers are given in kilo-Daltons (kDa).

4.4.5

SclA and Gls24 contribute to NS88.2 survival in whole blood and neutrophil

resistance
Taken collectively, the presence of SclA and Gls24 in the NS88.2 secretome; upregulation of sclA as a result of covS mutation; up-regulation of Gls24 after incubation
in whole blood, the presence of secretion signal peptides in both proteins and their
putative roles in virulence indicated these factors may function alone or in synergy as
virulence determinants of NS88.2. SclA exhibits a variety of binding propensities
including alternative complement factor H (FH) and FH-related protein 1 (Caswell et al.,
2008), thrombin-activatable fibrinolysis inhibitor (Pahlman et al., 2007), low-density
lipoproteins (Han et al., 2006) and α2β1 integrins (Humtsoe et al., 2005). It has also
been shown that SclA is expressed during human infection, and that SclA elicits a
humoral immune response against the collagen-like region of this protein (Hoe et al.,
2007). Gls24 contributes to the virulence of Enterococcus faecalis in an endocarditis
model and is involved in stress tolerance of that pathogen (Nannini et al., 2005; Teng
et al., 2005). To assess the effect of these proteins on NS88.2 innate immune
resistance, the sclA and gls24 genes were isogenically deleted from the NS88.2
genome

via precise

allelic replacement

with the

cat

gene

(Appendix D).
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Complementation of the sclA and gls24 deficient strains was conducted via
transformation with sclA or gls24 expressing pDCerm variants (Appendix D).
The ability of NS88.2 and the sclA and gls24 isogenic deletion mutants to replicate in
whole blood was assessed via Lancefield bactericidal assays (Humtsoe et al., 2005)
(Fig. 4.7A-B). Deletion of either sclA or gls24 significantly impaired the survival of the
isogenic mutants in comparison to NS88.2 (NS88.2∆sclA, P < 0.001; NS88.2∆gls24, P
< 0.01). Complementation of the sclA or gls24 deletion via heterologous expression
restored survival in whole blood to both isogenic mutants (P > 0.05) (Fig. 4.7A-B).
These changes were resultant of the activity of SclA and Gls24 in whole blood, as the
growth kinetics of the isogenic mutants and complemented strains in THY were
unchanged relative to the wild-type NS88.2 (Fig. 4.8A). Further examination of the role
of SclA and Gls24 in innate immune responses was studied via measurement of the
NS88.2 strains resistance to neutrophil mediated killing (Fig. 4.7C-D). In comparison
with the NS88.2 wild type, both NS88.2∆sclA and NS88.2∆gls24 displayed significantly
reduced neutrophil resistance (P < 0.05) whilst the complemented isogenic mutants
exhibited neutrophil resistance equivalent to the wild-type (P > 0.05) (Fig. 4.7C-D). This
difference in resistance to neutrophil killing was independent of capsule expression as
the isogenic deletion mutations and complemented strains express equivalent amounts
of hyaluronic acid (Fig. 4.8B).
4.5

Discussion

Genetic integrity of the two-component gene regulator covRS is a major determining
factor of GAS virulence and colonisation. M1T1 GAS that bear the intact form of this
operon are more highly suited to adherence and colonisation of host tissues (Hollands
et al., 2010). In this study we have characterised the emm98.1 invasive isolate NS88.2.
Phenotypically, this isolate is hypervirulent and neutrophil resistant (Maamary et al.,
2010), whilst the covS intact derivative (NS88.2rep) is avirulent, and exhibits increased
biofilm formation and adhesion to epithelial cells. However, NS88.2 does not contain
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sda1 nor does it degrade neutrophil NETs, and so the mechanism of neutrophil
resistance exhibited by NS88.2 is unaccounted for. Transcriptomic and proteomic data
generated here demonstrates a cohort of immunomodulating virulence factors is upregulated as a result of covS mutation in NS88.2, including the antiphagocytic M
protein and SclA.

Fig. 4.7 Deletion of sclA or gls24 impairs NS88.2 growth in whole blood and
resistance to neutrophil-mediated killing. Fold growth of NS88.2, the sclA deficient
mutant NS88.2∆sclA and complemented derivative NS88.2∆sclA (pDC-sclA) (A); the gls24
deficient mutant NS88.2∆gls24 and complemented derivative NS88.2∆gls24 (pDC-gls24)
(B) after 3 h incubation in human whole blood. Ability of NS88.2, NS88.2∆sclA,
NS88.2∆sclA (pDC-sclA) (C), NS88.2∆gls24 and NS88.2∆gls24 (pDC-gls24) (D) to survive
neutrophil-mediated killing following co-culture with purified human PMNs. All assays were
performed with a minimum of 3 donors and all assays were conducted in triplicate. Values
shown for all panels are means ± standard deviations of triplicate assays. *** indicates P <
0.01, ** indicates P < 0.01, * indicates P < 0.05.
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A

B

Fig. 4.8 Deletion of NS88.2 sclA or gls24 does not impact growth in Todd-Hewitt broth
or capsule synthesis. A Growth of NS88.2, sclA and gls24 isogenic knock-mutant mutants
and complemented strains growth kinetics in Todd-Hewitt broth. B NS88.2, sclA and gls24
isogenic knock-out and complemented strains hyaluronic acid capsule biosynthesis. Capsule
is expressed as femtograms of hyaluronic acid per colony forming unit (fg/CFU). Values
shown for panel B are means ± standard deviations.

Isogenic deletion of sclA and gls24 from the NS88.2 genome was conducted to
investigate their role in providing resistance to innate immune responses. Multiple
attempts to generate a double-knockout mutant were unsuccessful. This is a
noteworthy finding as it may indicate such a knockout is lethal in GAS. The finding that
loss of sclA expression results in attenuated growth in whole blood and increased
neutrophil sensitivity, is consistent with previous work describing the binding of
complement regulatory factors to SclA (Caswell et al., 2008; Pahlman et al., 2007;
Reuter et al., 2010). SclA is ubiquitously distributed in GAS strains; however sclA
shows evidence of recombination and immune-selection analogous to the gene
encoding M protein (Hoe et al., 2007; Rasmussen et al., 2000). This gives credence to
a potential anti-phagocytic role in pathogenesis, as sclA hyper-variability could drive
antigenic variation on the GAS cell surface and thus enhanced immune evasion
through decreased FcR-mediated bacterial uptake. GAS binding of mammalian
integrins with SclA may also facilitate escape from phagolysosomal killing via uptake
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into the cytoplasm (Humtsoe et al., 2005). Previous work implicates Gls24 in the
survival of E. faecalis during culture in human blood and in urine (Vebo et al., 2009;
Vebo et al., 2010). Gls24 was also found to be up-regulated at a protein level in
response to growth of GAS in hyaluronic acid enriched media simulating an infection
scenario (Zhang et al., 2007) and during microarray analysis of murine soft tissue GAS
infection (Graham et al., 2006). To date this is the first work demonstrating the direct
impact of gls24 mutation on GAS survival and work is currently ongoing to determine
the precise mechanism of action of Gls24 in systemic GAS infection.
Mutations in covRS have been linked to the hypervirulence of GAS in animal models of
infection (Cole et al., 2006; Maamary et al., 2010). Moreover, the recently published
recovery of an emm81.0 covS mutant GAS isolate following 13 days of human
carriage, supports a model which predicts that such mutations occur clinically in a
range of serotypes and in doing so escalate the severity of infection (Garcia et al.,
2010; Ikebe et al., 2010; Maamary et al., 2010). Recent work has shown that functional
emm and hasA genes, are also essential for the acquisition of covRS mutations (Cole
et al., 2010). Data from this study supports a model in which GAS utilise a cohort of
immune modulating virulence factors to attain a highly neutrophil resistant phenotype,
leading to more severe infection.
Despite ongoing research effort, the burden of GAS infection in developing areas and
indigenous populations remains high, and is likely to be underestimated. Here, we
demonstrate the utility of systems biology approaches to identify novel bacterial
virulence factors. Such virulence factors may prove valuable targets for future
therapeutic or vaccine interventions to treat this globally important pathogen.
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CHAPTER 5: GROUP A STREPTOCOCCUS MODULATES TISSUE
INFLAMMATION BY MANIPULATING POLYMORPHONUCLEAR LEUKOCYTE
CELL DEATH RESPONSES

The results presented are in preparation for submission to the Journal of Infectious
Diseases and are formatted accordingly.
Reference:
James A. Tsatsaronis, Oliver Goldmann, Manfred Rohde, Jude Taylor, Diane Ly,
Robert Geffers, Mark J. Walker, Eva Medina, Martina L. Sanderson-Smith. (2014)
Group

A

Streptococcus

modulates

tissue

inflammation

by

manipulating

polymorphonuclear leukocyte cell death responses.
5.1

Abstract

The nature of polymorphonuclear leukocyte (PMN) cell death can strongly influence
resolution of inflammatory episodes, and may also exacerbate tissue damage resulting
from immunopathology in response to infection. Virulent group A Streptococcus (GAS)
strains

generally

induce

robust

inflammatory

responses

that

underlie

the

pathophysiology of suppurative GAS diseases. In this study we examined the influence
of PMN cell death induced by avirulent and virulent GAS in the modulation of tissue
inflammation. PMNs phagocytosed virulent GAS less efficiently in in vitro infection
assays, produced less reactive oxygen species, and underwent reduced mitochondrial
membrane depolarisation than avirulent GAS strains. Morphological and biochemical
analyses revealed a dichotomy in GAS-infected PMN cell death responses, whereby
PMNs infected with avirulent GAS exhibited nuclear fragmentation and caspase-3
activation consistent with an anti-inflammatory PMN apoptotic phenotype. Conversely,
virulent GAS induced PMN vacuolisation and plasma membrane permeabilisation,
leading to oncotic cell death. Cutaneous infection of C57BL/6 mice with virulent GAS
engendered localised infiltration of neutrophils exhibiting reduced apoptotic potential,
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whereas avirulent GAS infection was associated with tissue PMN apoptosis. We
propose differences in PMN cell death mechanisms influence inflammatory responses
to infection by GAS.
5.2

Introduction

Polymorphonuclear leukocytes (PMNs) are highly abundant, phagocytic immune cell
indispensable for host defence against infection. Massive numbers of PMNs are rapidly
recruited to sites of bacterial infection, which utilise highly potent mechanisms to
destroy infecting pathogens (Nathan, 2006). Resolution of such infections depends
greatly upon the ability of recruited PMNs to quickly eliminate infecting bacteria. This is
accomplished in part by the release of cytotoxic granules. The recruitment and
degranulation of PMNs are key processes that underlie initiation of acute phase
inflammation. PMN responses during inflammation are required to provide host
defence, however this process is implicated in contributing to tissue damage during
infections (Gautam et al., 2001; Johansson et al., 2009). As such, the cytotoxic granule
components with which PMNs are equipped, and the inherent risk of collateral damage
to the host, necessitates tightly regulated control systems to reign in PMN activity.
Programmed cell death determines the ultimate fate of circulating PMNs and those
recruited to sites of infection. PMNs are rapidly and spontaneously apoptotic under
physiological conditions, a phenotype also prominent during bacterial infection
(Kennedy and DeLeo, 2009). Post-phagocytosis, senescent PMNs initiate an apoptotic
program that shuts down cellular processes and blunts inflammatory potential
(Kobayashi et al., 2003a; Kobayashi et al., 2003b). Initiation of phagocytosis induced
cell death triggers the expression of “eat-me” signals on these cells and marks them for
phagocytosis by tissue resident and recruited macrophages, termed efferocytosis
(Silva, 2011). Macrophage efferocytosis of apoptotic PMNs reduces accidental release
of stored PMN granules, and thus prevents the potential for PMN-mediated collateral
damage to surrounding tissues (Bratton and Henson, 2011). However, numerous
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pathogens have been shown capable of prompting alternative leukocyte cell death
mechanisms; including pyroptosis and oncosis (Fink and Cookson, 2007; Goldmann et
al., 2009). Whilst induction of PMN apoptosis and efferocytosis impart strong antiinflammatory effects on surrounding tissues, pathogenic stimulation of pyroptosis and
oncosis prompt pro-inflammatory cell phenotypes that lead to eventual cell death.
Thus, dysregulation of native PMN apoptosis may stimulate gratuitous inflammatory
responses via uncontrolled release of granular contents and other pro-inflammatory
cytosolic factors (Kono and Rock, 2008).
Group A Streptococcus (Streptococcus pyogenes; GAS) is the etiological agent of
severe diseases with inflammatory involvement, including necrotising fasciitis (NF) and
septic shock (Cole et al., 2011). Epidemiologically, GAS disease accounts for more
than 663,000 cases of invasive infections globally (Carapetis et al., 2005). Almost a
third of NF cases lead to mortality in developed countries, a fraction that rises to 50% in
NF cases with associated toxic shock (Lamagni et al., 2008). Severe inflammation and
destruction of focal tissues is a hallmark of NF infection. Furthermore, GAS sepsis is
accompanied by systemic release of numerous pro-inflammatory mediators, with the
magnitude of inflammatory cytokine response strongly correlated to the severity of
disease (Norrby-Teglund et al., 2000). GAS alteration of PMN cell death therefore may
strongly influence clinical manifestations of inflammatory GAS disease. Here, we
examine the potential of virulent and avirulent GAS strains to modulate PMN cell death
responses, and the associated effect of GAS-induced PMN cell death on tissue
inflammation.
5.3

Materials and methods

5.3.1

Ethics approval

All work involving the use of human blood and blood products was conducted with the
informed consent of volunteers and was approved by the University of Wollongong
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Human Ethics Committee. All animal use and procedures were approved by the
University of Wollongong Animal Ethics Committee.
5.3.2

Electron Microscopy

For scanning electron microscopy, 5 x 106 PMNs were infected with 5 x 107 GAS CFU
as described (2.16.2) for 5 h. Samples were fixed with 5% formaldehyde and 2%
glutaraldehyde in HEPES buffer, kept at 4°C before dehydrating with a graded series of
acetone, critical point dried with CO2 and sputter coated with gold-palladium. Samples
were examined in a Zeiss Merlin (Oberkochen, Germany) at an acceleration voltage of
5 kV using the Everhart-Thornley SE-detector and the Inlens SE-detector in a 25:75
ratio. For transmission electron microscopy, PMNs were infected and samples fixed as
above, and treated with 1% aqueous osmium tetroxide for 1 h prior to dehydration with
a graded series of acetone, treatment with 2% uranyl acetate in 70% acetone for
overnight, dehydrated further with acetone, and embedded in the Spurr epoxide resin.
Ultrathin sections were cut with a diamond knife, counterstained with uranyl acetate
and observed in a Zeiss EM910 at an acceleration voltage of 80 kV. Images were
recorded digitally with a Slow-Scan CCD-Camera (ProScan, 1024 x 1024) with ITEMSoftware (Olympus Soft Imaging Solutions). Contrast and brightness of images were
adjusted with Adobe Photoshop.
5.4

Results

5.4.1

PMN

phagocytosis,

ROS

production

and

mitochondrial

membrane

depolarisation are differentially modulated by virulent GAS
The initial interactions of PMNs with GAS are mediated via phagocytosis of the
infecting bacteria. Incubation of eGFP expressing virulent GAS (NS88.2) and avirulent
GAS (NS88.2rep) with PMNs revealed that phagocytosis occurred rapidly for both
NS88.2 and NS88.2rep GAS (<5 min), with a higher percentage of PMNs tending to
associate with NS88.2rep compared with NS88.2 (Fig. 5.1A). The relative quantity of
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NS88.2rep associated with each PMN cell was significantly higher than NS88.2, an
effect that was exaggerated at increasing MOIs (Fig. 5.1B, P < 0.001 for all). NS88.2
was frequently visualised in the extracellular space during PMN infection, whereas
NS88.2rep was more often localised within infected PMNs (Fig. 5.1C-D).

Fig. 5.1 PMN phagocytosis of virulent GAS is impaired in vitro. A PMN phagocytosis of
virulent GAS strain NS88.2 and avirulent GAS strain NS88.2rep at a constant multiplicity of
infection (MOI). B Relative quantification of NS88.2 and NS88.2rep phagocytosis at increasing
MOIs. C-D Double immunofluorescence microscopy of PMNs infected with NS88.2 (C) or
NS88.2rep (D), with inset pictures drawn to a higher magnification. Extra-cellular GAS are
depicted in yellow, intra-cellular GAS in red, and PMN nuclei in blue. Scale bars in panels C-D
are drawn to the sizes indicated. Microscope images were altered for brightness to highlight
infecting GAS cells. Results shown for panels A and B are pooled means ± standard deviations
(n = 3). Images shown in panels C and D are representative of duplicate experiments. Asterisks
indicate statistical significance, *** P < 0.001.

The PMN respiratory burst against ingested pathogens plays a key role in the
destruction of phagocytosed microbes, and in regulation of down-stream cell death
pathways (Galluzzi et al., 2012). Kinetic measurement of PMN ROS production during
phagocytosis of GAS revealed avirulent NS88.2rep GAS stimulated higher ROS activity
than the virulent NS88.2 strain (Fig. 5.2A). ROS also play an important function in
regulation of the mitochondrial membrane potential (ΨM), which in turn reflects cellular
viability, as uncoupling of this proton gradient plays a central role in multiple cell death
pathways (Galluzzi et al., 2012). Incubation with NS88.2rep elicited a large, significant
reduction in ΨM compared with uninfected PMNs and cells infected with NS88.2 (P <
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0.001) (Fig. 5.2B). Infection of PMNs with NS88.2 also elicited a significant, albeit
smaller reduction in ΨM compared to uninfected cells (P < 0.001) (Fig. 5.2B).
Collectively, these results suggest that downstream PMN cell death responses, such
as apoptosis, may be influenced by differential ROS generation and ΨM depolarisation
post-phagocytosis of GAS.

Fig. 5.2 Virulent GAS differentially modulate PMN ROS production and mitochondrial
membrane depolarisation. A GAS-induced PMN reactive oxygen species (ROS) production
during NS88.2 or NS88.2rep infection. ROS production is expressed as a change in relative
fluorescence units over time (∆F.min-1). B Determination of mitochondrial membrane potential
(ψM) of GAS-infected PMNs. Results shown for panel A are means pooled from multiple
experiments (n = 4). Results shown for panel B are pooled means ± standard deviations (n =
3). Asterisks indicate statistical significance, *** P < 0.001.

5.4.2

Avirulent GAS infection induces an apoptotic PMN phenotype

During many forms of cell death pathways, cells undergo characteristic alterations in
external cell morphology which are indicative of the cell death mechanisms occurring
(Kroemer et al., 2009). Visualisation of GAS-induced PMN cell death was conducted by
scanning electron microscopy. Uninfected PMNs exhibited typical neutrophil exterior
morphology with few membrane irregularities (Fig. 5.3A). Comparatively, NS88.2
infected PMNs exhibited slight cellular swelling but similar membrane morphology to
uninfected cells (Fig. 5.3B). In contrast, NS88.2rep infected PMNs exhibited both
cellular shrinkage and extensive membrane blebbing, features indicative of apoptotic
cell death (Fig. 5.3C).
Biochemical interrogation of GAS-induced cell death was conducted via fluorescent
measurement of nuclear DNA fragmentation (TUNEL staining) and caspase-3
cleavage. Infection of human PMNs with the avirulent NS88.2rep strain induced
105

significantly higher TUNEL staining at 4 h (P < 0.01) and 6 h (P < 0.001) post-infection
compared to both NS88.2 and uninfected PMNs (Fig. 5.3D), whereas NS88.2 infection
induced comparable TUNEL staining to uninfected cells (P > 0.05). An increased
amount of the active caspase-3 protein was present in NS88.2rep infected cells relative
to uninfected and NS88.2 infected cells 5 h post-infection (Fig. 5.3E), further indicating
an apoptotic cellular response in PMNs exposed to NS88.2rep.

A

B

1 µm

PMN

D

C

1 µm

NS88.2

2 µm

NS88.2rep

E
Caspase-3

17 kDa

Actin

43 kDa

Fig. 5.3 Avirulent group A Streptococcus promotes PMN apoptotic responses. Uninfected
PMNs (A), PMNs infected with NS88.2 (B) or PMNs infected with NS88.2rep (C) analysed by
scanning electron microscopy 5 h post-infection. Scale bars in panels A-B are drawn to the
sizes indicated. D Quantification of oligonucleosomal DNA fragmentation of uninfected PMNs
and PMNs infected with NS88.2 and NS88.2rep by TUNEL. E Detection of active caspase-3
protein in uninfected (PMN), NS88.2 and NS88.2rep infected PMNs by western blot. Results
shown in panel D are pooled means ± standard deviations (n = 3), results shown in panel E are
representative of duplicate experiments. Asterisks indicate statistical significance, ** P < 0.01;
*** P < 0.001.

5.4.3

PMNs infected by virulent GAS exhibit plasma membrane disintegration and

oncosis
Oncotic leukocyte mechanisms (also referred to as regulated necrosis) have been
previously shown to result in proinflammatory phenotypes, and precede cell death
following infection by other pathogens (Bergsbaken and Cookson, 2009; Dacheux et
al., 2000). To investigate potential oncotic consequences of GAS infection of PMNs,
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cell membrane integrity (LDH release) was assayed (Fig. 5.4A). Infection of PMNs with
NS88.2rep resulted in minimal LDH release and maintenance of plasma membrane
impermeability, in contrast to NS88.2 infected PMNs, which provoked significantly
higher LDH release (P < 0.05). Substantiating this biochemical data, transmission
electron microscopy revealed a large degree of vacuolisation and evidence of cell
membrane disintegration in NS88.2 infected PMNs in comparison to uninfected cells
(Fig. 5.4B-C). Both extensive vacuolisation and loss of cell membrane integrity have
been

previously

associated

with

oncotic

cell

death

processes,

leading

to

proinflammatory cell responses (Fink and Cookson, 2005). Although proinflammatory
PMN cell-death responses are well characterised in vitro, the in vivo role of GASinduced oncotic PMN cell death and oncotic PMN-mediated cutaneous inflammation is
less well defined.

A

B

2 µm

C

PMN

2 µm

NS88.2

Fig. 5.4 PMN cell death induced by virulent GAS is associated with loss of membrane
integrity and vacuolization consistent with oncosis. A Quantification of NS88.2 and
NS88.2rep-induced PMN plasma membrane permeabilisation via LDH measurement. B and C
Transmission electron microscopy of uninfected (B) and NS88.2 infected (C) human PMNs.
Filled arrowheads indicate PMN vacuoles and unfilled arrowheads indicate cell membrane
disruption. Scale bars in panels B and C are drawn to the sizes indicated. Results shown in
panel A are representative means ± standard deviations (n = 4). Asterisks indicate statistical
significance, ** P < 0.01.

5.4.4

PMNs recruited to virulent GAS infection have impaired apoptotic ability and

accompany heightened inflammatory responses
Oncotic PMN cell death results in eventual cell lysis, and as such the release of
damage-associated molecular pattern (DAMPs) molecules from these injured and
dying cells (Kono and Rock, 2008). GAS-induced dysregulation from a more
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physiological apoptotic PMN response may contribute to destructive tissue pathologies
noted in murine infection models, and in clinical manifestations of severe GAS disease
(Stevens et al., 2005). To characterise the dynamics of PMNs recruited to virulent GAS
infection in vivo, C57BL/6 mice were intradermally injected with eGFP expressing
NS88.2 and NS88.2rep, and the infection site lavaged 6 h post-infection. Murine
neutrophils (Ly6-G+ cells) showed increased uptake of NS88.2rep compared with
NS88.2 (Fig. 5.5A, P < 0.001), corroborating previous data described above using
human PMNs (Fig. 1). Reduced phagocytic uptake of NS88.2 by murine neutrophils is
likely to contribute to the significantly enhanced survival of this strain within the dermis
of infected mice at 6 h (Fig. 5.5B, P < 0.01), and to NS88.2 virulence during 10-day
infection, relative to NS88.2rep (Fig. 5.5C, P < 0.001).

A

B

C

Fig. 5.5 Murine PMN phagocytosis and killing of virulent GAS is impaired in vivo, leading
to mortality. A Relative quantification of NS88.2 and NS88.2rep phagocytosis by murine Ly6G+ neutrophils. B NS88.2 and NS88.2rep cutaneous survival in vivo. Survival is expressed as
percentage recovered bacteria over inoculum. C Survival of wild-type C57BL/6 mice subcutaneously infected with NS88.2 or NS88.2rep. Results shown for panels A-B are pooled
means ± standard deviations (n = 3). Asterisks indicate statistical significance, ** P < 0.01; ***
P < 0.001.

Histopathological assessment of H&E stained infected murine dermal tissues was
undertaken

24

h

post-infection.

Saline

injection

engendered

no

adverse

histopathologies. (Fig. 5.6A-C). Infection with virulent NS88.2 elicited suppurative
inflammation manifested by disintegration of the extracellular matrix and PMN
infiltration (Fig. 5.6D; Fig. 5E, black arrowheads). Infiltrating PMNs exhibited a high
degree of pyknotic (Fig. 5.6F, red arrowheads) and karyorrhexic (Fig. 5.6F, unfilled
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arrowheads) nuclei morphologies. Intradermal infection with avirulent NS88.2rep also
elicited robust inflammation, however in contrast to NS88.2, gross histological
architecture was maintained (Fig. 5.6G). Infiltrates to the site of NS88.2rep infection
were primarily PMNs (Fig. 5.6H, black arrowheads), and displayed frequent pyknotic
cell morphology (Fig. 5.6I, red arrowheads) with the appearance of numerous apoptotic
body structures (Fig. 5.6I, white arrowheads).

Fig. 5.6 Murine PMNs exhibit degeneracy and adverse histopathologies during
cutaneous infection by virulent GAS. Murine dermis injected with sterile saline (A-C),
NS88.2 (D-F) or NS88.2rep (G-I) was H&E stained 24 h post-injection. E, H black arrowheads,
PMNs; F, I red arrowheads, pyknotic cells; F unfilled arrowheads, karyorrhexic cells; I white
arrowheads, apoptotic bodies. Results shown are depicted at the following magnifications; A,
D, G, 10x; B, E, H, 40x; C, F, I, 460x.

Biochemical analysis of murine infiltrates associated with GAS infection was assessed
via TUNEL to confirm apoptotic nuclear DNA fragmentation (Fig. 5.7A-I).

Saline

injection was not associated with significant TUNEL staining (Fig. 5.7A-C). Cells
associated with NS88.2 infection were infrequently TUNEL positive, indicating a paucity
of apoptotic cell nuclei (Fig. 5.7D-F). Infiltrating cells within and surrounding the bolus
of NS88.2rep infection exhibited stronger and more frequent positive TUNEL staining
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(Fig. 5.7G-I). Thus, immuno-histological evidence supports previous in vitro data
described above, and demonstrates that PMNs recruited to cutaneous, virulent GAS
infection display a reduced apoptotic phenotype.

Fig. 5.7 PMN responses during cutaneous infection by virulent GAS infection exhibit
decreased apoptosis. Murine dermis injected with sterile saline (A-C), NS88.2 (D-F) or
NS88.2rep (G-I) was stained 24 h post-injection using TUNEL to detect apoptotic cells (A, D,
G); propidium iodide (PI) as a counter stain for the total cell population (B, E, H) and merged
channels with differential interference (C, F, I). Results shown are representative of
quadruplicate sections taken from six flanks of three animals per condition. Scale bars are
drawn to the sizes indicated.

5.5

Discussion

Induction of PMN apoptosis is critical to resolution of inflammation in a variety of noninfectious and infectious scenarios, including wound healing, meningitis and
pneumonia (Fox et al., 2010). This process is essential to preventing excessive
inflammatory reactions, whereby aging cells and those recruited to sites of infection
may be disposed of safely without sustained stimulation of immune responses. In
animal models of meningitis, the persistence of PMNs lacking crucial apoptotic factors
is strongly associated with adverse clinical outcomes (Garrison et al., 2010). The
present study indicates that phagocytosis of avirulent GAS elicits a programmed PMN
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cell death mechanism which is apoptotic in nature. Avirulent GAS are rapidly
phagocytosed by PMNs and elicit robust ROS production, triggering downstream
mitochondrial membrane depolarisation and activation of the primary apoptotic effector,
caspase-3. These data indicate that phagocytosis of avirulent GAS elicits a regulated
PMN cell death mechanism reflective of the caspase-dependent, intrinsic apoptotic
pathway (Elmore, 2007). The induction of apoptotic PMN cell-death by avirulent GAS
could be crucial to preventing excessive inflammatory reactions, whereby PMNs
exhausted from microbicidal responsibilities may be disposed of safely without undue
immune stimulation (Fox et al., 2010). As apoptotic cell death does not induce further
inflammatory responses, it is considered to be immunologically silent (Labbe and
Saleh, 2008). However, exposure to virulent GAS appears to elicit a distinct PMN cell
death process that lacks typical apoptotic markers.
Leukocyte oncosis results in a pro-inflammatory phenotype, and precedes leukocyte
cell-death following infection by other pathogens (Bergsbaken and Cookson, 2009;
Dacheux et al., 2000; Kroemer et al., 2005). However, a dearth of knowledge remains
in the literature concerning the mechanisms by which PMN oncosis proceeds, and the
relationship between infection-mediated PMN cell death responses and tissue damage
during disease. Here, we show that in contrast to avirulent GAS, PMNs infected with
virulent GAS undergo mitochondrial membrane depolarisation, as shown for avirulent
GAS, but this event precedes early loss of plasma membrane integrity and
vacuolisation, which are all morphological features indicative of oncotic cell death (Fink
and Cookson, 2005). In vivo data describing the pathophysiological relevance of
leukocyte oncotic cell death has been lacking. We propose that the manner of PMN cell
death by either apoptotic or oncotic demise affects the magnitude and nature of
subsequent host immune responses.
Multiple reports have described a pivotal role for pore-forming toxins in shaping host
leukocyte cell death, including the GAS cytotoxins SLO and SLS (Miyoshi-Akiyama et
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al., 2005; Sierig et al., 2003), and GAS different serotypes can acquire covRS
mutations (Maamary et al., 2010; Ikebe et al., 2010). Virulent GAS bestowed with
covRS mutations are highly encapsulated, and express higher levels of SLO (Chapter
4). As such, this suggests a role for GAS-induced PMN oncosis in the pathogenesis of
multiple GAS serotypes.
Induction of PMN apoptosis has been postulated as a viable strategy to reduce harmful
pathologies during acute inflammation (Fox et al., 2010; Rossi et al., 2006). Attempts to
induce PMN apoptosis in vivo, and therapeutically reduce inflammation caused by GAS
infection as part of this study were unsuccessful (data not shown). However, treatment
of mice with a cyclin-dependent kinase inhibitor (CDKi) inducing PMN apoptosis has
been previously shown to improve resolution of inflammation and clinical symptoms
during experimental pneumococcal infection (Hoogendijk et al., 2012; Koedel et al.,
2009). CDKi drugs show promise as a novel class of anti-inflammatory therapeutics,
which combined with traditional antibiotics, could be used as adjunctive treatments to
reduce harmful immune-mediated pathologies during severe GAS infection (Fox et al.,
2010; Leitch et al., 2009).
In summary, this work describes dynamic host PMN cell death responses to GAS
infection. PMN cell death in response to avirulent GAS infection is associated with an
apoptotic program resulting from intra-cellular triggers, post-phagocytosis. Whereas
PMNs recruited to virulent GAS infection in the dermis lack apoptotic markers, and
bear hallmarks of proinflammatory cell death, which may amplify immune reactions
during infection.
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS

Streptococcus pyogenes inflicts a devastating global burden of mortality through
severe, invasive infections. The World Health Organisation has placed GAS in the top
10 human pathogens, and of this list of organisms, GAS occupies the 4th most deadly
bacterial pathogen by cause of mortality (Carapetis et al., 2005). Severe GAS disease
imparts a large burden of death and morbidity; however more mild afflictions, such as
streptococcal pharyngitis, impart a large financial cost. The societal cost of paediatric
pharyngitis in the USA alone has been estimated to be up to $538 million (Pfoh et al.,
2008). Multiple GAS serotypes are associated with severe GAS disease, however the
M1T1 serotype is epidemiologically overrepresented from invasive and non-invasive
infections, and has disseminated on a global scale (Aziz and Kotb, 2008). The precise
molecular triggers for M1T1 invasive disease have been recently described, and
highlight the importance of a combination of factors including phage-mediated lateral
gene transfer and interactions with PMNs, in determining disease severity (Walker et
al., 2007). This multi-faceted nature of the disease process requires a complementary
multi-disciplinary approach to identifying both host and bacterial factors that influence
GAS immune survival and disease pathologies. High-throughput techniques such as
genomics, transcriptomics, proteomics; as well as traditional molecular and
immunological functional assays, are requisite to identifying and characterising factors
that influence GAS immune resistance and the host mechanisms that act in response
to GAS infection.
The recent advent of NGS technologies has revolutionised the manner and speed at
which we conduct full genomic characterisation of bacterial isolates. Small genetic
modifications such as SNPs, transfer of larger genetic elements from other
streptococcal species, and prophage-mediated gene transfer can be rapidly identified
in response to bacterial outbreaks (Musser and Shelburne, 2009). NGS enables the
113

precise tracking of GAS evolution, which can be linked to epidemiological data in the
reconstruction of pathogen disseminations (Maamary et al., 2012). This study utilised
NGS technologies to genetically characterise a virulent and neutrophil resistant GAS
isolate, NS88.2, which represents a skin tropic emm-pattern D strain from a remote
region of Australia’s Northern Territory (McKay et al., 2004). Data from this study
suggest that this isolate, similar to M1T1 and other serotypes of GAS, harbours at least
one lysogenised prophage-like element; however no factors with obvious roles in
mediating neutrophil responses were identified in this region. Further bioinformatic
analyses of genes divergent from other fully sequenced GAS, and prediction of
secreted and cell surface proteins, indicated that a number of virulence factors may
mediate host-pathogen interactions. However, the positive confirmation of these
putative functions required further experimental verification. The genome constructed
as part of this study provides a useful starting point for such studies.
Mutations of the two-component regulator covRS result in enhanced virulence in the
M1T1 GAS serotype (Sumby et al., 2006). These mutations are selected for by GAS
interactions with PMNs, due to the preservation of extracellular DNase Sda1 activity
(Walker et al., 2007). Although no obvious phage-acquired factor influencing PMN
resistance was identified by NS88.2 genomic sequencing (Chapter 3), it has been
shown that multiple virulence factors encoded by the GAS core genome, including M
protein and capsule, are essential for covRS phase-switching to occur (Cole et al.,
2010). In addition, mutations of covRS in a variety of serotypes result in a unanimous
increase in virulence potential (Maamary et al., 2010). The NS88.2 isolate encodes a
non-functional covS gene, exhibits hypervirulence in humanised plasminogen murine
infection models, and is highly resistant to PMN killing (Maamary et al., 2010).
Inactivation of the covRS in virulent M1T1 exerts a counterbalancing decrease in the
ability to adhere and colonise murine dermal tissues (Hollands et al., 2010). Data
presented in this study demonstrates that this compensatory aspect of GAS virulence
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is also noted in the non-M1T1 NS88.2, as NS88.2rep, a functional covS encoding
derivative mutant, exhibits enhanced biofilm formation and colonisation potential.
Expansion of the previous genomic characterisation of NS88.2 through transcriptomic
and proteomic analyses suggested that the activity of NS888.2 gls24 and sclA are
regulated both directly by covRS mutation and indirectly through SpeB-mediated
degradation, and bestow enhanced survival in human blood and resistance to PMN
killing. It is feasible that SclA interacts with PMN integrins in order to assist bacterial
survival (Caswell et al., 2007), however potential mechanisms of Gls24-mediated PMN
resistance are currently unknown. Future work should focus on determining potential
metabolic functions of Gls24, as multiple studies of E. faecalis Gls24 and Gls24homologs have shown a role for this protein in providing resistance to bile salt stress
and involvement in pyruvate metabolism (Giard et al., 2000).
Multiple reports have described mechanisms by which GAS resists killing by innate
immune responses, while comparatively less attention has been given to differences in
host cellular responses to virulent and avirulent GAS, and host processes underlying
pathophysiologies during GAS infections. Previous studies indicate that multiple
leukocyte cell death responses are triggered by GAS infection (Cortes and Wessels,
2009; Goldmann et al., 2009; Kobayashi et al., 2003a). However, data elucidating the
relevance of these processes to inflammation and disease pathophysiology have been
elusive. Results presented in this study demonstrate that avirulent and PMN-sensitive
NS88.2rep induces a morphologically, biochemically and immunologically distinct PMN
cell death program which is characterised by an apoptotic phenotype. Infection by the
virulent and PMN resistant NS88.2 strain triggers an oncotic cell death mechanism,
leading to amplified immune responses and adverse histopathologies. This polarity in
cell death responses may underlie differences in clinical GAS disease outcomes, as
oncotic PMN cell death is pro-inflammatory and may perpetuate excessive immune
responses. Further work should assess the potential of modulating PMN cell death as
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an adjunctive therapeutic intervention to alleviate damaging GAS disease symptoms,
as has been applied to other pathogens and inflammatory syndromes (Fox et al., 2010;
Hoogendijk et al., 2012). This work also has implications for the pathogenesis of other
GAS serotypes, and further studies should investigate whether manipulation of PMN
cell death is a general pathogenic mechanism utilised by other GAS serotypes.
The economic pressure and large burden of mortality imparted by both M1T1 and nonM1T1 GAS diseases necessitate in-depth study of GAS pathogenesis. GAS interaction
with host immune mediators, in particular PMNs, determines the ability of GAS to
persist in the host and severity of disease. The use of high-throughput techniques
greatly assists the identification of critical factors that determine GAS virulence and
immune resistance. Host cellular responses also govern inflammatory reactions to GAS
infection and resolution of inflammation. This study describes the generation of a new
GAS genomic sequence draft and the identification of new roles for factors that
influence GAS interactions with human PMNs. In addition, a divergence in PMN cell
death is described in response to virulent and avirulent forms of a non-M1T1 GAS
isolate. These data provide key insights into a variety of aspects of GAS biology,
including the genomic makeup, secreted proteome, transcriptional behaviour, virulence
determinants, and manipulation of the host innate immune responses to cause
disease. The results described here expand our understanding of the bacterium in of
itself, and how clinical manifestations of GAS disease are generated.
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APPENDIX A: MEDIA AND GENERAL BUFFER COMPONENTS

Unless noted otherwise, all media and buffers were made up to volume with distilled
H2O.
Media
Lysogeny-Broth (LB)
Tryptone
Yeast Extract
NaCl

10 g/L
5 g/L
10 g/L

LB Agar
LB
Agar

15 g/L

Todd-Hewitt Broth (THY)
Todd-Hewitt Broth
Yeast Extract

30 g/L
10 g/L

THY Agar (THYA)
THY
Agar

15 g/L

TSS Media
Tryptone
Yeast Extract
NaCl
Polyethylene Glycol (PEG) 3330

1.25 g/250 ml
2.5 g/250 ml
1.25 g/250 ml
25 g/250 ml

Make up to 225ml volume with dH2O, just before culture add 12.5 ml sterile DMSO and
12.5 ml sterile 1 M MgCl2
General buffers
1X Phosphate buffered saline (PBS)
NaCl
KCl
Na2HPO4
KH2PO4

8 g/L
0.2 g/L
1.44 g/L
0.24 g/L

Make up to 800 ml volume with dH2O, adjust to pH 7.4 and expand to 1L with dH2O
1X Phosphate buffered saline with 0.05% Tween-20 (PBST)
PBS
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Tween-20

500 μl/L

Alkaline Lysis Solution 1
Glucose
Tris-HCl
EDTA

0.9 g/100 ml
2.5 g/100 ml
0.29 g/100 ml

Alkaline Lysis Solution 2
NaOH
SDS

0.8 g/100 ml
1 g/100 ml

Alkaline Lysis Solution 3
Potassium acetate
Glacial acetic acid

29.4 g/100 ml
11.5 ml/100 ml

1X Tris-Acetate-EDTA (TAE) buffer
Tris-base
4.84 g/L
Glacial acetic acid
1.14 ml/L
EDTA
0.292 g/L
DNA Loading Buffer
Bromophenol Blue
Glycerol

5 mg/10 ml
7.5 ml/10 ml

Make up to 10 ml volume with TAE buffer.
Ethidium Bromide Staining Solution
Ethidium bromide
1 μg/100 ml
5X Protein Cracking Buffer
Tris-HCl (pH 6.8)
Glycerol
SDS
Bromophenol blue

4.5 ml/10 ml
5 ml/10 ml
0.5 g/10 ml
5 mg/10 ml

Coomassie Blue Rapid Stain
Coomassie Blue R-250
Methanol
Glacial Acetic Acid

2 g/L
400 ml/L
100 ml/L

Make up to 1 L with dH2O.
Rapid Destain
Methanol
Glacial Acetic Acid

400 ml/L
100 ml/L

Make up to 1 L with dH2O.
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1X SDS-PAGE Running Buffer
Tris base
Glycine
SDS

3.03 g/L
14.33 g/L
1 g/L

Western Transfer Buffer
Glycine
Tris base
Methanol

14.4 g/L
3.02 g/L
200 ml/L

Make up to 1 L with dH2O.
Native Cell Lysis Buffer
Lysozyme
DNase I
PMSF
MgCl2
CaCl2
Triton X-100
NaCl
NaH2PO4
Imidazole

50 mg/50 ml
25 μg/50 ml
8.725 mg/ 50 ml
476 μg/50 ml
1.4 μg/50 ml
50 μl/50 ml
1.055 g/50 ml
0.3 g/50 ml
85 μg/50 ml

Native Wash Buffer
NaCl
NaH2PO4
Imidazole

17.5 g/L
6.9 g/L
1.36 g/L

Native Elution Buffer
NaCl
NaH2PO4
Imidazole

17.5 g/L
6.9 g/L
17 g/L

Standard Sample Solubilisation (SSS) Buffer
Urea
9.6 g/20 ml
DTT
0.308 g/20 ml
CHAPS
0.8 g/20 ml
Carrier ampholytes
400 μl/20 ml
Tris base
0.097 g/20 ml
Make up to 20 ml with ddH2O.
5X Tris HCl Gel buffer
Tris HCl

56.8 g/250 ml

Adjust to pH 8.8 with HCl. Make up to volume with ddH2O.
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Equilibration Buffer
Urea
SDS
Glycerol
Acrylamide (25%)
5X Tris HCl gel buffer

3.6 g/10 ml
0.2 g/10 ml
4 ml/10 ml
1 ml/10 ml
2 ml/10 ml

Make up to volume with ddH2O.
Colloidal Coomassie Blue Stain
Ammonium sulphate
Orthophosphoric acid (85%)
Coomassie G-250
Methanol

170 g/L
36 ml/L
1 g/L
340 ml/L

Mix (NH4)2SO4, methanol, phosphoric acid and 500 ml of ddH2O in a 1 L Schott bottle.
Add Coomassie G-250 and stir with heating (60-70ºC) until Coomassie is completely
dissolved (overnight). Make up to 1 L with ddH2O.
Colloidal Coomassie Destain
Glacial acetic acid

1 ml/L

Make up to volume with ddH2O.
MALDI Mass Spectrometry Matrix
Acetonitrile
Trifluoroacetic acid

3.5 ml/5 ml
25 μl/5 ml

Make up to volume with ddH2O.
Acid alcohol
Ethanol
HCl

70 ml/100 ml
437 mg/100 ml

Scott’s blueing solution
MgSO4
NaHCO3

2 g/100 ml
370 mg/100 ml
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APPENDIX B: LIST OF PRIMERS USED IN THIS STUDY
Table B.1 List of primers used in this study.
Primer name
Cloning primers

GLS24-X F
GLS24-X R
pDC-SCLA F
pDC-SCLA R
pDC-GLS24 F
pDC-GLS24 R

Sequence (5’-3’)
CGCGCATGCCTGGTTCCGCGTGGCTCTGTGGAAGTTGGAAAAAAACAAGTTGCCGTT
GATCTTG
GGCCCCGGGTTATTTTACACGTGGCTCAGCTTTTTGATC
CCGGTCTAGATAAAGGAGGACTCTTCATGTTGACATCAAAACACCACAA
ATATGAATTCTTAGTTGTTTTCTTTGCGTTTTGT
CCGGTCTAGATAAAGGAGGACTCTTCGTGGAAGTTGGAAAAAAACAAGTTGCCG
ATATGAATTCTTATTTTACACGTGGCTCAGCTTTTTGATC

LIC primers

SCLA-LIC 1 F
SCLA-LIC 1 R
SCLA-LIC 2 F
SCLA-LIC 2 R
GLS24-LIC 1 F
GLS24-LIC 1 R
GLS24-LIC 2 F
GLS24-LIC 2 R
CAT LIC F
CAT LIC R

TTCTTCCTGTCTGTTTACATTTCAAAAAAGAGTGACC
GTGGCTTTTTTCTCCATATGTTGTTCTCTCTTTCTCT
GTGGCTGGGCGGGGCGTAATCCTCTAAATTGAGAGGCCT
TTGTCCTCTTCTGTTTTCGTTCCTCATCTAGCATTT
TTCTTCCTGTCTGTTTAAGGTATTATTGATCAATTTC
GTGGCTTTTTTCTCCATGTTCACGCCATCACGTACAG
GTGGCTGGGCGGGGCGTAATCATATGTCGTCAATTAGGT
TTGTCCTCTTCTGTTTATGTCCCCTTTATTTATCTT
GGAGAAAAAAGCCACTGGATATACCACC
ACGCCCCGCCCAGCCACTCATCGCAATACTGTT

Screening and sequencing primers
GATTAAGTTGGGTAACGCCAG
CAGGAAACAGCTATGACCATG
CCCAGTCACGACGTTGTAAA
AGCGGATAACAATTTCACACA
CGGATAACAATTTCACACAG
GTTCTGAGGTCATTACTGG
GAAGGAGTGATTACATGAAC
CATAGAATTATTTCCTCCCG
CGCGCATGCCTGGTTCCGCGTGGCTCTGAGGCTGCTTCTACGATTATGACGT
GGCCCCGGGTAGACGTCTGTGGTTGTTAGCTACAG

pHY304 F
pHY304 R
M223 F
M224 R
pQE30 F
pQE30 R
ERMB F
ERMB R
SCLA-X F
SCLA-X R

RT-PCR primers

PROS F
PROS R
GLS24 F
GLS24 R
SCLA F
SCLA R
HASA F
HASA R
SPEB F
SPEB R
EMM F
EMM R

GCCTTGGCAGAAGTTGAGAC
GCAAAGCAACAACAGGTTCA
TCGATCGTTGAAGAAGAAGTGA
GAACGTGCCATGTCTGAAAC
CTGAGGCTGCTTCTACGATTATG
TTGTATCCCAAAAGGCCACTC
AGCGTGCTGCTCAATCATTA
CATCCCCAATGCTAACAGGT
CCAAATCAACCGTAGCGACT

AGAAGTTACGTCCGTCAGCA
GACTCACAAACCCCTGATGC
GCTGCTTCACCTGTTGATGG

146

APPENDIX C: VECTOR CONSTRUCTION, ALLELIC EXCHANGE AND PROTEIN
EXPRESSION
Primer pairs used for all PCR reactions listed here are given in parentheses, and
sequences are given in Appendix C.
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ii
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Fig. C.1 Construction of pHY-∆sclA and pHY-∆gls24 via ligation independent cloning.
A PCR amplicons of 250 bp NS88.2 genomic flanks upstream (i, iv) and downstream (ii, v)
of gls24 (i, GLS24-LIC 1 F and R; ii, GLS24-LIC 2 F and R) and sclA (iv, SCLA-LIC 1 F and
R; v, SCLA-LIC 2 F and R), and the cat coding sequence (iii, CAT LIC F and R). B Agarose
gel showing uncut pHY304-LIC (i) and PmeI digested pHY304-LIC (ii). C Representative
agarose gel of pHY304-LIC transformants screened by alkaline lysis for pHY-∆gls24 (i-iii)
and pHY-∆sclA (iv-vi). All agarose gels are 1% (w/v). Molecular size markers are from
Hyperladder I (Bioline, Australia), with sizes indicated in base pairs.
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Fig. C.2 Generation of NS88.2∆gls24 and NS88.2∆sclA by precise allelic replacement
using pHY-∆gls24 and pHY-∆sclA. A Representative agarose gel showing NS88.2
transformants screened by PCR for the presence of ermB (ERMB F and R) from pHY-∆gls24
(i-ii) or pHY-∆sclA (iii-iv) and the positive control from pHY304-LIC plasmid. B
Representative agarose gel of putative NS88.2∆gls24 mutants (i-iii) screened by PCR for
the presence of gls24 (i, iv; GLS24-X F and R), cat (ii, v; CAT LIC F and R) and ermB (iii,
vi; ERMB F and R), with positive controls from NS88.2 gDNA (iv) and pure pHY-∆gls24 DNA
(v-vi). C Representative agarose gel of putative NS88.2∆sclA mutants (i-iii) screened by
PCR for the presence of sclA (i, iv; SCLA-X F and R), cat (ii, v; CAT LIC F and R) and ermB
(iii, vi; ERMB F and R), with positive controls from NS88.2 gDNA (iv) and pure pHY-∆sclA
DNA (v-vi). All agarose gels are 1% (w/v). Molecular size markers are from Hyperladder I
(Bioline, Australia), with sizes indicated in base pairs.
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Fig. C.3 Construction of pDC-gls24 and generation of NS88.2∆gls24 (pDC-gls24). A
Representative agarose gel of pCR2.1 PCR screening for gls24 (i-ii; M223 F and M224 R)
from positive (i) or negative (ii) clones. B Restriction enzyme digestion of pDCerm (i-iii) and
pCR-gls24 (iv-vi) using XbaI (i, iv), EcoRI (ii, v) or XbaI and EcoRI (iii, vi). C Representative
agarose gel of pDCerm PCR screening for gls24 (i-iii; GLS-X F and R) or ermB (iv-vi;
ERMB F and R) from transformant E. coli colonies (i, iv), sterile water (ii, v) or positive
control pCR-gls24 DNA (iii, vi). D Representative agarose gel of PCR screening for gls24 (ii,
iv, v; GLS24-X F and R) or ermB (i, iii, vi; ERMB F and R) from transformant GAS colonies
(i-ii), positive control pCR-gls24 DNA (iii-iv) or sterile water (v, vi). All agarose gels are 1%
(w/v). Molecular size markers are from Hyperladder I, with sizes indicated in base pairs.
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Fig. C.4 Construction of pDC-sclA and NS88.2∆sclA (pDC-sclA) A Representative
agarose gel of pCR2.1 transformants PCR screened for sclA (M223 F and M224 R) from
either positive (i) or negative clones (ii). B Restriction enzyme digestion of pCR-sclA using
XbaI (i), EcoRI (ii) or XbaI and EcoRI (iii). C Representative agarose gel of pDCerm PCR
screening for sclA (SCLA-X F and R) from transformant E. coli colonies (i), sterile water (ii)
or positive control pCR-sclA DNA (iii). D Representative agarose gel of pDCerm PCR
screening for sclA (i, iii, v; SCLA-X F and R) or ermB (ii, iv, vi; ERMB F and R) from
transformant GAS colonies (i-ii), positive control pCR-sclA DNA (iii-iv) or sterile water (v,
vi). All agarose gels are 1% (w/v). Molecular size markers are from Hyperladder I, with sizes
indicated in base pairs.
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Fig. C.5 Construction of the pQE-gls24 expression vector. A Agarose gel showing gls24
PCR amplicon (i, GLS24-X F and R). B Representative agarose gel of pPCRscript
transformants screened via alkaline lysis for blue colonies containing, self-ligated
pPCRScript (i) and white colonies with gls24 insert (ii-vi). C PaeI/SmaI double digest of
pPCRscript clones showing excision of gls24 insert (i-ii), PaeI/SmaI double digest of pQE-30
vector (iii), PaeI digest of pQE-30 (iv), SmaI digest of pQE-30 (v). D Representative agarose
gel of pQE-30 transformants screened by alkaline lysis containing self-ligated pQE-30 (i) or
colonies with gls24 insert (ii-iii). E PaeI/SmaI double digest of pQE-30 clones showing
excision of gls24 insert (i-ii). All agarose gels are 1% (w/v). Molecular size markers are from
Hyperladder I, with sizes indicated in base pairs.
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Fig. C.6 Expression and purification of NS88.2 Gls24 protein. Representative expression of the
pQE-gls24 vector in M15 (pREP4) E. coli showing crude lysate from uninduced culture (i) and culture
induced with 1 μM IPTG for 4 h (ii). Induced E. coli culture were pelleted and stored at -20°C prior to
thawing and lysing. Samples were added in batch to 2 ml 50% Nickel-NTA resin, incubated for 1 h at
4°C with agitation and purified over Nickel-NTA column with samples taken pre-purification (iii), after
batch addition (iv) and post-elution (v). Results shown are from a 12% SDS-PAGE gel. Molecular
weight markers are from Unstained Pageruler, with weights indicated in kilo-Daltons.
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APPENDIX D: MALDI-TOF SPECTRUM AND PMF

Fig. D.1 Example spectrum of streptococcal enolase (SEN) protein identified in the
supernatant of NS88.2.

Fig. D.2 Example Mascot peptide mass finger print search results for
streptococcal Enolase protein.
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APPENDIX E: QPCR PRIMER EFFICIENCIES AND ANALYSIS
Efficiency calculation
Primer efficiencies were calculated via serial 10-fold dilution of NS88.2 cDNA, and
subsequent qPCR quantification using the thermocycling program described previously
(2.12). Crossing threshold cycles (Cp) were plotted against the logarithm of the
template quantity and simple linear regression performed for each primer. Efficiency
(Ep) of each primer was then calculated as follows:
Efficiency (Ep) = (10(-1/Slope

of linear regression line)

- 1) x 100%

Fig. E.1 Crossing threshold cycles (Cp) of serially diluted NS88.2 cDNA used to calculate
primer efficiencies. NS88.2 200 ng of cDNA was diluted ten-fold 5 times and subject to qPCR
quantification. Cp cycles for each dilution were then plotted against the logarithm of template
quantity, and the slope of the resulting regression line used to calculate relative primer
efficiencies. Results shown are means ± standard deviations of triplicate determinations.
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Melt curve analyses
Melt curves analyses were performed for each qPCR primer set (Appendix C) to
ensure that single amplicons were generated from each gene. Single amplicons are
demonstrated by sharp, singular peaks in the measured change in fluorescence ([d/dT]fluorescence) resulting from SYBR green disassociation from heat denatured,
single stranded DNA.

proS

emm

speB

hasA

gls24

sclA

Fig. E.2 Melt curve analyses generated for each primer set used to quantify GAS gene
expression. Melt curves were generated following amplification of serially ten-fold diluted
cDNA template used to calculate primer efficiencies.
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Calculation of normalised gene expression
Expression of GAS genes were normalised to the proS house-keeping gene and primer
efficiency according to the equation:
Normalised fold change = (Ep-target)∆Cp-target/(Ep-proS)∆Cp-proS
Eg:

hasA: Cp-NS88.2: 14.2, Cp-NS88.2rep: 20.6. Efficiency: 91% (1.91)
proS: Cp-NS88.2: 18.9, Cp-NS88.2rep: 19.2. Efficiency: 94% (1.94)
∆Cp-hasA = (Cp-NS88.2rep – CpNS88.2) = 20.6 - 14.2 = 6.4
∆Cp-proS = (Cp-NS88.2rep – CpNS88.2) = 19.2 – 18.9 = 0.3
Normalised hasA fold change (NS88.2 relative to NS88.2rep): (1.91)6.4/(1.94)0.3

= 51.6
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APPENDIX F: FLOW CYTOMETRY GATING STRATEGIES

Fig. F.1 Gating strategy to assess in vitro purified PMN phagocytosis of eGFP
expressing GAS. In vitro infections of PMNs with eGFP expressing GAS was conducted
as described to assess PMN phagocytosis dynamics (2.16.2, 2.16.4). PMNs were identified
by their characteristic forward and side scatter profile, and a single gate used to exclude
debris, free GAS and other cell types (A, marked region). Gated PMNs (B, 20,000 events)
were analysed for eGFP fluorescence using a 515_20 filter (B, marked region) to quantify
association of PMNs with eGFP GAS and measure mean fluorescence intensity. Data
shown are representative of six experiments; analysed results are presented in Fig 5.1A-B.
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Fig. F.2 Gating strategy to assess in vitro purified PMN mitochondrial membrane
depolarisation post-phagocytosis of GAS. In vitro infections of PMNs with GAS was
conducted as described to assess PMN mitochondrial membrane potential (ψm) (2.16.2,
2.16.10). PMNs were identified by their characteristic forward and side scatter profile, and a
single gate used to exclude debris, free GAS and other cell types (A, marked region).
Gated PMNs (B, 10,000 events) were analysed for DiOC(6)3 fluorescence using the FL-1
channel. A shift in DiOC(6)3 fluorescence relative to uninfected PMNs at 0 h was used to
determine ψm integrity (B, marked region). Data shown are representative of three
experiments; analysed results are presented in Fig 5.2D.
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Fig. F.3 Gating strategy to assess in vitro purified PMN apoptosis by TUNEL staining
post-phagocytosis of GAS. In vitro infections of PMNs with GAS was conducted as
described to assess PMN apoptosis (2.16.2, 2.16.9). PMNs were identified by their
characteristic forward and side scatter profile, and a single gate used to exclude debris (A,
marked region). Note that the forward and side scatter profile of TUNEL stained PMNs
differs from other experiments due to fixation and overnight ethanol incubation. Gated
PMNs (B, 20,000 events) were analysed for fluorescein fluorescence using a 515_20 filter
(B, marked region) to quantify TUNEL staining of apoptotic PMN nuclei. Data shown are
representative of five experiments; analysed results are presented in Fig 5.2D.
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Fig. F.4 Gating strategy to assess in vivo murine neutrophil phagocytosis of eGFP expressing
GAS. Intradermal infection of C57BL/6 mice with eGFP expressing GAS was conducted as described
(2.17.2) to quantify murine neutrophil phagocytosis of eGFP expressing GAS in vivo. PMNs were
identified in lavage fluid by their characteristic forward and side scatter profile, and a single gate used
to exclude debris, free GAS and other cell types (A, marked region). Gated PMNs (B, 10,000 events)
were analysed for the murine neutrophil specific Ly6-G antigen using a 575_26 filter (B, marked
+
region). Ly6-G cells (C) were analysed for eGFP fluorescence as described for human PMNs (2.16.4)
using a 515_20 filter (C, marked region). Data shown are representative of three experiments; analysed
results are presented in Fig 5.4A.
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APPENDIX G: SUPPLEMENTARY GENOME ANALYSES

Table G.1 Genes contained within the NS88.2 prophage-like region.
Loci
888122
888425
889080
889304
889595
890274
891100
891546
892802
894273
895203
895612
896155
896559
897645
897901
898251
898547
898900
899286
899865
900254
900572
901441
903318
904085
904575
906114
908241
908967
909529
910029
910219
910679
912336
913194
913469
913795
914169
914360
914937
915741
915876
916304

Genome annotation
Paratox
SpeL
Phage holin
Phage holin
Phage protein
Hypothetical phage protein
Phage protein
Phage terminase, large
subunit
Phage portal
Hypothetical protein
Hypothetical protein
Phage capsid and scaffold
Putative structural phage
protein
Phage major capsid protein
Hypothetical phage protein
Conserved hypothetical
protein, phage associated
Conserved hypothetical
protein, 370.2 phage
Hypothetical protein
Hypothetical protein
Phage tail protein
Hypothetical protein
Hypothetical protein
Phage tail length tapemeasure protein
Putative human plateletbinding protein - phage
associated
Tail protein, putative
Minor structural protein
Phage endopeptidase
Phage hyaluronidase
Phage protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Putative DNA primase,
phage associated
Phage protein
Hypothetical protein
Hypothetical protein
Unknown phage protein
Hypothetical protein
Hypothetical protein
Prophage ps3 protein 13
Phage protein
Phage protein
Transcriptional regulator

Significant matches to Pfam motifs
None
streptococcal toxin, beta-grasp domain
Bacteriophage holin
Bacteriophage holin
None
N-6 DNA Methylase
None
None
Phage portal protein, SPP1 Gp6-like
Phage Mu protein F like protein
None
None
None
Phage major capsid protein E
None
Phage QLRG family, putative DNA packaging
None
Bacteriophage tail protein family
None
Phage major tail protein 2
Phage protein
None
Phage-related minor tail protein
None
Siphovirus Phage tail protein
None
None
gp58-like protein
Protein of unknown function (DUF1617)
None
None
None
None
D5 proteins of DNA viruses and bacteriophage P4 DNA primases
phages
Primase C terminal 1
None
None
None
None
None
Phage regulatory protein Rha
None
None
Helix-turn-Helix
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916538
916898
917334
917513
917871
918323
919275
919596
920070
920460
920898
921363
923157
923824
925752
926444
928759
929102
929701
930087
930361
930965
931301
931530
931828
932264
932476
933381
933956
935435
935697
935926
936156
937642
938907
939839
940680
942031
942750
943190
943678
943944
944125
944634
945168
946206

Conserved hypothetical
protein, phage associated
Putative repressor protein,
phage associated
Hypothetical protein
Unknown phage protein
Phage antirepressor protein
ORF2
Hypothetical protein
Hypothetical protein
Hypothetical protein
Repressor protein
Hypothetical protein
Phage hyaluronidase
Hyaluronate lyase, phage
associated
Phage hyaluronidase,
phage endopeptidase
Phage associated protein
Phage minor tail protein
#GP26 human plateletbinding protein
Hypothetical protein
Phage minor tail protein
#GP26 human plateletbinding protein
Phage protein
Phage protein
Phage major tail protein
Phage associated protein
Phage associated protein
Phage protein
Phage protein
Hypothetical protein
Phage major capsid protein
Phage capsid and scaffold
Phage terminase
Hypothetical protein
Hypothetical phage protein
Phage associated protein
Phage protein
Phage portal protein; phage
capsid and scaffold
Phage protein
Phage protein
Phage protein
Conserved hypothetical
protein, phage associated
Phage protein
Putative methyltransferase
Hypothetical protein
Hypothetical phage protein
Hypothetical protein
Hypothetical protein
Conserved hypothetical
protein, phage associated
Phage related protein
lin1242

Helix-turn-Helix
Helix-turn-Helix
None
None
ORF6C domain (anti-repressor from Lactococcus phage)
Protein of unknown function (Possible Mu DNA binding domain)
Helix-turn-helix domain
None
None
Helix-turn-Helix
Protein of unknown function (DUF1617)
gp58-like protein
Hyaluronidase protein (HylP)
None
None
None
NUMOD4 motif (found in homing endonucleases)
None
None
None
None
None
Phage minor tail protein
None
Phage protein Gp19/Gp15/Gp42
None
Phage capsid family
None
Phage Terminase
None
None
None
None
Phage portal protein, SPP1 Gp6-like
No sig matches
Protein of unknown function
None
None
N-6 DNA Methylase
DNA methylase
None
None
None
None
Protein of unknown function (DUF1351)
RecT family (ssDNA binding)
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947000
947385
947600
947737

957042
957816
958003
958457
958835

Hypothetical protein
Hypothetical protein
Hypothetical protein
Hypothetical protein
Dna replication protein
dnaD
Phage transcriptional
regulator Cro/Cl
Conserved hypothetical
protein, phage associated
Hypothetical protein
Phage integrase
Phage protein
Phage lysin
Phage protein
Phage lysin
Phage protein
Phage protein
Hypothetical protein
Hypothetical protein
Putative ABC transporter
Hypothetical protein
Conserved hypothetical
protein, phage associated
Hypothetical protein
Hypothetical protein
Phage excisionase
Hypothetical phage protein
Putative protein Ymh

959874

Phage antirepressor protein

947951
949069
949420
949812
950205
951580
952241
952995
953920
954599
954781
955091
955391
955663
956319
956601

963211

Conserved hypothetical
protein, phage assocaited
Hypothetical phage protein
Phage protein
Hypothetical protein
Conserved hypothetical
protein, phage assocaited
DNA primase

964682

Phage protein

960602
961661
961828
962306
962646

965497
965971

Conserved hypothetical
protein, phage assocaited
Putative helicase, phage
associated

967302

NTP binding protein

967983
968692

Hypothetical protein
Hypothetical phage protein
Conserved hypothetical
protein, phage associated
Unknown phage protein
Hypothetical phage protein
Hypothetical protein
Integrase
Integrase
Lipoprotein, putative

969022
969153
969527
969852
970110
970615
971544

None
None
None
None
Replication initiation and membrane attachment protein (DnaB)
Helix-turn-Helix
Domain of unknown function (DUF955)
None
Phage integrase family
None
CHAP domain, SH3 domain
AP2 domain (DNA binding)
Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase
None
None
None
None
None (Weak match to ABC transporter family)
None
ParB-like nuclease domain
None
None
None
No sig matches (weak match to phage minor tail protein)
Protein of unknown function (associated with phage/plasmids)
AntA/AntB antirepressor, Phage antirepressor protein KilAC
domain
None
None
Protein of unknwon function (DUF3310)
None
VRR-NUC domain (associated with members of the PD-(D/E)XK
nuclease superfamily)
Poxvirus D5 protein-like
Bifunctional DNA primase/polymerase, N-terminal, Primase C
terminal 1 (PriCT-1)
Protein of unknown function (DUF669)
Type III restriction enzyme - res subunit, Helicase conserved Cterminal domain
ATPase family associated with various cellular activities (Often act
as chaperones)
Siphovirus Gp157 (Sfi type)
Helix-turn-Helix
None
None
Helix-turn-Helix
None
None
Phage integrase family
None
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Table G.2 List of phage regions from fully sequenced GAS genomes Maq mapped by
NS88.2 read pairs
Phage

Region of mapped reads
Start

End

Size (bp)

315.1
315.1
315.1
315.1

10506
31101
33927
34663

11141
31265
34208
35258

635
164
281
595

315.2
315.2
315.2
315.2
315.2
315.2
315.2
315.2
315.2

39550
44890
45691
46511
50813
54635
72161
74384
74825

40873
45106
46141
50561
51308
55688
72737
74627
75374

1323
216
450
4050
495
1053
576
243
549

315.3
315.3
315.3
315.3
315.3

93262
94828
97474
102013
103966

94387
96547
98959
102895
106738

1125
1719
1485
882
2772

315.4
315.4
315.4

127231
128599
146785

128095
130741
147379

864
2142
594

315.5
315.6

161446
227794

167647
228703

6201
909

370.1
370.1

249178
268210

249934
268813

756
603

370.2
370.2
370.2
370.2

275970
283048
305884
317392

277119
283381
313120
318481

1149
333
7236
1089

370.3
370.3
370.3

335332
337537
339769

336790
338185
341497

1458
648
1728

370.4
370.4
370.4
2069.1

352027
358528
365287
379381

355690
364081
365647
380515

3663
5553
360
1134

2069.2

None

5005.1
5005.1
5005.1

447769
473389
484852

448354
475216
486148

585
1827
1296

5005.2
5005.2
5005.2
5005.2
5005.2

486159
500292
502488
504747
512697

486477
501768
504144
506439
518430

318
1476
1656
1692
5733

561471
581217
592908

747
630
1809

5005.3

None

6180.1
6180.1
6180.1

560724
580587
591099
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6180.1

606018

608277

2259

6180.2
6180.3
6180.3
6180.3
6180.3
6180.3

None
650796
652884
658266
661833
664686

652083
656025
659409
663840
665163

1287
3141
1143
2007
477

6180.4
8232.1

None
687348

688257

909

8232.2

721881

723537

1656

8232.3
8232.3
8232.3

757449
760857
796605

758907
764340
797181

1458
3483
576

8232.4
8232.4
8232.4

812856
821514
823929

818490
822981
827898

5634
1467
3969

8232.5
9429.1

864522
None

866007

1485

9429.2
9429.2
9429.2
9429.3

922824
926319
942789
962436

925272
933600
943392
963246

2448
7281
603
810

10270.1
10270.1

1010118
1011312

1011099
1012113

981
801

10270.2
10270.2
10270.2
10270.2

1072071
1075464
1080255
1084746

1072701
1079694
1082190
1086024

630
4230
1935
1278

10270.3

None

10270.4
10270.4

1127967
1138959

1133160
1141137

5193
2178

10270.5
10394.1

1143141
None

1150035

6894

1212095
1217205
1240593
1246209

1293
1728
1233
2412

10394.2

None

10394.3
10394.3
10394.3
10394.3

1210802
1215477
1239360
1243797

10394.4

None

10394.5
10394.5
10394.5

1307526
1315368
1334859

1309875
1318158
1336206

2349
2790
1347

10394.6
10394.7
10394.7

None
1367883
1379955

1368918
1380549

1035
594

10394.8
10394.8

1383999
1394094

1392288
1396446

8289
2352

10750.1

None

10750.2
10750.2

1440330
1444134

1441608
1451046

1278
6912

10750.3
10750.3

1483242
1484520

1483926
1485069

684
549

165

10750.3
10750.3

1488609
1495980

1491543
1497816

2934
1836

10750.4
10750.4

1514124
1519386

1516293
1520745

2169
1359

PhiMan1
PhiMan1
PhiMan1

1538625
1541901
1562448

1540452
1542792
1563870

1827
891
1422

PhiMan2
PhiMan3
PhiMan3
PhiMan4

1575552
1605543
1639752
None

1577379
1607217
1641111

1827
1674
1359

PhiMan5

1686186

1686942

756

131.1
131.1
131.1

1699812
1707930
1714401

1700964
1708578
1714644

1152
648
243

131.2
131.3

1749927
1772754

1752555
1773483

2628
729

SPsP1

1832781

1833789

1008

SPsP2
SPsP3

1843992
None

1850733

6741

SPsP4
SPsP4

1932237
1943247

1938240
1946019

6003
2772

SPsP5
SPsP5
SPsP5
SPsP5

1954347
1961268
1987905
1995222

1955634
1966038
1990326
1995627

1287
4770
2421
405
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Table G.3 List of proteins with putative secretion signal peptides from SignalP
Loci
7511 - 8797
12889 - 14148
15939 - 17135
30538 - 31662
58741 - 60045
82349 - 82675
83083 - 83319
83730 - 84056
95904 - 97478
98014 - 98595
99823 - 100410
102159 - 103943
105468 - 106874
111859 - 112878
115644 - 116123
123564 - 124442
126499 - 127542
128626 - 129981
130485 - 132209
132348 - 132566
133005 - 133148
156498 - 157037
159085 - 160305
160718 - 161191
165785 - 166486
166586 - 167485
170983 - 172767
186683 - 188002
188107 - 188994
189007 - 189837
201997 - 204618
210810 - 212378
212576 - 214501
223024 - 224205
224373 - 225605
225936 - 227906
227971 - 229473
240786 - 241628
241955 - 242800
246465 - 247679
251346 - 252242
253974 - 255476
268549 - 269472
279538 - 280101
280103 - 280756
288778 - 289710
318523 - 318909
327369 - 327710
328614 - 329546
331368 - 332174
332391 - 334796
340237 - 341397

Signal peptide containing proteins (SignalP)
Hypothetical protein
Cationic amino acid transporter - APC Superfamily
Secreted antigen GbpB SagA PcsB, putative peptidoglycan hydrolase
Putative choline binding protein
Preprotein translocase secY subunit TC 3.A.5.1.1
Late competence protein ComGC, access of DNA to ComEA, FIG007487
Late competence protein ComGE, FIG075573
Late competence protein ComGG, FIG068335
Putative collagen binding protein
Hypothetical protein
Hypothetical protein
Protein F2-like protein
Short chain fatty acids transporter
Transcriptional regulator pfoR
V-type ATP synthase subunit K EC 3.6.3.14
Hypothetical protein spyM18_0155
Nucleoside-binding protein
Nicotine adenine dinucleotide glycohydrolase NADGH EC 3.2.2.5
Thiol-activated cytolysin pneumolysin
Hypothetical protein
Hypothetical protein
Substrate-specific component BioY of biotin ECF transporter
S-layer homology domain putative murein endopeptidase
streptococcal pyrogenic exotoxin G SpeG
Integral membrane protein Rhomboid family
UTP--glucose-1-phosphate uridylyltransferase EC 2.7.7.9
Lipid A export ATP-binding permease protein MsbA
ABC transporter, predicted N-acetylneuraminate-binding protein
ABC transporter, predicted N-acetylneuraminate transport system permease
protein 1
ABC transporter, predicted N-acetylneuraminate transport system permease
protein 2
Surface exclusion protein
Amino acid ABC transporter, glutamine-binding protein permease protein
Hypothetical protein
D-alanyl-D-alanine carboxypeptidase EC 3.4.16.4
D-alanyl-D-alanine carboxypeptidase EC 3.4.16.4
Oligopeptide ABC transporter, periplasmic oligopeptide-binding protein oppA TC
3.A.1.5.1
Oligopeptide transport system permease protein oppB TC 3.A.1.5.1
Cysteine ABC transporter, substrate-binding protein
Methionine ABC transporter substrate-binding protein
Dicarboxylate amino acid cation Na or H symporter
Heat shock protein HtpX protease EC 3.4.24
Transmembrane histidine kinase CsrS
OxaI YidC membrane insertion protein
Substrate-specific component RibU of riboflavin ECF transporter
Membrane-associated phospholipid phosphatase
Ferrichrome-binding periplasmic protein precursor TC 3.A.1.14.3
Hypothetical protein
Hypothetical protein
Manganese ABC transporter, periplasmic-binding protein SitA
Peptidyl-prolyl cis-trans isomerase EC 5.2.1.8
Cell division protein FtsK
Group B streptococcal surface immunogenic protein
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351376 - 352440
360270 - 360506
418560 - 418988
427804 - 428652
428977 - 429480
429464 - 429847
462403 - 463332
475711 - 477258
498025 - 499152
500852 - 503584
521883 - 522959
533048 - 533410
554083 - 556254
566064 - 567257
579005 - 580276
580998 - 582218
585828 - 587165
589459 - 590334
593572 - 593775
600228 - 600935
601892 - 602917
609417 - 611429
612987 - 614219
622641 - 622811
638772 - 639635
653717 - 654625
654743 - 654919
674498 - 675496
689186 - 691603
696023 - 696289
706686 - 707735
722764 - 723999
724115 - 725077
732575 - 733648
739936 - 740667
777814 - 778563
779690 - 780058
794026 - 795432
798259 - 799146
811327 - 811755
820449 - 821999
834196 - 835152
835154 - 836218
837882 - 838934
850502 - 851368
859452 - 862013
865721 - 866308
872840 - 873613
873982 - 874818
878742 - 879299
886549 - 887037
889080 - 889307
971544 - 972164
977591 - 977704

Hypothetical protein
Preprotein translocase subunit SecG TC 3.A.5.1.1
General stress protein, putative
Phage lysin, glycosyl hydrolase, family 25
Substrate-specific component SCO2325 of predicted cobalamin ECF transporter
Additional lipoprotein component of predicted cobalamin ECF transporter
Cell division protein FtsX
Candidate zinc-binding lipoprotein ZinT
Streptolysin S export transmembrane permease SagH
Endonuclease Exonuclease phosphatase family protein
ABC transporter permease protein
Large-conductance mechanosensitive channel
Phosphoglycerol transferase
Capsule biosynthesis protein capA
periplasmic component of efflux system
ABC transporter permease protein
Cell surface protein
Cobalt-zinc-cadmium resistance protein CzcD
Membrane protein
Peptidoglycan hydrolase, Autolysin2 EC 3.5.1.28
Immunoglobulin G-endopeptidase IdeS Mac Secreted immunoglobulin binding
protein Sib38
5 -nucleotidase EC 3.1.3.5
Two component system histidine kinase EC 2.7.3.Hypothetical protein
Cystine-binding periplasmic protein precursor
Exfoliative toxin A
Hypothetical protein
ABC transporter substrate-binding protein
Hyaluronate lyase precursor EC 4.2.2.1
uncharacterized secreted protein, YBBR Bacillus subtilis homolog
Hypothetical protein
D-alanyl-D-alanine carboxypeptidase EC 3.4.16.4
Polysaccharide deacetylase
ABC transporter, periplasmic spermidine putrescine-binding protein potD TC
3.A.1.11.1
Class B acid phosphatase precursor EC 3.1.3.2
Sortase A, LPXTG specific
Hypothetical protein
Mg2 citrate complex transporter
Citrate lyase beta chain EC 4.1.3.6
Hypothetical protein
Cardiolipin synthetase EC 2.7.8.Putative deoxyribose-specific ABC transporter, permease protein
Putative deoxyribose-specific ABC transporter, permease protein
Nucleoside-binding protein
Phosphate ABC transporter, periplasmic phosphate-binding protein PstS TC
3.A.1.7.1
ABC transporter permease protein
Hypothetical protein
CAMP factor
Amino acid ABC transporter, amino acid-binding protein
Signal peptidase I EC 3.4.21.89
ABC transporter, ATP-binding protein
Phage holin
lipoprotein, putative
Maltose maltodextrin ABC transporter, substrate binding periplasmic protein
MalE
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982811 - 984061
989735 - 991909
995287 - 995598
1000449 - 1001144
1002746 - 1002874
1022129 - 1022497
1025938 - 1028304
1032896 - 1033114
1035958 - 1036443
1044295 - 1045521
1047117 - 1047878
1051456 - 1052511
1067262 - 1067924
1081695 - 1082237
1085195 - 1087057
1087796 - 1088383
1088361 - 1089203
1090885 - 1091238
1129138 - 1130175
1132610 - 1133560
1134928 - 1136421
1145580 - 1146686
1146729 - 1147352
1147365 - 1148075
1167182 - 1168906
1169807 - 1171252
1171333 - 1172259
1172269 - 1173219
1207151 - 1208758
1220091 - 1222256
1253228 - 1253572
1276009 - 1276995
1287507 - 1288790
1289921 - 1291381
1327794 - 1328363
1334598 - 1336268
1338854 - 1339876
1341817 - 1345644
1354169 - 1357132
1388916 - 1389761
1411405 - 1411956
1413608 - 1414462
1436355 - 1436489
1455925 - 1456722
1458695 - 1458925
1481795 - 1485292
1489850 - 1491172
1494199 - 1495125
1497283 - 1499469
1502246 - 1504219
1508634 - 1509287
1509957 - 1511585
1511698 - 1512675

Poly glycerophosphate chain D-alanine transfer protein DltD
Glutamine ABC transporter, glutamine-binding protein permease protein
PTS system, cellobiose-specific IIB component EC 2.7.1.69
Ribosyl nicotinamide transporter, PnuC-like
Hypothetical protein
Protein G-related alpha 2 macroglobulin-binding protein GRAB
internalin, putative
Hypothetical protein
Peptidoglycan N-acetylglucosamine deacetylase EC 3.5.1.Chloride channel protein
Hypothetical protein
Foldase protein prsA 1 precursor EC 5.2.1.8
Late competence protein ComEA, DNA receptor
Substrate-specific component NiaX of predicted niacin ECF transporter
Lead, cadmium, zinc and mercury transporting ATPase EC 3.6.3.3 EC 3.6.3.5
Copper-translocating P-type ATPase EC 3.6.3.4
YfaA
Lipase Acylhydrolase with GDSL-like motif
Hypothetical protein
Lon-like protease with PDZ domain
Carbamate kinase EC 2.7.2.2
Arginine ornithine antiporter ArcD
Peptide methionine sulfoxide reductase MsrA EC 1.8.4.11
Thiol disulfide oxidoreductase associated with MetSO reductase
Cytochrome c-type biogenesis protein CcdA homolog, associated with MetSO
reductase
Two-component sensor kinase YesM EC 2.7.3.Multiple sugar ABC transporter, substrate-binding protein
Multiple sugar ABC transporter, membrane-spanning permease protein MsmG
Multiple sugar ABC transporter, membrane-spanning permease protein MsmF
Hydrolase HAD superfamily
Multimodular transpeptidase-transglycosylase EC 2.4.1.129 EC 3.4.-.Penicillin-binding protein 1A 1B PBP1
Hypothetical protein
putative esterase
Cell envelope-associated transcriptional attenuator LytR-CpsA-Psr, subfamily F2
as in PMID19099556
Guanine-hypoxanthine permease
ABC transporter permease protein
Putative ABC transporter ATP-binding protein, spy1790 homolog
Heme ABC transporter Streptococcus , permease protein
streptococcal cell surface hemoprotein receptor Shr
Secreted Endo-beta-N-acetylglucosaminidase EndoS
Integral membrane protein
Hypothetical protein
Acid phosphatase EC 3.1.3.2
Hypothetical protein
Hypothetical protein, Spy1939 homolog
Hypothetical protein
Pullulanase EC 3.2.1.41
Streptokinase
Collagen-like surface protein
PTS system, maltose and glucose-specific component EC 2.7.1.69
6-aminohexanoate-cyclic-dimer hydrolase EC 3.5.2.12
streptococcal mitogenic exotoxin Z SmeZ
Dipeptide-binding ABC transporter, periplasmic substrate-binding component TC
3.A.1.5.2
Dipeptide transport system permease protein DppB TC 3.A.1.5.2
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1517854 - 1518774
1519408 - 1519935
1520032 - 1523493
1523828 - 1524637
1525960 - 1527126
1529593 - 1529844
1529922 - 1531511
1535638 - 1536906
1537330 - 1537734
1538808 - 1539737
1540523 - 1541719
1549901 - 1551244
1551254 - 1551562
1559918 - 1561558
1561842 - 1563341
1624727 - 1625599
1625642 - 1626520
1636106 - 1636948
1638699 - 1639778
1646322 - 1648298
1654679 - 1655293
1658143 - 1658685
1664443 - 1665357
1674190 - 1675905
1678922 - 1680145
1689580 - 1692978
1698719 - 1699006
1710326 - 1710646
1713949 - 1715313
1717615 - 1717845
1721798 - 1721920

Laminin-binding surface protein
Cell surface protein
C5a peptidase EC 3.4.21.
Antiphagocytic M protein
CDS Antiphagocytic M protein
Mga-associated protein
Immunogenic secreted protein
periplasmic component of efflux system
Hypothetical protein
Peptidylproline cis-trans-isomerase EC 5.2.1.8 Proteinase maturation protein
RopA
Strepotococcal cysteine protease SpeB
PTS system, cellobiose-specific IIC component EC 2.7.1.69
PTS system, cellobiose-specific IIB component EC 2.7.1.69
Hypothetical protein SPy2065
Dipeptidase EC 3.4
Transporter
Membrane protein, putative
Membrane protein
Hypothetical protein
Phosphoesterase, DHH family protein
Immunodominant antigen A
CDP-diacylglycerol--glycerol-3-phosphate 3-phosphatidyltransferase EC 2.7.8.5
UTP--glucose-1-phosphate uridylyltransferase EC 2.7.7.9
ABC transporter, permease protein
Serine protease, DegP HtrA, do-like EC 3.4.21.
Extracellular Protein Factor, epf
Hypothetical protein
Hypothetical protein
Competence-stimulating peptide ABC transporter permease protein ComB
Hypothetical protein
Hypothetical protein
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Table G.4 List of NS88.2 genes with putative cell-surface anchor HMM motifs
Loci
705653
1090263
1481795
1494199
1519026
1523828
1524846
1525960
1696680
1698781

Signal peptide containing proteins (SignalP)
Collagen-like surface protein SclB
Hypothetical protein
Pullulanase
Collagen-like surface protein
Cell surface protein
Antiphagocytic M protein
M protein
Antiphagocytic M protein
Extracellular Protein Fator, epf
Endonuclease/exonuclease/phosphatase family protein
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Table G.5 List of NS88.2 genes bearing <80% sequence identity to other fully
sequenced GAS genomes
Loci
98014
319582
705357
891546
894273
896155
898251
898547
898900
899286
899865
900254
900572
901441
903318
904085
904575
917871
918323
919596
920070
932264
932476
939839
1494199
1523828
1689580

Genome annotation
FctA
Phage protein
SclB
Phage terminase, large subunit
Hypothetical protein
Putative structural phage protein
Conserved hypothetical protein, 370.2 phage
Hypothetical protein
Hypothetical protein
Phage tail protein
Hypothetical protein
Hypothetical protein
Phage tail length tape-measure protein
Putative human platelet-binding protein,
phage associated
Tail protein, putative
Minor structural protein
Phage endopeptidase
Phage antirepressor protein
ORF2
Hypothetical protein
Hypothetical protein
Hypothetical protein
Phage major capsid protein
Phage protein
streptococcal collagen-like protein A (sclA)
M protein
Extra-cellular protein factor (epf)

Significant matches to Pfam
motifs
None
None
Collagen triple helix
Terminase family
Phage Mu protein F like protein
None
None
Bacteriophage tail protein family
None
Phage major tail protein 2
Phage protein
None
Phage-related minor tail protein
None
Siphovirus Phage tail protein
None
None
ORF6C domain)
DUF3102
None
None
None
Phage capsid family
Protein of unknown function
Collagen triple helix
Gram positive anchor
DUF1542
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Table H.1 Greater than 2.0 fold differential transcription in the covRS mutant NS88.2
relative to NS88.2rep. (All genes significantly differentially expressed, P < 0.05 by Student’s
unpaired T-test)
Array Spot ID

Description

NT01SP0378_1P8
NT01SP1759_5I1
NT01SP1784_5J2
NT01SP1761_5I3
NT01SP1785_5J3
7M14

Hypothetical M6 protein
Collagen-like protein (Scl1/SclA)
C5a peptidase precursor
Hypothetical protein
C5a peptidase
Putative acetyl-CoA acetyltransferase
Fibronectin- and factor H-binding protein
FbaB
NAD glycohydrolase
Streptolysin O
Streptolysin O precursor
UDP-glucose 6-dehydrogenase HasB
Hypothetical protein
Nicotinate-nucleotide pyrophosphorylase
(carboxylating)
Nicotine adenine dinucleotide/Transposase
Putative collagen-like protein (SclA protein)
Hyaluronate synthase hasA
Ribosomal protein S15
Transposase
Kinase, GHMP family, putative
Putative antibiotic resistance protein NorA
Putative uncharacterized protein
Hypothetical membrane associated protein
(DUF1700)
Pyrogenic exotoxin B SpeB
Inhibitor of SpeB; co-transcribed
M1 protein precursor
Hypothetical protein (signal peptide)
Gene regulated by Mga
Exotoxin type C precursor
Conserved hypothetical protein
Aspartate-ammonia ligase
SagC (Streptolysin S)
30S ribosomal protein S14 homolo
Glucosamine--fructose-6-phosphate
aminotransferase [isomerizing]
Hypothetical protein
Putative N-acetylmannosamine-6-phosphate
2-Epimerase
Streptolysin S associated protein
Hypothetical phage protein
IgG-degrading protease
Hypothetical protein
YlbN-like protein

NT01SP1783_5J1
7M12
7M16
NT01SP0151_1G5
NT01SP1949_5P21
7M22
NT01SP0154_1G8
NT01SP0149_1G3
SpyM3_1703_6H6
NT01SP1948_5P20
NT01SP1736_5H2
NT01SP1786_5J4
NT01SP0079_1D5
NT01SP1644_5D8
NT03SP0426_6I18
NT01SP1923_5O21
NT01SP1804_5J22
NT01SP1803_5J21
NT01SP1788_5J6
NT01SP0380_1P10
NT01SP1801_5J19
NT01SP0756_2P2
NT01SP1307_4F17
NT01SP1375_4I6
NT01SP0645_2K11
NT01SP1922_5O20
NT01SP1140_3P1
NT01SP0123_1F1
NT01SP0230_1J8
NT01SP0643_2K9
NT03SP0690_6L2
NT01SP0757_2P3
NT01SP1790_5J8
NT01SP0299_1M4

Fold change
NS88.2/NS88.2rep

P value

88.229614
55.097668
20.991302
19.6434
18.886713
16.645632

>0.0001
0.0002
0.0015
0.0401
0.0012
0.0007

15.769812

0.0010

15.673019
14.658403
13.490279
11.588559
10.115629

0.0002
0.0004
0.0007
0.0000
0.0007

8.680448

0.0105

8.645583
7.2604804
6.0195627
5.670866
5.5987473
-5.5788984
-5.3511586
4.91205

0.0001
0.0276
0.0104
0.0020
0.0097
0.0247
0.0218
0.0123

4.818099

0.0126

-4.5816684
-4.518096
4.3725247
4.189857
4.066102
3.8816411
-3.6440828
-3.6189883
-3.506283
3.496096

0.0341
0.0479
0.0260
0.0261
0.0374
0.0009
0.0026
0.0398
0.0284
0.0225

3.4258008

0.0171

-3.3847964

0.0011

-3.3678224

0.0437

-3.0084574
2.9954643
2.9946172
2.9226377
2.8479881

0.0245
0.0464
0.0120
0.0150
0.0360
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NT01SP1321_4F24
NT01SP1807_5K1
NT01SP1296_4F6
NT01SP1300_4F10
NT01SP0846_3C19
NT01SP1645_5D9
SpyM3_0694_6A21
SpyM3_0102_6A17
NT01SP1627_5C15
NT01SP1876_5M22
NT01SP1777_5I19
NT01SP0651_2K17
NT01SP1850_5L20
NT01SP0647_2K13
NT01SP0648_2K14
NT03SP0350_6I8
NT03SP1629_6P1
SpyM3_1260_6D14
NT01SP0891_3E16

Excisionase-related protein
Putative transcription regulator (RopB/Rgg)
Conserved hypothetical protein
Hypothetical protein (Prophage)
Hypothetical protein (Prophage)
PrfA, putative
Putative uncharacterized protein
Putative uncharacterized protein
A/G-specific adenine glycosylase
Hypothetical protein (Prophage)
Peptide ABC transporter, ATP-binding
Conserved hypothetical protein
Endopeptidase O
Hypothetical protein
Hypothetical protein
Exotoxin type A (SpeA)
Hypothetical phage protein
Putative uncharacterized protein
Exotoxin H precursor (Prophage)

-2.7499423
-2.7335727
-2.7113366
-2.693816
-2.565225
2.4824119
-2.418434
-2.3645484
2.3582458
-2.294977
2.2753694
2.2155092
-2.2019196
-2.1831903
-2.1643605
2.1022217
2.0912435
-2.0735266
2.0626948

0.0200
0.0355
0.0390
0.0166
0.0224
0.0441
0.0292
0.0250
0.0044
0.0144
0.0126
0.0158
0.0174
0.0204
0.0033
0.0138
0.0016
0.0500
0.0446
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ABSTRACT
In Western countries, invasive infections
caused by M1T1 serotype group A Streptococcus (GAS)
are epidemiologically linked to mutations in the control
of virulence regulatory 2-component operon (covRS). In
indigenous communities and developing countries, severe GAS disease is associated with genetically diverse
non-M1T1 GAS serotypes. Hypervirulent M1T1 covRS
mutant strains arise through selection by human polymorphonuclear cells for increased expression of GAS
virulence factors such as the DNase Sda1, which promotes neutrophil resistance. The GAS bacteremia isolate NS88.2 (emm 98.1) is a covS mutant that exhibits a
hypervirulent phenotype and neutrophil resistance yet
lacks the phage-encoded Sda1. Here, we have employed
a comprehensive systems biology (genomic, transcriptomic, and proteomic) approach to identify NS88.2
virulence determinants that enhance neutrophil resistance in the non-M1T1 GAS genetic background. Using
this approach, we have identified streptococcal collagen-like protein A and general stress protein 24 proteins as NS88.2 determinants that contribute to survival
in whole blood and neutrophil resistance in non-M1T1
GAS. This study has revealed new factors that contribute to GAS pathogenicity that may play important roles
in resisting innate immune defenses and the development of human invasive infections—Tsatsaronis, J. A.,
Hollands, A., Cole, J. N., Maamary, P. G., Gillen, C. M.,
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